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General 
 introduction 
Aging and Renal Transplantation
Because of the limited supply and the increasing demand for kidney grafts, the number 
of patients on the wait lists does not decrease. In the Eurotransplant region alone, 11.080 
patients were registered in 2014 for receiving a kidney transplant (Annual rapport Euro-
transplant 2014).1 Given the scarcity of kidney grafts for transplantation, the criteria for ac-
cepting kidneys for transplantation have been expanded. Organs that only a few years 
ago would have been considered unacceptable are now transplanted routinely, including 
kidneys from elderly donors or from donors with significant comorbidity. In the Eurotrans-
plant region, 21% of deceased donor kidney transplants in 2014 were 65 years or older. 
With the use of these expanded criteria donors, older donor age and pretransplant kidney 
quality are becoming main determinants of outcome after transplantation. Older age as-
sociates with specific senescence processes, that impact on renal histology and function. 
A good understanding of the interaction between donor age, senescence mechanisms and 
pathways, and kidney graft quality is essential to further optimize kidney allocation sys-
tems, to disentangle donor kidney quality from post-transplant phenomena, and perhaps 
even to provide targeted therapies aimed at slowing senescence in itself.
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 1.1
Donor Kidney
1.1.1 Clinical assessment of donor kidney quality
Renal allograft function, graft functional decline and the risk for acute rejection are in-
creased in older-aged donor kidneys. Consequently, several studies showed increased risk 
of graft failure of older donor kidneys.2-5 
The association between older donor age and impaired graft survival is continuous, ac-
cording to the United Network of Organ Sharing (UNOS) Kidney Transplantation Commit-
tee database.6 The rates of graft loss among recipients of grafts from donors 70 years of 
age or older are 24% higher than rates among recipients of grafts from donors 60 to 69 
years of age.7 Even in living donor kidneys, where the donors are screened prior to trans-
plantation and comorbidities are avoided, increasing donor age is associated with lower 
kidney function after transplantation and reduced graft survival.8 
Not only increased donor age in itself appears to be relevant for transplantation outcome. 
Many kidney donors have significant comorbidities, with potential impact on kidney qual-
ity. In 2002, based on a retrospective analysis, the term Extended Criteria Donor (ECD) was 
coined. This donor criterion was empirically attributed to deceased donors aged over 60 
years, or to deceased donors aged 50 to 59 years with at least 2 of the following character-
istics: history of hypertension, serum creatinine level greater than 1.5 mg/dL and cerebro-
vascular cause of death.9 The definition of ECD was based on the presence of variables 
that increased the risk for graft failure by 70% (relative hazard ratio 1.70) compared with an 
standard criteria donor (SCD) kidney.
A limitation of the ECD definition for clinical purposes is that it is a binary classification 
of donor quality, and largely ignores the great variability in allograft quality. The Kidney 
Donor Profile Index (KDPI) could be a more accurate formula than ECD to assess the donor 
risk index, by providing a continuous scale to estimate the likelihood of graft failure.10 KDPI 
is derived by first calculating the Kidney Donor Risk Index (KDRI) for a deceased donor. 
The KDPI is a remapping of the KDRI onto a cumulative percentage scale. The KDRI is a 
continuous score which incorporates 10 donor demographics: age, height, weight, ethnic-
ity, history of hypertension, history of diabetes, cause of death, serum creatinine, hepatitis 
C virus status and donation after circulatory death status.10 The KDPI ranges from 0% to 
100%. Higher KDPI values are associated with lower expected post-transplant longevity.11 
Fifteen to twenty percent of donor kidneys are in the top 20th percentile for KDPI.11
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allocation policy on waiting time in dialysis, access to transplantation of sensitized pa-
tients, and post-transplant outcome, will need to be evaluated in the coming years. 
1.1.3 Histological assessment of donor kidney quality
To evaluate the intrinsic quality of donor organs, many centers perform zero-time biopsies, 
prior to transplantation. Pre-transplantation kidney biopsies are mostly evaluated in older 
donors and are a significant cause of discard in different transplantation centres over the 
world. In 2012, 40% of deceased donor kidneys and 45% of ECD kidneys in the USA were 
discarded based on biopsy results.15 The rationale for this practice was first published in 
1995, when Gaber et al. showed that >20% glomerulosclerosis in a zero-time biopsy as-
sociated with significantly reduced graft survival.16 Other centers consider zero-time donor 
kidney histology for decisions on single versus dual transplantation.17
Despite the initial suggestion that zero-time histology could be used as predictor for kid-
ney graft outcome, subsequent literature has been very heterogeneous, with some stud-
ies showing no association18-21, while other studies confirmed a significant association 
between zero-time biopsy histology and outcome after transplantation.17,22-27 Several 
composite histological scoring schemes have been proposed for prediction of graft sur-
vival, based on the addition of semiquantitative scores of several individual histological 
lesions in the donor biopsy: “Remuzzi score”17, the “Donor Chronic Damage Score”24, the 
“Maryland Aggregate Pathology Index”25, and the “Total Chronic Banff Score”.26
A recent systematic review concluded that there are no consistent associations between 
donor biopsy findings and post-transplant outcome.28 Both histology-based kidney dis-
card and dual kidney allocation lead to a decrease in the absolute number of effective kid-
ney transplants, and thus increase the waiting times for deceased donor kidney transplan-
tation. Given the inconsistent association between zero-time histology and graft survival, 
basing kidney allocation on zero-time histology is not well supported. Moreover, the obvi-
ous benefits for individual patients, who receive a better-quality instead of a poor-quality 
(discarded) kidney, or receiving a dual kidney transplant instead of a single kidney trans-
plant, have not been weighed against the impact on the wait list, where the consequence 
is that more patients are waiting longer time for a kidney graft. Evaluation of the net effect 
on the total transplant population is necessary, before implementing and promoting these 
strategies on a wider scale. Finally, despite the great appeal of basing kidney allocation 
on the intrinsic (histological) quality of the graft, further research is necessary to elucidate 
which histological lesions or scores are most predictive of post-transplant outcome, and 
could be implemented in organ allocation policies.
1.1.2 Clinical donor parameters for kidney allocation
As it is clear that the quality of kidneys for transplantation is often suboptimal, and as 
this associates with decreased graft longevity, it seems logical to allocate kidneys with 
the longest survival probability to recipients with the longest life expectancy. Conversely, 
suboptimal donor kidneys could be allocated to recipients with shortest life expectancy. 
On the one hand, premature graft loss would be avoided in patients with a long life expec-
tancy. On the other hand, also premature loss of perfectly functioning grafts due to patient 
death would also be avoided. Allocation regimens that match renal allograft prognosis 
with recipient survival probability likely lead to the highest increase in the number of dialy-
sis-free years for the transplant population as a whole. But then, recipient life expectancy 
comes into play.
As donor age and recipient age are the single best predictors of respectively organ quality 
and recipient survival probability, simple age matching is the most straightforward strat-
egy to match renal allograft prognosis with recipient survival probability. Age matching 
criteria to optimize allocation of kidney graft have been adopted in most European coun-
tries, like the Eurotransplant Senior Program (“old-for-old” program). The ESP allocates 
kidneys from deceased donors of 65 years and older to recipients of 65 years and older.12 
Since initiation of the ESP (1999), availability of elderly donors doubled and waiting time 
for ESP patients decreased from 4,64 years to 3,55 years. Graft and patient survival were 
not negatively affected by the ESP allocation when compared to the standard allocation.13 
In the Eurotransplant region, a new kidney allocation program, proposed in June 2014, 
aims to allocate the donor kidneys based on donor and receptor age discrepancy, kidney 
function, donor comorbidities, time on the wait list and distance between donor and recipi-
ent centre, this in addition to the Eurotransplant Senior Program (www.eurotransplant.org). 
Recipient survival probability can be evaluated from the EPTS (Estimated Post Transplant 
Survival score), which calculates the years that a candidate on the waiting list would ben-
efit from transplantation.14 This score is based on receptor age, time on dialysis, prior trans-
plantation of any solid organ, and presence of diabetes mellitus. 15-25% of candidates 
on the waiting list are in the top 20th percentile for EPTS. The EPTS score is designed to 
achieve better longevity matching between donor and receptor, by linking EPTS with KDPI. 
A simulation study on the SRTR database suggested that allocating kidneys from donors 
with a KDPI < 20% to candidates in the top 20th percentile of post-transplant survival, will 
improve overall post-transplant survival of the transplant cohort as a whole.11 Based on 
these simulations, UNOS has recently approved a new allocation policy, implemented in 
December 2014, which includes matching KDPI and EPTS. The true impact of this changed 
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1.1.4 Donor age, aging and zero-time transplant biopsy histology
What is the cause of histological injury in zero-time biopsies, prior to transplantation? Ob-
viously, kidney allografts have had a previous life and often show donor-derived “wear 
and tear”. Zero-time renal allograft histology reflects donor age.21,29,30 In young deceased 
donors less than 40 of age, 54% of renal biopsies were histologically normal, in contrast to 
only 7% of kidney biopsies from donors older than 40 years.31 Next to accumulation of sev-
eral injury events over time, also specific aging processes (senescence) are thought to play 
a role in the histological and function decline of kidneys with increasing age. 
Aging is characterized by a progressive loss of physiological integrity, leading from im-
paired function and increased vulnerability to increased morbidity and death.32 It is essen-
tial to distinguish aging from age-related disease. Aging itself is not a disease but seems 
to be the greatest risk factor for age-related pathology and mortality.33 It is a complex 
process in which significant changes are observed in the genes, proteins, tissue structures 
and physical abilities of older members compared with younger members of a species. 
Humans, especially modern humans, have a very steep rise in relative mortality risk with 
increasing calendar age, more important than any other species.34 
1.2
The aging phenotype on cellular level
The aging phenotype is most extensively described on cellular level. Cellular aging result 
from the incapacity of cells to adjust to stress environments. Aging cells can permanent-
ly arrest the cell cycle (cellular senescence), or initiate programmed cell death. Apoptosis 
(self-killing) is the best-known form of programmed cell death, but also autophagy (“self-
eating”) leads to cell death.35 Cellular senescence was formally described more than 50 
years ago, as a process that limited the proliferation of normal human cells in culture (the 
“Hayflick phenomenon”).36 Senescent cells remain viable but show a changed morphol-
ogy, greater heterogeneity, expression of beta-galactosidase, accumulation of lipofuscin 
granules, lack of response to mitogenic stimuli and resistance to apoptosis. They secrete a 
common set of proteins, the senescence-associated secretory phenotype (SASP).37 Apop-
tosis leads to cell shrinkage and blebbing, nuclear fragmentation, chromatin condensation, 
and chromosomal DNA fragmentation, and consequently, cell death. Autophagy leads to 
lysosomal degradation of the cytoplasmic contents, protein aggregates, and damaged 
organelles, which finally leads to cell death.38 
Although senesence and programmed cell death are both cell responses to cellular stress, 
it is still not clear what determines if the cell choses one or the other. Most cells are capa-
ble of both mechanisms, though both processes are exclusive.35 Autophagy on the other 
hand, though referred to as type II cell death also promotes cell survival by adapting cells 
to stress environments mainly in senescent cells. For example in senescent fibroblasts the 
renewal of organelles is enabled by autophagsomes.35 
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1.3
Aging pathways
Biological theories of aging in humans can be divided into two categories, the programmed 
aging theories and the damage theories. The first theories imply that aging follows a bio-
logical clock, which depends on changes in genetic expression that affect repair systems. 
The damage theories emphasize that the environment triggers cumulative damage to liv-
ing organisms.39 The main aging pathways and their interactions are described below.
1.3.1 Metabolic senescence, igf1 and Mtor pathway.
The first relevant pathway for aging, the insulin/insulin-like growth factor 1 (IGF1 pathway), 
was identified in 1990s, and its inhibition associated with a doubling of the lifespan of 
worms.40 In response to insulin and IGF1, protein kinase B (PKB) is activated, which leads 
to phosphorylation of multiple downstream targets, finally promoting cell survival and cell 
growth.41,42 IGF 1 production is stimulated by growth hormone, protein intake, and inhibited 
by undernutrition and lack of glucose. AMPactivated protein kinase (AMPK), a central sen-
sor for energy status (cfr mTOR pathway) also targets the insulin IGF1 signaling. 
Likewise, the mammalian target of rapamycin (mTOR) signaling pathway controls lifes-
pan, in response to nutrient availability through AMPK an energy sensor.43 In response to 
insulin, other growth factors, nutrients or mitogenic signaling, mTOR phosphorylates S6 
kinase (S6K) via AMPK. Inhibition of this kinase results in significant increase in lifespan in 
yeast, worms and flies.44
1.3.2 Cellular or replicative senescence 
Of the wide spectrum of mechanisms of aging, cellular senescence is classically seen as 
one of the most important. Cellular senescence, also named intrinsic or replicative senes-
cence, comprises exhaustion of a predetermined proliferative capacity, depends on tel-
omere shortening with increasing age, but can also be induced by extrinsic factors (then 
called stress-induced premature senescence, SIPS). SIPS can be induced by oxidative 
stress, DNA damage (e.g. due to X-rays, oxidative stress and UV irradiation), mitogenic 
signals mainly produced by oncogens (Ras induction), non-genotoxic stress like epigenetic 
changes (chromatin perturbation) and lack of nutrients.37,45,46 Cellular senescence is medi-
ated through the ARF-p53-p21 signaling pathway, which is partially telomere dependent, 
and the p16-pRb pathway, which is mostly independent of telomere dysfunction. These 
pathways interact but can also act independently.37,47 
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These two conflicting roles of cellular senescence suggest that cellular senescence is a bio-
logical process that can be both beneficial and deleterious, depending on the age of the 
organism. Evolutionary, it is presumed that cellular senescence was initially advantaged 
in its promotion of fitness in young organisms (beneficial: tumor suppression, tissue re-
generation), but appeared deleterious in older organisms (harming: aging/age-related dis-
ease, tumor promotion), related to the declining force of natural selection with increasing 
age.65,66 The recently proposed senescence associated function in tissue repair considers 
senescence as a ‘resting state for healing’, to suppress excessive cell proliferation or matrix 
deposition during wound repair. If the damage can be repaired during the cells growth ar-
rest the cell restarts its cell cyclus, otherwise apoptosis can be induced.66 
the p16-prB pathway
DNA damage by environmental stress (reactive oxygen species) is the main stressor for in-
duction of p16 expression and activation of the p16-pRB pathway.37 p16 is encoded by the 
CDKN2A gene, which generates several transcript variants. P14ARF is an alternate reading 
frame protein product of the CDKN2A locus (p53 pathway). 
The p16-pRB senescence pathway is mainly telomere-independent, and referred to as 
‘STASIS’ (Stress and Aberrant Signaling-Induced Senescence), although it should be em-
phasized that p16 can also be induced by dysfunctional telomeres. p16 is an inhibitor of 
CDK4/CDK6, which phosphorylate retinoblastoma protein (pRB) to its activated state. 
When pRB is active, it disassociates from a transcription factor, which is then free to enter 
the nucleus. Once in the nucleus, it promotes the transcription of target genes that are es-
sential for transition from G1 to S phase. pRB inactivation, by p16 expression, thus leads to 
cell cycle arrest in the G1 phase, and thus to cellular/replicative senescence.
1.3.3 Mitochondrial decline
Not only progressive DNA damage but also mitochondrial decline is considered a prime 
instigator of natural aging.63 Mitochondria are the energy-producing cell organelles via 
oxidative phosphorylation, which leads to generation of adenosine triphosphate (ATP). In 
addition to supplying cellular energy, mitochondria are involved in cell signaling, cell dif-
ferentiation, cell death, as well as in maintaining the control of the cell cycle and cell growth. 
Each cell contains approximately 200 to 2000 mitochondria, each carrying 2 to 10 copies 
of the mitochondrial DNA (mtDNA). Only few of the proteins present in mitochondria are 
encoded by mtDNA, but these mtDNA-encoded proteins form an essential part of the oxi-
dative phosphorylation machinery as well as of the RNA components of the mitochondrial 
translation system. The majority of proteins and enzymes present in mitochondria are nu-
clear gene products (nature education.com). 
the Arf-p53-p21 pathway 
Telomeres comprise tandem TTAGGG repeats of 5000 to 15000 base pairs that normally 
reside at the ends of chromosome ends as protection and prevent end-to-end fusion of 
chromosomes. Telomere length is regulated by telomerase.48,49 Telomerase is a ribonu-
cleoprotein that adds the nucleotide “TTAGGG” to the 3’ end of telomeres. Most somatic 
cells do not express telomerase, and mature telomeres tend to progressively shorten with 
every cell division.49 Telomere length thus reflects time and the number of cell cycles. Al-
though telomere length is partly heritable50, there are major differences in telomere length 
even among monozygotic twins, which illustrates that environmental factors (e.g. lifestyle 
factors like smoking, physical activity, alcohol, air pollution) play a major role in telomere 
attrition.51-54 Due to their high content of guanines, telomeres are highly sensitive to oxida-
tive damage.55 In vitro, telomere attrition is caused by hyperglycemia56,57 and oxidative 
stress by hydrogen peroxide.58 
When telomeres become critically short (reach the “Hayflick limit”) a classical DNA-damage 
response is triggered by activation of the tumor-suppressor protein p53, through phospho-
rylation by a protein kinase.59,60 These protein kinases can be divided into two groups. A first 
group known to respond to several types of stress, such as membrane damage, oxidative 
stress, osmotic shock, heat shock, etc. A second group with a function in the genome integ-
rity checkpoints. Oncogenes also stimulate p53 activation, mediated by the protein p14ARF 
(alternate reading frame protein of CDKN2A, p16 pathway), a stabilizer of p53. 
Activated p53 enhances expression WAF1/CIP1 (p21), also known as cyclin-dependent ki-
nase inhibitor 1 or CDK-interacting protein 1, which inhibits the cyclin-dependent kinases 
CDK4/CDK6, CDK2, and CDK1 complexes. These complexes regulate the transition from 
G1 to S phase in the cell cycle. When p21 inhibits the cyclin-dependent kinases, the cell re-
mains in the G1 phase and cell division arrests. Consequently, p53 prevents the cell from 
replicating by stopping the cell cycle at G1 phase, and thus inducing replicative senescence. 
However, it should also be mentioned that at this stage, p21 expression can also induce 
apoptosis, if the damage is too extensive and repair efforts fail.61-63 
P53 is not by accident involved in both aging as in cancer development. P53 expression 
leads to cell senescence, which is the mechanism by which cancer development is inhibited. 
If p53 is defective (e.g. mutated), cells could proliferate indefinitely and can become can-
cer cells. P53-associated cellular senescence is primarily tumor-suppressive, by inducing 
growth arrest and thus inhibition of relentless cell proliferation. Nevertheless, it should be 
mentioned that cellular senescence and SASP have also been associated with tumor pro-
motion, by secretion of inflammatory cytokines and induction of angiogenesis.64 
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related disease, including stroke, arteriosclerosis and osteoporosis, and overexpression of 
Klotho in mice extends their lifespan.46
It needs to be emphasized that the different aging pathways closely interact with each 
other, and share several key players. For instance, Sahin and colleagues have recently 
demonstrated that activated p53 (through telomere shortening) represses peroxisome 
proliferator–activated receptor γ (PPAR-γ) co-activator-1α and peroxisome proliferator–
activated receptor γ (PPAR-γ) co-activator-1 β, which are key regulators of mitochondrial 
function (PGC-1α and PGC-1β). These interactions are called the telomere–p53–PGC axis or 
the “axis of aging” (Figure 1).63 Also decreased activity of the mTOR and the IGF1 pathways 
has been associated with improved mitochondrial function(Figure 2).78-80
The mitochondrial genome is very susceptible to damage and the estimated mutation 
rate is 5-10 times higher compared to nuclear DNA. MtDNA lacks protective histones, chro-
matin structure and introns and the repair mechanisms work less efficiently than that of 
nuclear DNA.70 MtDNA is mainly sensitive to reactive oxygen species generated by the 
respiratory chain, due to its proximity.
Over time, mitochondrial DNA undergoes irreversible mutations, which leads to increased 
reactive oxygen species production, dysfunctional oxidative respiration, and changes in 
adenosine triphosphate uncoupling and thus impaired ATP generation.63 These mutations 
and subsequent decline in mitochondrial function are considered important modulators of 
lifespan, based on a large body of experimental data in animal models.71-73 
In humans, mitochondrial degeneration, which is hallmarked by impaired ATP generation, 
associates with increasing age and with several age-related disorders like Alzheimer’s and 
Parkinson’s disease.74,75 Recent evidence shows that mitochondrial dysfunctions promotes 
atherosclerosis directly.76,77 
1.3.4 other mechanisms of aging 
Next to age-associated activation of the IGF1 and mTOR pathways, replicative senescence 
and decreased mitochondrial function, the aging phenotype has also been associated 
with other processes like increased susceptibility to apoptosis with older age, impaired re-
generation and repair, decreased functional capacity of stem cells and progenitor cells, 
changes in the expression of growth factors with increasing age, dysregulation of autoreg-
ulatory pathways, epigenetic alterations, immune system alterations and increased im-
munogenicity of older tissue. It is beyond the scope of this overview to discuss these phe-
nomena, despite their great importance for organismal aging. 
Second, also sirtuins are implicated in a wide range of cellular processes, including aging 
and apoptosis. Sirtuins control circadian clocks and mitochondrial biogenesis. Mainly SIR-
tuin 1 (SIRT 1) has been a major focus of investigation due to its antiaging effects.81
Sirtuin 1 (SIRT1) associates with many key aging factors such as p53 (inhibition), PGC-1α 
(a central regulator of mitochondrial function) and AMPK, the energy sensor of the mTOR 
pathway (AMPK induces SIRT1).46,63 
Klotho expression is another example of a molecular that interacts with several aging 
pathways. Klotho is an anti-aging factor with effects on insulin/IGF-1 pathway and phos-
phate/calcium homeostasis. Moreover Klotho expression is stimulated by reactive oxygen 
species (ROS) signaling.82 Mice genetically deficient of klotho develop accelerated aging-
General introduction   2120   General introduction
Figure 1 — Telomere attrition induces expression of p53, wich binds to PPARγ co-activator 1α (PGC1α) and PPARγ co-
activator β 1 (PGC1β). By binding of p53, the expression of both molecules, which are key regulators of mitochondrial 
function, is repressed the expression of PGC1A and PGC1B. 
Figure 2 — Increased DNA damage, telomere attrition, p53 and p16 activation and mitochondrial dysfunction promote 
aging. On the other hand, inhibition of the mTOR pathway and the IGF 1 pathway increase lifespan. 
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1.4
The aging phenotype of the organism and the kidney
1.4.1 Aging and age-related disease
Senescence associates with age-related disease.37 Senescence of astrocytes accelerates 
age-related neurodegeneration and causes cognitive impairment, Alzheimer’s and Parkin-
son’s disease.83 Similarly, in joint arthrosis and intervertebral disc degeneration, senescent 
chondrocytes accumulate.84,85 Senescent endothelial and smooth muscle cells have been 
associated with age-related cardiovascular disease.86 The list of age-related pathologies, 
in which senescent cells have been observed or contribute is long, and involves major age-
related diseases like macular degeneration, chronic obstructive pulmonary disorder, lung 
emphysema and decreased insulin sensitivity.65 
Lately there is more evidence that senescence is more than a deleterious process. The re-
cently proposed senescence associated function in tissue repair considers senescence as a 
‘resting state for healing’ as we discussed above.66 
The Senescence Associated Secretory Phenotype (SASP) can attract immune cells and 
by that start tissue remodeling. Macrophages engulf and destroy the senescent cells and 
oligopotent progenitor cells can regenerate the damaged tissue. If the damage cannot be 
repaired during the cells growth arrest, apoptosis can be induced.66,87 
1.4.2 renal senescence phenotype
The phenotype of renal senescence is characterized by a decreasing cortical mass with 
corresponding presence of glomerulosclerosis, interstitial fibrosis, tubular atrophy, and ar-
teriosclerosis. The renal senescent phenotype also comprises changes in renal function, 
reduced renal plasma flow and reduced glomerular filtration rate.2,46,88 Here, we will dis-
cuss several studies that evaluated the phenotype and mechanisms of renal senescence, 
focusing on replicative senescence and mitochondrial decline. 
replicative senescence in native kidneys
Replicative senescence has only been studied scarcely in native kidneys.89 Cell proliferation 
in normal circumstances is very low in human kidneys.90,91 Studies in telomerase-deficient 
mice suggested that critical telomere shortening in kidneys leads to increased senescence 
and apoptosis, thereby limiting regenerative capacity.92 In vitro experiments have shown 
that hyperglycemia and oxidative stress in tubular epithelial cells provoke telomere attri-
tion.57,58,93,94 Animal models have shown that renal ischemia can induce telomere shorten-
ing of renal cells.95-97
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In acute kidney injury (AKI) pathophysiology, mitochondrial dysfunction has been de-
scribed as a keystone. Different studies have demonstrated that mitochondria are dam-
aged at beginning of AKI and also the regaining of mitochondrial function is correlated 
with recovery of renal function.114
Moreover kidney cells depend on mitochondria-produced energy and so mitochondrial 
aging not surprisingly affect renal function and renal aging.115 In animal models age re-
lated decline of oxidative phosphorylation in rat kidney mitochondria is described.116 In the 
proximal tubular epithelial cells of older rats, the number of mitochondria per cell was lower 
than in younger groups and there are functional decreases in complexes I, II, IV, and V.117
These previously described relation between telomere attrition and mitochondrial decline, 
the “telomere–p53–PGC axis”63 possibly also play a role in kidney degeneration, eg inter-
stitial fibrosis and tubular atrophy.118 Further studies are needed to explore the role of the 
“axis of aging” in renal aging and disease. 
Other senescence pathways in native kidneys
The kidney is an insulin-responsive organ and the IGF1/Insulin pathway is involved in dif-
ferent renal processes in a variety of different ways. Different renal cell types have altered 
responses as extensively described by Hale et al.119 
The mTOR pathway also appeared as an essential modulator of several forms of renal 
disease. mTOR is activated after acute kidney injury, and inhibition delays recovery of re-
nal function after acute kidney injury.120 The mTOR pathways possibly contributes to renal 
repair, which was proven in animal models of diabetic nephropathy.121 
The current understanding of sirtuin biology in the kidney is limited. During calorie restric-
tion, still the most successful antiaging therapy in animals, SIRT1 is increased in the kid-
ney.81 Experimental findings in animal models suggest that renal sirtuins also are involved 
in the regulation of oxidative stress responses and erythropoëtin production. The role of 
SIRT1 in the kidney is mainly found in the regulation of blood pressure and sodium bal-
ance.122
Klotho is seen as a very sensitive biomarker of chronic kidney disease, which is charac-
terized by klotho deficiency. This deficiency is associated with vascular calcification, car-
diac hypertrophy, and secondary hyperparathyroidism, which are chronic complications in 
chronic kidney disease.123
In adult human kidneys, telomerase activity is very low, which results in telomere shorten-
ing by every cell division, as was demonstrated by Melk et al. Telomere length decreases 
more rapidly in the renal cortex than in the medulla.98
 
Next to telomere length, also other markers of replicative senescence have been evalu-
ated in kidneys. Diabetic mice showed markedly higher p53 levels in response to acute 
kidney injury then non-diabetic mice.101 Moreover, these pathways seem important in re-
nal fibrogenesis, both in toxic, obstructive and ischemic models of acute renal injury.102 
Acute kidney injury in aged mice resulted in an accelerated chronic kidney disease with a 
higher expression of p53, p21 and (SA)β-galactosidase, all markers of cellular senescence, 
compared to young animals.103 This finding was confirmed in human kidneys, where p53-
dependent pathways are activated in cases of acute ischemic injury.104 Finally, glomerular 
diseases like IgA nephropathy, lupus nephritis, and focal glomerulosclerosis are associated 
with increased p53 expression compared to kidneys without lesions, both in animals105 and 
in humans.106,107 Whether this increased p53 expression relates to accelerated telomere at-
trition, as would be predicted from the ARF-p53-p21 aging pathway, has not been studied 
to date. 
In human kidneys, p16 is significantly upregulated with age.108 Both in aging humans and 
mice, increased p16 expression associates with histological changes. Increased p16 expres-
sion is also found in human kidneys with glomerular disease, with interstitial fibrosis, with 
diabetic nefropathy and in animal kidneys with hypertension.93,109,110 89 
Despite these studies, which associate cellular senescence with renal injury, it remains un-
clear whether these associations have any causal relation. Moreover, renal replicative se-
nescence is not necessarily a detrimental process. On the contrary, there is scant sugges-
tion that induction of renal replicative senescence is a protective phenomenon, followed 
by tissue remodeling. Presence of senescent cells, restricts renal fibrosis and renal injury by 
ischemia in a mice model.111,112 
Mitochondrial decline in native kidneys
There is growing evidence that mitochondrial dysfunction is involved in a broad spectrum 
of renal diseases, like acute renal injury due to ischemia-reperfusion injury, renal Fanconi 
syndrome, and glomerular disorders such as focal segmental glomerulosclerosis.113 
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In human renal transplants with interstitial fibrosis, tubular atrophy and impaired graft 
function, Melk et al described increased p16 expression, possibly suggestive of accelerated 
senescence, although p16 is a non-specific marker.109 Furthermore, the same group de-
scribed rapid increase in p16 expression after transplantation in murine kidney grafts, most 
pronounced in older animals.108 
p16 expression in baseline biopsies predicted outcome in a small study with only 54 pa-
tients. These findings have not been confirmed in larger patients cohorts.138 
Notwithstanding the aforementioned studies, suggesting the presence of post-transplant 
accelerated senescence, no definite proof of accelerated telomere shortening has been de-
scribed in kidney grafts. Further studies in the human setting with long follow up data and 
stronger end points, are needed.
Mitochondrial decline and kidney transplantation 
Ischemia reperfusion injury in kidney transplantation results in the production of reactive 
oxygen species. In rats, renal transplantation induces mitochondrial dysfunction and renal 
oxygen damage but this without increase of damage markers.139 
It could be hypostasized that mitochondria may be important organelles during renal 
transplantation, since they undergo major changes that may contribute to the injury oc-
curring during ischemia reperfusion injury.140 A better understanding of this mechanism 
and the mitochondrial pathways and interactions is crucial for designing therapeutic strat-
egies to protect organs at the time of transplantation. 
Prevention and treatment of senescence
The knowledge of underlying aging mechanisms and pathways could pave the way to-
wards targeted preventative measures and therapy. Global companies have embarked on 
the ultimate quest for longevity, e.g. Calico project (Alphabet; former Google), and  phar-
maceutical industry, funding institutions, academic institutes and private foundations 
spend incredible amounts of money in this field. In this chapter, we briefly discuss a few 
potential targets and approaches, potentially relevant for kidney diseases and transplan-
tation. 
Telomerase, as prolongation factor for telomeres, represents a very interesting and specific 
target for increased longevity. Direct delivery of telomerase through gene therapy seems 
a promising experimental anti-aging therapy. Mice, when given supplemental telomerase 
through a genetically engineered viral vector, lived 13-24% longer, without increased cancer 
risk.141 In addition, a small molecule activator of telomerase prolongs health span in female 
mice.41
Senescence and kidney transplantation
The senescence phenotype in native kidneys, as discussed above, possibly becomes more 
obvious when older kidneys are transplanted and are exposed to ischemia/reperfusion or 
preservation stresses, post-transplant stresses like size mismatches, hypertension, drug 
toxicity, CMV positivity and immune stresses (donor-specific antibodies and acute rejec-
tion episodes).124 Previous literature suggested that after kidney transplantation, immune 
and non-immune injury to the kidney can cause accelerated aging of the graft.89,124 
Accelerated senescence after transplantation could play a role in long-term graft survival, 
independent of chronological organ age.124 In animal studies, ischemia-reperfusion injury 
(I/R), chronic rejection and hypertension in the peri- and post-transplant period have all 
been associated with accelerated senescence expressed by telomere shortening.125-128 
I/R in rats also upregulates p53 in proximal tubule cells, which can be prevented by siRNA 
mediated silencing of p53. This findings suggests a potential therapeutic benefit for is-
chemic kidney injury.129 Furthermore I/R in mice, pigs and primates also results in upregu-
lation of p21.92,125,126,130,131 
Human date show association between shorter telomeres and the development of chronic 
allograft nefropathy (CAN). Important note in this study is that the age of the donor ap-
pears to be the major determinant factor in replicative senescence.132
In humans, the association between renal senescence and graft outcome was suggested 
in a small study, where shorter telomere length in biopsies obtained at implantation was 
associated with lower graft function at one year after transplantation. However, in this 
study, this did not correlate with alterations in p21 or p53 expression.133 In contrast, a much 
larger study in 1038 living kidney donors did not find an association between peripheral 
blood leukocyte telomere length and acute rejection risk or graft failure.134 Given that this 
study does not exclude the possibility that intrarenal (instead of leukocyte) telomere length 
of less selected (deceased) donors is a significant risk factor for outcome, further research 
about the association between telomere length or attrition, and post-transplant events or 
outcome, is necessary.
Next to the potential importance of the ARF-p53-p21 pathway, also the p16-pRB pathway 
has been implicated in transplantation. I/R in mice and pigs result in a upregulation of 
p16.130,135,136 Also acute and chronic rejection and hypertension in mice and rats leads to an 
increased expression of p16.95,110,137 
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suggests that statins could actually slow aging in itself, and not just the cardiovascular dis-
eases associated with aging. Moreover, this finding also indicates that preventing telomere 
attrition could be achieved through therapeutic telomerase activation. In kidneys a small 
study showed upregulation of klotho expression in mice.158 
Finally, it has been suggested that renal senescence can be diminished by inhibition of the 
renin-angiotensin system (RAAS), potentially by modulation mitochondrial functions.159 
Pharmalogical RAAS blockade is a known treatment for hypertension and renal and cardi-
ovascular disease.118 Abadir et al recently discovered a mitochondrial RAAS, which inhibits 
respiratory chain function by increasing NO production.160 
Further investigation to identify the precise role of this system are needed but in a review of 
Schmitt and Melk they suggest that inhibition of RAAS might slow down accelerated aging 
in renal transplants.118 
Also non-pharmaceutical interventions have been studied for their effect on replicative 
senescence.142 For example, physical activity and calorie restriction slow telomere short-
ening.143,144 In mice, calorie restriction (CR) delays telomere attrition an increases SIRT ex-
pression in the kidney.145,146 On the other hand, telomere length positively associates with 
nutritional status in human and animal studies.147 Additionally multivitamin use is associ-
ated with longer telomere length among women.148 Of course, the pleiotropic effects of 
these interventions make it complicated to disentangle the net effect on senescence from 
the effects on other pathways, and validation of these findings is necessary.
Next to strategies that impact on telomere length, also other aging pathways are targeta-
ble. In oncology, promotion of senescence through e.g. activation of the p16 pathway by 
CDK4 inhibitors (mimicking p16 activity) is very promising.87 In nephrology, acute kidney 
injury-induced injury could be inhibited by a pro-senescent CDK4 inhibitor.87
Because inhibition of the mTOR pathway has emerged as one of the most robust ways 
of increasing longevity across species, the identification and the modulation of the down-
stream targets is critical in the regulation of the mechanisms that underlie life-span regu-
lation.149 Metformin augments AMPK activation and extends the life of female mice.150 
Conservation of the TOR pathway (mammalian TOR) from plants to humans, as well as 
the fact that drugs targeting these pathway is already in clinical use, bodes well for the 
possibility of pharmalogic intervention in renal aging and transplantation.151
 
Resveratrol, a natural sirtuin activator, slows down age-associated degeneration.152 Phar-
macological SIRT 1 activation proofs to decrease renal injury after oxidative stress in a mice 
model.145 Other studies found the role of the Sirtuin family in extending longevity contro-
versial153, and further investigation is needed.
Oxidative stress induces senescence (stress-induced premature senescence SIPS) but also 
chronic oxidant stress contributes to telomere shortening. This relation is confirmed by the 
of senescence by antioxidants. Consequently antioxidant drugs may also be used to re-
duce cell senescence.154,155,156 
Several therapies that affect senescence are already approved for human use. Statins, 
which are used safely and have many pleiotropic effects, increase the expression of tel-
omere repeat-binding factor, a protein involved in telomere capping in endothelial progeni-
tor cells.157 In humans, statin treatment augmented telomerase activity in white blood cells, 
which was associated with decreased telomere shortening. Although these associations do 
not prove any causality, the positive effects of statins in cardiovascular disease outcome, 
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1.5
Conclusion 
The increasing use of older donors and recipients of kidney grafts, and the impact of se-
nescence on graft quality, graft function and graft outcome, is becoming a central topic in 
the field of kidney transplantation. The future success of kidney transplantation depends 
on the way these issues will be handled in allocation rules, pre-transplant organ optimiza-
tion and post-transplant modulation of senescence progression. Escaping cell senescence 
mechanisms with drugs or gene therapy could extend renal longevity, and improve out-
come after transplantation.
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1.6
Aims of the phd project 
Aim 1
To build and validate a clinical-histological scoring system for baseline renal allograft biop-
sies to predict graft survival and for assessment of kidney quality before transplantation. 
Aim 2
To assess the phenotype and risk factors of replicative senescence in human kidneys, and 
to elucidate the importance of replicative senescence for renal allograft histology, function 
and survival in humans.
Aim 2.1
Identification of the renal senescence phenotype in implantation biopsies and define the 
renal senescence marker panel. 
Aim 2.2
Validation of the renal senescence marker panel in post transplantation biopsies
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Abstract
Background
The impact of baseline histology and of the individual histological lesions at time of 
transplantation on long-term graft survival is not well known. 
Methods 
All kidney recipients who were transplanted between 1991 and 2009, and who un-
derwent a baseline biopsy at time of transplantation, were included in this pro-
spective study (N=548). These biopsies were not used to guide kidney allocation. 
All baseline biopsies were rescored according to the current updated Banff clas-
sification. The relationship between the individual histological lesions and donor 
demographics was assessed using hierarchical clustering and principal component 
analysis. Survival analysis was performed using Cox proportional hazards analysis 
and log-rank testing. The existing scoring systems and a newly created scoring 
systems were evaluated by ROC analyses. Mean follow-up time was 6.7±3.3 years. 
results
Interstitial fibrosis (ci; p=0.0003), tubular atrophy (ct; p=0.05) and glomeruloscle-
rosis (gs; p=0.006) predict death-censored graft survival, while arteriolar hyalinosis 
(ah; p=0.4) and vascular intimal thickening (cv; p=0.9) did not. Donor age proved to 
be a highly significant correlated with ci, ct and gs (p=0.0001) and is independently 
associated with graft survival. In principal component analysis, we confirmed the 
dichotomy in the histological lesions at baseline, and the association with donor 
age. Based on these findings, a novel scoring system for prediction of 5-year graft 
survival was calculated by using logistic regression analysis. This score proved to 
have clinical utility (AUC= 0.74). The predictive performance of previously published 
histological scoring systems validated in our cohort were insufficient to use any of 
these scoring systems for kidney discard or acceptance (AUC< 0.65). 
Conclusion
Interstitial fibrosis, Tubular atrophy, glomerulosclerosis and donor age are higly sig-
nificant predicitors of longterm graft survival. A novel scoring system created based 
on this findings proved to by of higly clinical significance and should be taken into 
account when evaluating baseline biopsies for kidney allocation and in algorithms 
to predict transplantation outcome.
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biopsy histological features were used for kidney acceptance and allocation.15 A previous 
European study that explicitly excluded this type of selection bias, evaluated the predictive 
capacity of the “Total Chronic Banff Score” in implantation histology for graft survival, but 
only in a small subgroup of older donors after cardiac death.16 Based on data obtained in 
52 donor biopsies, these authors concluded that a total chronic Banff score of ≥ 4 was as-
sociated with unacceptable graft survival. Replication of these findings in a larger cohort, 
and in donors after brain death, has not been performed. 
Thus, whether assessing pre-implantation biopsies prior to transplantation for allocation 
purposes, and which histological cut-off values or score should be used for discarding a 
kidney for transplantation, is currently not known. In the current study, we evaluated the 
impact of the histological appearance of implantation biopsies on long-term renal allo-
graft outcome, and assessed the histology of implantation biopsies as prognostic clinical 
tool for kidney allocation. 
 
Background
The demand for kidney grafts far exceeds the supply of available organs. As a result there 
is an increasing use of older and extended criteria donor kidneys . This is not without conse-
quences. The risk of graft failure after an extended criteria donor kidney transplant is 70% 
higher than after transplantation with a standard criteria donor.1 The intrinsic quality of the 
kidneys at transplantation becomes increasingly important for the post-transplant renal 
allograft histological evolution and thus for long-term graft survival.2-4
To evaluate the intrinsic donor organ quality, baseline biopsies are increasingly used by 
many transplant centers. Pre-transplantation kidney biopsies are mostly evaluated in old-
er donors and are a significant cause of discard in different transplantation centres over the 
world. In 2001, 47% of kidneys in the USA were discarded based on biopsy results. The odds 
of discard increase progressively with increasing degrees of glomerulosclerosis and many 
transplant centers reject kidneys with extensive glomerulosclerosis (e.g. >20%).5 Another 
approach is to consider baseline histology for decision between single and dual kidney 
transplantation, as proposed by Remuzzi et al.6,7 The latter study showed that the risk of 
graft failure in patients older than 60 years was 3.68 times greater when transplanted kid-
neys were not histologically assessed and used for kidney allocation. Both kidney discard 
and dual kidney allocation lead to a decrease in the absolute number of effective kidney 
transplants, and thus increase the waiting times for deceased donor kidney transplanta-
tion. Detailed study of implantation biopsy histology, and its prognostic value, is therefore 
necessary to avoid any unwarrantable loss of kidneys suited for transplantation. 
Several centers have studied the value of baseline biopsies of kidneys procured for kidney 
transplantation. Most of these studies correlated baseline biopsy data with post-trans-
plant graft function, but not with graft survival8-11, while others showed a significant as-
sociation between baseline histology and graft survival.6,12-17 Based on this association 
between baseline histology and post-transplant graft survival, several histological scoring 
schemes have been proposed for prediction of graft survival based on donor biopsy histol-
ogy: the “Remuzzi score”6, the “Donor Chronic Damage Score”14, the “Maryland Aggregate 
Pathology Index (MAPI)”15 and the “Total Chronic Banff Score”.16 The score proposed by 
Remuzzi et al.6 associated with graft survival, and using this histological score for decision 
of dual kidney transplantation was beneficial for graft outcome. However, this score was 
not validated in itself, and the predictive capacity of this specific score for graft outcome 
and for kidney discard remains unclear. Also the “Donor Chronic Damage Score” signifi-
cantly associated with graft survival, but the predictive performance of this score has not 
been assessed.14 The MAPI needs potentially cumbersome morphometric analysis of the 
arterial wall-to-lumen ratio, which is not readily available in many centers.15 In addition, 
the construction of this scoring system is subject to selection bias, as the implantation 
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Statistical analysis
Histological covariates entered in the univariate analysis were interstitial fibrosis (Banff “ci” 
score), tubular atrophy (Banff “ct” score), arteriolar hyalinosis (Banff “ah” score), vascu-
lar intimal thickening (Banff “cv” score) and glomerulosclerosis. Donor demographics en-
tered in the univariate analysis were history of hypertension, diabetes, smoking, age and 
cerebrovascular cause of death. All covariates associated at the p=0.2 level with death-
censored graft survival in univariate analysis were included in the multivariate analysis. 
The multivariate cox proportional hazards analysis included only recipients with complete 
data on: graft survival; donors’ and recipients’ age and sex; donor source (living or de-
ceased) and cause of death; number of HLA mismatches; original kidney disease; primary 
immunosuppressive regimen; year of transplantation. Also the explanatory effect of the 
donor demographics on the histological lesions was analyzed. Final Cox proportional haz-
ards regression models were constructed by backward variable selection. For illustrations, 
Kaplan-Meier survival curves with log-rank testing were used. 
From the individual Banff scores that were recorded for every biopsy, previously published 
histological scores were calculated. The Remuzzi score was calculated by the addition of 
four different parameters: glomerular global sclerosis (0-3), tubular atrophy (0-3), inter-
stitial fibrosis (0-3) and arterial and arteriolar narrowing (0-3).6 The “Donor Chronic Dam-
age Score” was calculated as adding glomerulosclerosis (0=glomerulosclerosis <10%; 1=glo-
merulosclerosis >10%, vascular intimal thickening score and interstitial fibrosis score.14 The 
“Total Chronic Banff Score” was calculated as cg+mm+ct+ci+cv+ah+([fraction sclerosed 
glomeruli]*3).16 The Maryland Aggregate Pathology Index (MAPI)15 was not calculated be-
cause of the need for rescoring and for morphometric biopsy analysis. 
In the historic cohort a new clinicopathological scoring system was created with the histo-
logical lesions and donor demographics that were significant in multivariate Cox propor-
tional hazards analyses for association with graft survival. The new scoring system was 
constructed using logistic regression analysis, with death-censored graft survival at 3, 5 
and 10 years after transplantation as dependent variables. Receiver operating character-
istic (ROC) analysis was used to evaluate the predictive performance of the newly created 
scoring system in the validation cohort, and to compare this predictive performance with 
the previously determined scoring systems. 
For variance analysis of continuous variables in different groups, non-parametric Wil-
coxon-Mann-Whitney U, non-parametric ANOVA and parametric one-way ANOVA were 
used, as appropriate. Dichotomous variables were compared using the chi-square test. 
For evaluation of the correlation of the different histological lesions, spearman correlation 
Materials and Methods 
Patient inclusion
Between January 1991 and June 2009, 2163 kidney transplants were performed in adult 
patients at the University Hospitals Leuven. Between 1991 and 2003, baseline biopsies 
were not systematically performed, but only at the request of the transplant surgeon in 
case of donor demographic variables that were perceived to be associated with post-
transplant outcome. These biopsies were not systematically used for allocation purposes 
or for kidney discard, but as benchmark for comparison of post-transplantation histology 
in case a post-transplant indication biopsy was necessary because of graft dysfunction. 
Since 2004, baseline biopsies were systematically performed but for post-transplant com-
parison, again without pretransplant histological assessment. All patients who underwent 
a baseline biopsy at time of transplantation were included in this study. To build and vali-
date a histological scoring system in baseline biopsies, the cohort was divided in a historic 
cohort (transplantation before 2004) and a validation cohort (transplantation after 2004). 
Biopsies and histologic evaluation
One dedicated pathologist (EL) retrospectively reviewed all baseline biopsies, without 
knowledge of any clinical information. The biopsy specimens were wedge biopsies, with 
slides containing 4 to 10 paraffin sections (2 μm) that were stained with hematoxylin eosin, 
periodic acid–Schiff, and a silver methenamine staining method (Jones). The severity of 
chronic histologic lesions (interstitial fibrosis, tubular atrophy, arteriolar hyalinosis, vascular 
intimal thickening) was scored semiquantitatively according to the revised Banff criteria.18 
In addition, the number of sclerosed glomeruli was scored. 
Clinical data collection
Patient and donor data were prospectively collected in an electronic clinical patient charts. 
The clinical database was transferred to SAS date files (SAS institute, Cary, NC) at time of 
analysis. The following data were collected: donor characteristics (age, sex, cause of death, 
history of hypertension of diabetes, serum creatinine levels prior to organ recovery, ex-
tended criteria donation), cold ischemia time and recipient characteristics at time of trans-
plantation (age, sex, number of previous kidney transplantations, pre-existing kidney dis-
ease, number of HLA mismatches). Graft outcome data were also recorded. Delayed graft 
function was defined as the need for dialysis within the first week after transplantation. 
Graft failure was defined as either return to haemodialysis, or transplant nephrectomy, or 
recipient death with a functioning graft. Death-censored graft survival was calculated as 
the time from transplantation to graft nephrectomy or return to dialysis, with time from 
transplantation to death of the recipient with a functioning graft as censoring variable. The 
definition of extended criteria donation included all donors aged ≥60 years and donors 
aged 50-59 years with at least two of three other conditions (cerebrovascular cause of 
death, terminal creatinine >1.5 mg/dl and hypertension). 
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Results
Population characteristics
The study group consisted of 548 kidney recipients who had a baseline biopsy performed 
at time of transplantation. Six biopsies were of insufficient quality, leaving 542 baseline 
biopsies for analysis. The recipient and donor characteristics are summarized in Table 1. 
The mean recipient age was 51.9±13.4 years. Most recipients received their first allograft 
(88%). Mean donor age was 43.2±15.6 years. Brain death was caused by stroke in 40.5% 
of the donors. A history of hypertension was reported in 15.7% (N=86) of donors and 1.3% 
(N=7) had reported diabetes. Delayed graft function occurred in 21% (N=119) of recipients. 
Ninety-five percent of patients reached at least 1-year graft survival. The 2-, 5- and 10-
year survival was 93.5%, 89.8% and 81.9%. The mean graft survival of functioning grafts 
at time of data extraction was 5.5±3.2 years (10.7±1.7 in the historic cohort, 4.3±1.8 in the 
validation cohort). The demographics of the historic cohort, in which baseline biopsies were 
not systematically performed but only at the request of the transplant surgeon, proved to 
be similar to the demographics of the validation cohort (Table 1).
Association between clinical donor characteristics, baseline histology 
and graft survival
In univariate Cox proportional hazards analysis of the donor demographics and death-
censored graft survival, only older donor age (HR 1.72 per year [1.2-2.46]; p= 0.003) was 
a significant predictor of long-term graft loss (Table 2, Figure 1). The other donor factors 
(hypertension, smoking, stroke as reason of donor death and diabetes mellitus) were not 
associated with graft post-transplant outcome. 
analysis was used, as well as principal component analysis. From the principal component 
analysis, a 2D scatter plot was generated to represent the histological lesions according to 
their score in the loading matrix. 
The results are expressed as numerical values and percentages for categorical variables 
and as mean ± standard deviation for continuous variables, unless stated otherwise. All 
tests were two-sided and p values of less than 0.05 were considered to be statistically sig-
nificant. Analyses were done with SAS (version 9.2; SAS institute, Cary, NC), JMP9.0 (SAS in-
stitute, Cary, NC) and GraphPad Prism (version 5.00; GraphPad Software, San Diego, CA).
Figure 1 — Association of death-censored graft survival and donor age, by Kaplan-Meier survival analysis. The P-value 
is calculated with the log-rank test.
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The distribution of the histopathological lesions in the biopsies of sufficient quality and di-
agnosis is shown in Table 3. The mean number of glomeruli measured in the biopsies was 
21.3±15.2. Twenty-two percent (N=117) of patients had glomerulosclerosis >10%. One hun-
dred and five (19.1%) biopsies showed interstitial fibrosis/tubular atrophy and 17.3% of bi-
opsies had arteriolar hyalinosis (N=93). Only twenty- three biopsies (4.3%) showed vascular 
intimal thickening. 
In univariate analysis, interstitial fibrosis (HR=1.98 [1.32-2.57] grade>0 vs. grade=0; 
p=0.0003), tubular atrophy (HR=1.60 [0.99-2.58] grade>0 vs. grade=0; p=0.05) and glo-
merulosclerosis (HR=1.98 [1.21-3.26] >10% vs. <10%; p=0.007) associated with death-cen-
sored graft survival, while arteriolar hyalinosis (HR=1.30 [0.71-2.38]; p=0.4) and vascular 
intimal thickening (HR=1.08 [0.26-4.43]; p=0.92) did not (Table 2; Figure 2). In multivariate 
analysis, only interstitial fibrosis (adjusted HR=1.51 [1.02-2.26l]; p=0.03) was independently 
associated with graft survival, adjusted for donor age (Table 2).
 Hazard ratio in P value in  Hazard ratio in P value in
 univariate  univariate multivariate multivariate 
 analysis analysis analysis analysis
Donor demographics
Donor age (<40 vs. 40-60 vs. >60 years) 1.72 (1.2-2.46) 0.003 1.90 (1.24-2.9) 0.003
Stroke as reason of donor death 1.38 (0.83-2.29) 0.60 -- --
Donor history of hypertension 1.18 (0.61-2.29) 0.62 -- --
Donor diabetes mellitus 1.69 (0.23-12.2) 0.60 -- --
Donor history of smoking 0.90 (0.49-1.69) 0.75 -- --
Baseline biopsy histology
Tubular atrophy (present vs. absent) 1.60 (0.99-2.58) 0.05 0.98 (0.59-1.76) 0.9
Arteriolar hyalinosis (present vs. absent) 1.230 (0.71-2.38) 0.40 -- --
Interstitial fibrosis (present vs. absent) 1.85 (1.32-2.57) 0.0003 1.51 (1.02-2.26) 0.03
Vascular intimal thickening (present vs. absent) 1.08 (0.26-4.43) 0.9172 -- --
Glomerulosclerosis (≥10% vs. <10%) 1.98 (1.21-3.26) 0.006 1.32 (0.73-2.39) 0.35
Table 2 — Univariate and multivariate Cox proportional hazards analysis of death-censored graft survival based on 
baseline histology and donor demographic variables (N=542). 
 Banff grade 0 Banff grade 1  Banff grade 2 Banff grade 3
Arteriolar hyalinosis^ 82.7% (446) 14.1% (76) 2.7% (15) 0.3% (2)
interstitial fibrosis 75% (407) 18% (99) 4.7% (26) 1.8 (10)
tubular atrophy 52.9% (287) 44.2% (240) 2.2% (12) 0.5% (3)
Vascular intimal thickening 97.5% (519) 3.9% (21) 0.3% (2) 0.0% (0)
glomerulosclerosis*^ 78.2% (420) 14.9% (80) 6.9% (37) --
Table 3 — Distribution of the histological lesions in 542 implantation biopsies. *Grade 1: glomerulosclerosis of <10% 
of glomeruli; grade 2: glomerulosclerosis in 10-25% of glomeruli; grade 3: glomerulosclerosis of >25% of glomeruli. ^ Not 
all biopsies had sufficient numbers of glomeruli or arterioles to evaluate this lesion. °The mean number of glomeruli 
was per biopsy was 21.3±15.1 (range 1-89).
Table 1 — Demographic and clinical characteristics of transplant donors and recipients (N=548). Data are expressed 
as mean ± standard deviation. P-values compare the historic vs. the validation cohort, and were calculated using Chi-
square testing or two-way ANOVA. 
 All Historic cohort Validation cohort P-value
N 548 181 367 
recipients Characteristics
Age (years) 51.9 ± 13.4 51.4 ± 13.5 52.2± 13.4 < 0.0001
Male gender % (N) 60.3% (327) 64% (117) 57% (210) 0.12
Repeat transplantation % (N) 12% (66) 9.0% (17) 13.4% (49) 0.21
Donor Characteristics
Age (years) 43.16 ± 15.65 40.9 ± 15 44.2 ± 14 < 0.0001
Male gender % (N) 53.9% (301) 57.4% (104) 53.7% (197) 0.41
Deceased donor % (N) 99.2% (544) 99.4% (180) 98.9% (363) 1.00
Brain death /cardiac death  40.5%(222)/59.5%(326) 40.8%(74)/59.2%(107) 40.3%(148)/59.9%(219) 0.92
Stroke as reason for death % (N) 40.5% (301) 40.8% (74) 48.2% (177) 0.92
History of hypertension % (N) 15.7% (86) 13.2% (24) 16.9% (62) 0.32
History of diabetes mellitus % (N)  1.3% (7) 0.5% (1) 1.6% (6) 0.43
History of smoking % (N) 23.1% (127) 17.6% (32) 25.8% (95) 0.04
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Clinical determinants of baseline histology
The correlation between donor demographic variables and baseline histology is provided 
in Table 4. Donor age was highly significantly correlated with interstitial fibrosis, tubular at-
rophy and glomerulosclerosis (all p<0.0001), but less with arteriolar hyalinosis and vascu-
lar intimal thickening. Vascular intimal thickening was highly significantly associated with 
donor history of diabetes, and arteriolar hyalinosis was most significantly associated with 
stroke and donor history of hypertension (Table 4).
Figure 3 — Principal component analysis using the individual histological lesions in baseline biopsies and the differ-
ent donor demographics of 548 renal allograft recipients. This analysis illustrates a dichotomy between the histologi-
cal lesions: closely clustering lesions associating with donor age: glomerulosclerosis (gs), tubular atrophy (ct), interstitial 
fibrosis (ci); other lesions (vascular intimal thickening (cv) and arteriolar hyalinosis (ah)) that correlate less with donor 
age, but better with history of smoking, diabetes mellitus (DM) and hypertension (AHT) (See also Table 4).
 Donor age Stroke as reason  Donor history Donor diabetes Donor History 
  of donor death of hypertension mellitus of Smoking
interstitial fibrosis r= 0.29 r= 0.11 r=0.17 r= 0.01 r= -0.009
 p< 0.0001 p=0.01 p= 0.0003 p=0.8 p= 0.8
tubular atrophy r= 0.38 r= 0.2 r= 0.22 r= -0.02 r= 0.02
 p< 0.0001 p< 0.0001 p= 0.001 P= 0.7 p= 0.7
Arteriolar hyalinosis r= 0.11 r= 0.13 r= 0.12 r=0.04 r=0.04
 p= 0.01 p= 0.003 p= 0.007 p= 0.43 p=0.4
Vascular intimal  r= 0.09 r= 0.02 r= 0.1 r= 0.34 r=0.08 
thickening p= 0.04 p= 0.7 p= 0.02 p= 0.003 p= 0.05
glomerulosclerosis r= 0.25 r= 0.12 r=0.18 r= 0.1 r= 0.03
 p< 0.0001 p= 0.006 P=0.0001 p=0.02 p=0.5
Table 4 — Spearman correlation between the histological lesions in implantation biopsies and clinical donor char-
acteristics (N=542).
Figure 2 — Association of death-censored graft survival and selected individual histological lesions in 542 baseline 
biopsies, by Kaplan-Meier survival analysis. P-values were calculated with the log-rank test.
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 Cox proportional  Logistic regression Logistic regression Logistic regression
 hazards analysis with 3-year survival with 5-year survival with 10-year survival
 Comparison HR (95% CI) P-value AUC under P-value AUC under P-value AUC under P-value
    ROC curve  ROC curve  ROC curve
Remuzzi score7 ≥7 vs. < 7 1.22 0.001 0.62 0.02 0.62 0.003 0.59 0.09
  (1.09-1.38)
Donor Chronic  ≥ 3 vs. < 3 1.52 0.0001 0.55 0.29 0.59 0.03 0.59 0.08 
Damage Score14  (1.23-1.88) 
Total Chronic  ≥ 6 vs. < 6 1.25 0.0004 0.6 0.05 0.6 0.01 0.59 0.08
Banff Score16  (1.1-1.42)
Table 5 — Predictive performance of the previously proposed histological scoring systems for death-censored graft 
survival, in all donor kidneys (N=542).
Figure 4 — Association of death-censored graft survival with the previously proposed “Remuzzi score”7, the “Total 
Chronic Banff Score”16 and the “Donor Chronic Damage score”14, using Kaplan-Meier survival analysis, and the cor-
responding ROC curves for prediction of (death-censored) 5-year graft survival.
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Figure 5B — (A) Association of death-censored graft survival with the newly constructed “Leuven Donor Risk Score”, 
using Kaplan-Meier survival analysis. (B) ROC curves for prediction of (death-censored) 5-year graft survival based on 
the “Leuven Donor Risk Score” in the historic cohort (N=181) and in the validation cohort (N=367). 
Figure 5A — (A) Association of death-censored graft survival with the newly constructed “Leuven Donor Risk Score”, 
using Kaplan-Meier survival analysis. (B) ROC curves for prediction of (death-censored) 5-year graft survival based on 
the “Leuven Donor Risk Score” in the historic cohort (N=181) and in the validation cohort (N=367). 
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Creation and validation of a new scoring system for implantation biopsies
As the previously proposed histological scoring systems did not provide sufficient predic-
tive performance in our cohort, we created an alternative scoring system (“Leuven Donor 
Risk Score”), based on both histological data and donor age. The reason for including do-
nor age in this clinicopathological scoring system was the finding that donor age was as-
sociated with death-censored graft survival, independent of the baseline graft histology. 
This scoring system was created by linear regression analyses, including interstitial fibro-
sis, tubular atrophy and glomerulosclerosis as histological parameters, and donor age as 
clinical parameter. Interstitial fibrosis, tubular atrophy and glomerulosclerosis scores were 
dichotomized. Three age groups were defined according to previous literature: <40 years, 
40-60 years and >60 years. The clinicopathological scoring system was created in the his-
toric cohort (N=181 for prediction of 3- and 5- year survival); N=124 for prediction of 10 year 
survival) for prediction of 3-year, 5-year and 10-year overall graft survival (Table 6). Then 
the predictive performance of this novel scoring system was tested in the validation cohort 
(N=367 for prediction of 3-year survival); N=145 for prediction of 5-year survival). 
As was predicted from the univariate association between the individual parameters and 
graft survival, all 3 newly created “Leuven Donor Risk Scores” (for prediction of 3, 5 or 10 
year survival) were highly significantly associated with graft survival. ROC analysis on the 
validation cohort showed for “Score 1”=4ct+gs+3age+1.5ci (3 year survival) an area under 
the curve of 0.64 (p= 0.03), for Score 2 = 8ct+2gs+11age+ci/2 (5 year survival) an area under 
the curve of 0.75 (p< 0.0001). (Table 6, Figure 5B). Based on the best performing algorithm 
(Leuven Donor Risk Score ‘8ct+2gs+11 Age+ ci), a “Leuven Donor Risk Score” > 37 had a 
specificity of 95% for prediction of graft loss by 5 years after transplantation (sensitivity 
28%). A “Leuven Donor Risk score” > 35 had a specificity of 92% for prediction of graft loss 
by 5 years after transplantation (sensitivity 40%). (Figure 5A). 
To further elucidate the complex relations between donor demographics and baseline 
histology, principal component analysis was applied. The summery plot is presented in 
Figure 3. This analysis illustrates the dichotomy in the histological lesions of implantation 
biopsies: a cluster with glomerulosclerosis, tubular atrophy and interstitial fibrosis, which 
correlate with donor age; and a second cluster vascular intimal thickening and arteriolar 
hyalinosis which correlate with donor smoking, donor diabetes mellitus and donor history 
of hypertension. 
Histological scoring systems for baseline biopsies and prediction 
of graft survival 
As was expected from the significant association between the individual histological le-
sions and death-censored graft survival, there was a highly significant association be-
tween each of the previously published histological scoring systems and death-censored 
graft survival in Cox proportional hazards analysis. The score that best associated with 
graft outcome was the score proposed by Lopes et al.14 (Table 5, Figure 4). The area under 
the ROC curve was largest for the score proposed by Remuzzi for prediction of 3-, 5- and 
10-year graft survival (Table 5). None of the previously proposed scoring systems however 
reached an area under the ROC curve higher than 0.62. 
 Algorithm obtained  Historic cohort Validation cohort
 from logistic regression 
 analysis on historic  AUC under P-value AUC under P-value
 cohort roC curve  roC curve 
Score 1 (3 year prediction) Age + 2 gs + 10 ifta 0.65 0.03 0.70 0.01
Score 2 (“Leuven Donor  Gs + 3 ifta + Age 0.67 0.002 0.81 < 0.0001
Risk Score”; 5 year prediction) 
Score 3 (10 year prediction) 1.5 Age +  14 gs + ifta 0.60 0.05 -- --
Table 6 — Predictive performance of the newly created clinicopathological “Leuven Donor Risk Score”. Logistic re-
gression analysis was performed on the historic cohort (N=181 for 3- and 5-year survival; N=124 for 10-year survival) to 
construct a predictive algorithm for graft survival at 3, 5 and 10 years after transplantation. This algorithm was then 
applied to the validation cohort (N=367 for 3-year survival); N=145 for 5-year survival). Gs = glomerulosclerosis score 
(gs<10%=0; gs>10%=1); ifta grade according to Banff classification.
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Previously, application of the “Remuzzi score” was proposed for deciding between single 
or dual transplantation, and proved to be beneficial for graft outcome.6 This study clearly 
demonstrated the benefit of dual kidney transplantation in case of high degree of chronic 
damage in the pretransplant biopsy. In our cohort, dual transplantation was not routinely 
performed. Moreover only a minority of our donors are older than 60, and only a small pro-
portion of our baseline biopsies had a Remuzzi score > 7. Therefore, the approach proposed 
by Remuzzi et al., to use baseline biopsy histology for deciding between dual and single 
kidney transplantation, cannot be evaluated in the current study. Taken together with our 
current findings however, it is clear that kidneys with chronic histological damage, from an 
older donor, should be evaluated before use for a single kidney transplantation. Whether 
these kidneys with high scores should be used for dual kidney transplantation or should be 
discarded, remains a topic of discussion.
In the current study, we demonstrated that arteriolar hyalinosis and vascular intimal thick-
ening in baseline biopsies did not associate with impaired long-term allograft survival. This 
finding contrasts with previous studies that showed that vascular luminal narrowing >25%13 
and arteriolar hyalinosis15 are independent predictors of graft failure. Four other studies 
however did not find any association of vascular intimal thickening and arteriolar hyalino-
sis with graft function at 12 months.11-13 The reason for these discrepancies could be found 
in the relatively low number of baseline biopsies with vascular intimal thickening in the 
current study, and selection bias by kidney discard based on these lesions in other studies 
(which was not present in the current study). In addition, the study of Munivenkatappa and 
the derivation of the Maryland Aggregate Pathology Index15 were partly based on biopsies 
imported from other OPO’s, after rejection of the kidneys by other local centers. This back-
ground could also have affected the results of this previous study. 
Clearly, our findings are subject to several limitations. Not all patients were treated with the 
same immunosuppressive regimen and all the patients included in the historic cohort re-
ceived an outdated regimen. However, when applying the scoring systems in a more recent 
validation cohort treated with more modern immunosuppression, more representative for 
current clinical practice, the results were similar. In addition, although donor clinical de-
mographics were collected prospectively, many parameters that could be of importance 
had not been recorded systematically, like history of cardiovascular events. In addition, the 
specific setting of deceased donor donation also leads to underreporting of medical risk 
factors like smoking status and hypertension. Vascular intimal thickening was relatively 
rare in the current study, and low numbers could partially be responsible for absence of 
association of this parameter with graft outcome. Furthermore, an important drawback 
to compare our data with previous data is that were not able to evaluate the MAPI score15 
Discussion
In the current study we evaluated the impact of baseline histological lesions and donor 
characteristics on the renal allograft survival, and demonstrated that global glomerulo-
sclerosis and interstitial fibrosis/tubular atrophy were significantly associated with im-
paired graft outcome, independent on baseline donor demographics like donor age and 
stroke as reason of donor death. Other lesions, like arteriolar hyalinosis and vascular inti-
mal thickening (which were closer related to donor history of hypertension, stroke, diabe-
tes mellitus and smoking), did not associate with graft survival. None of the histological 
scoring systems previously proposed by other groups7,14,16 sufficient prognostic value when 
applied on our cohort, while newly created clinicopathological algorithm for prediction of 
graft outcome provided better predictive accuracy to be used for donor kidney discard or 
acceptance. 
Previous studies already revealed that donor age and the histology of the graft at time of 
transplantation are major determinants of graft function. Anglicheau et al. showed that 
glomerulosclerosis at time of transplantation predicts low eGFR at 1-year post transplant8. 
Also Arias et al. demonstrated that glomerulosclerosis, interstitial fibrosis, tubular atrophy 
and arteriolar hyalinosis in implantation biopsies predicted eGFR at 3 years post-trans-
plant.9 Although previous studies showed that post- transplant renal function in the first 
year predicts long-term kidney transplant survival19, graft function at 1 year is unlikely to 
be the major endpoint that needs to be correlated with baseline findings, to decide whether 
to accept or discard a donor graft. Therefore, studies correlating baseline histology with 
graft survival serve as a better basis for guiding kidney allocation. 
Importantly, in the current study, baseline biopsies were not used to refuse a donor kidney. 
The current study thus represents an ideal setting to study the predictive performance of 
baseline biopsies for graft outcome. The validity of previous studies is indeed hampered by 
the inherent selection bias present in these studies, as the clinical transplant centers that 
analysed the predictive capacity of baseline histology for graft survival, discard kidneys 
based on histological lesions5, and can thus only evaluate histological risk factors in kid-
neys that were actually selected for transplantation. 
In the current study, the predictive performance of previously published and widely used 
histological scoring systems was insufficient to use any of these scoring systems for kidney 
discard or acceptance. Notwithstanding this, we demonstrated that it is possible to create 
a scoring system with sufficient predictive performance to guide clinical decisions at time 
of transplantation. Our newly constructed scoring system reaches 95% specificity for graft 
failure within the first 5 years after transplantation, if 37 is used as cut off. The predictive 
performance of our new scoring system is sufficient to promote incorporating systematic 
baseline biopsy scoring for kidney allocation purposes. 
62   The predictive value of kidney allograft baseline biopsies The predictive value of kidney allograft baseline biopsies   63
Conclusion
In conclusion, our study demonstrates that donor age and the histology of the graft at 
time of transplantation are major determinants of long-term graft outcome. In our cen-
tre, baseline biopsies are not systematically used for donor kidney allocation. The current 
cohorts thus represent an ideal study cohort, as selection bias is avoided. Based on the 
finding that age-associated histological lesions (interstitial fibrosis/tubular atrophy and 
glomerulosclerosis) are highly significant predictors of survival we have created a novel 
scoring system with these parameters. The predictive performance of the previously pro-
posed scoring systems proved to be poor in our cohort. In contrast, our newly constructed 
scoring system provided sufficient predictive performance to guide kidney allocation or 
discard in kidneys from older donors.
in our biopsy cohort. The ROC curve performed on the Maryland validation cohort had an 
AUC=0.74, which is similar to the performance of any of the newly created score tested in 
our validation cohort. However, application of the MAPI score at time of transplantation 
is cumbersome in many transplant centers, as morphometric analysis is not universally 
available. Finally, it has to be acknowledged that the reproducibility of histological scoring 
is known to be at best moderate20, and that sampling error is inherent to any biopsy study. 
For this reason, all biopsies were obtained in a comparable fashion (wedge biopsies), and 
one single pathologist, blinded for any clinical information, has rescored all biopsies retro-
spectively. Despite these measures, sampling error and intra-observer variability are still 
possible, and could account for the absence of association between arteriolar hyalinosis 
and vascular intimal thickening, which often have a patchy distribution and are known the 
be less reproducible than the other Banff qualifiers.21 Also the use of wedge biopsies in our 
cohort could be a possible explanation for the lack of significant association between vas-
cular intimal thickening and graft outcome in the current study, as it was shown previously 
that core biopsies are superior to wedge biopsies to evaluate this lesion.22
A standardized, more objective evaluation of biopsies, either by morphometric analysis, or 
by molecular profiling, could yield a better tool for assessment of organ quality and predic-
tion of organ survival after transplantation.23,24,25 
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3.1
Telomere length, cardiovascular risk  
and arteriosclerosis in human kidneys:  
an observational cohort study
Abstract
Background
Replicative senescence, associated with telomere shortening, plays an important 
role in aging and cardiovascular disease. The relation between telomere length, 
cardiovascular risk, and renal disease is unknown.
Methods 
Our study consisted of cohort of 257 kidney donors for transplantation, divided into 
a test and a validation cohort. We used quantitative RT-PCR to measure relative 
telomere length (log T/S ratio) in peripheral blood leucocytes, and in kidney biopsies 
performed prior to implantation. The association between leucocyte and intrarenal 
telomere length, and renal histology, was studied using multiple regression models, 
adjusted for calendar age, gender and other donor demographics.  
results
Subjects with intrarenal arteriosclerosis had significantly shorter leucocyte telomere 
length compared with patients without arteriosclerosis (log T/S ratio -0.3±0.4 vs. 
0.1±0.2 with vs. without arteriosclerosis; p=0.0008). Intrarenal arteriosclerosis was 
associated with shorter telomere length, independent of gender, calendar age, his-
tory of hypertension and history of cardiovascular events. For each increase of one 
standard deviation of the log T/S ratio, the odds for intrarenal arteriosclerosis de-
creased with 64% (Odds ratio 0.36; 95% CI 0.17-0.77; p=0.02). In accordance with 
leucocyte telomere length, shorter intrarenal telomere length associated significant-
ly with the presence of renal arteriosclerosis (log T/S ratio -0.04±0.06 vs. 0.08±0.01 
with vs. without arteriosclerosis, p=0.007), and not with other histological lesions. 
interpretation
We demonstrate that arteriosclerosis in smaller intrarenal arteries is associated with 
shorter telomere length. Our study therefore suggests a central role of replicative 
senescence in the progression of renovascular disease, independent of calendar 
age.
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Methods
inclusion and Exclusion Criteria
All prospective deceased donors of a single kidney transplant in adult recipients, which 
were performed between March 2004 and December 2010 at the University Hospitals 
Leuven (Leuven, Belgium), were eligible for Cohort 1 of this study. Since March 2004, kidney 
grafts undergo routine biopsies prior to implantation (N=352). In Cohort 2, donor kidneys 
transplanted after November 2012 were biopsied prior to implantation, and were used for 
evaluation of intrarenal telomere length (N=40). This study was approved by the Ethics 
Committee/Institutional Review Board of the University Hospitals Leuven, Leuven, Bel-
gium (OG032; ML7499 and ML9785; clinicaltrials.gov NCT01331668).  
Clinical Data Collection
Clinical data were obtained from the Eurotransplant database (“Eurotransplant Donor Re-
port”), which is maintained prospectively and is the central source of donor data for organ 
transplantation in the Eurotransplant region (www.donordata.eu). The following data were 
collected: calendar age, gender, cause of death, weight and length, living vs. deceased do-
nor, brain death vs. cardiac death donor, body mass index, history of hypertension, diabe-
tes mellitus, smoking, history of cardiovascular events prior to donation (including reason 
for death in deceased donors) and terminal serum creatinine levels before organ recov-
ery. Renal function was estimated by the 4-variable Modification of Diet in Renal Disease 
(MDRD) equation (estimated glomerular filtration rate; eGFR).19 
Kidney Biopsies and Histologic evaluation
One pathologist (EL) reviewed all pre-implantation kidney biopsies, without knowledge of 
any demographic information of the kidney donor. The biopsy specimens were wedge bi-
opsies with slides containing 4 to 10 paraffin sections (2 μm) that were stained with hema-
toxylin eosin, periodic acid–Schiff, and a silver methenamine staining method (Jones). The 
severity of histologic lesions, interstitial fibrosis (Banf “ci” score), tubular atrophy (Banf “ct” 
score), arteriolar hyalinosis (Banf “ah” score) and arteriosclerosis (Banf “cv” score = vascular 
fibrous intimal thickening = intimal hyperplasia), were scored semiquantitatively according 
to the Banff criteria.20 In addition, the total number of glomeruli in each biopsy, and the 
number of globally sclerosed glomeruli, were calculated separately. Only biopsies with >10 
glomeruli (A quality) were included for evaluation of glomerulosclerosis. 
telomere Length in Peripheral Blood Leucocytes
Peripheral blood samples for DNA extraction from leucocytes were routinely obtained 
from the donors at time of organ recovery. DNA was extracted using the simple salt-
ing out procedure for extracting DNA from human nucleated cells as described by S.A. 
Miller.21 Both DNA yield (ng/μL) and purity ratios A260/280 and A260/230 were deter-
Introduction
Cellular or replicative senescence, associated with telomere shortening is considered as one 
of the most important drivers of aging.1 This phenomenon leads to permanent and irre-
versible growth arrest.2 Telomeres comprise tandem TTAGGG repeats of 5000 to 15000 
base pairs that reside at the ends of chromosome ends. Their main function is to cap these 
chromosome ends and prevent chromosomal instability.3 Although telomere length is reg-
ulated by telomerase, telomeres tend to progressively shorten with every cell division.4,5
Although telomere length is partly heritable6 there are major differences in telomere length 
even among monozygotic twins, which illustrates that environmental factors play a major 
role in telomere attrition. Due to their high content of guanines, telomeres are highly sensi-
tive to oxidative-induced damage.7 Accelerated shortening of telomeres or senescence of 
cells is an important pathway by which oxidative stress accelerates biological aging and 
age-related diseases like atherosclerosis and cardiovascular disease.8,9 Obesity and smok-
ing are associated with leucocyte telomere attrition, as well as hypertension, insulin resist-
ance and diabetes, male gender and lower socioeconomic status.6,10-16
In contrast to studies that evaluated the determinants of telomere shortening and associa-
tion with disease risk, the relation between telomere shortening and organ histology was 
only studied scarcely. In kidneys, the histology and function deteriorates with increasing 
age. Animal studies and in vitro data suggested that replicative senescence plays a crucial 
role in this deterioration of renal histology and function.17 These findings have however 
not been validated in humans, except for a small study where intrarenal telomere length 
did not associate with renal histology.18 Moreover, the association of telomere length with 
non-diseased organ histology has not been evaluated in other organ systems, despite the 
central role of telomere shortening and replicative senescence in aging. Finally, the correla-
tion between telomere length measured in organ tissue, and peripheral blood leucocyte 
telomere length remains currently unclear. 
Therefore, we evaluated the association between renal histology, leucocyte and intrarenal 
telomere length, cardiovascular risk factors and calendar age, in a cohort of kidney donors 
for transplantation. 
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telomere Length in Kidney Biopsies
Since November 2012, next to the wedge biopsy that was used for histological evaluation, 
a full renal cortical biopsy core was obtained prior to implantation, and immediately stored 
in Allprotect Tissue Reagent (Qiagen, Venlo, The Netherlands) solution, until extraction. 
DNA extraction was performed by the Allprep DNA/RNA/miRNA Universal Kit (Qiagen, 
Venlo, The Netherlands) on a QIAcube instrument (Qiagen, Venlo, The Netherlands). Tel-
omere length in renal tissue samples was measured by a modified version of the protocol 
for the peripheral blood samples. Telomere length was measured as the telomere repeat 
copy number relative to a single gene nuclear control genes (36B4). The telomere reaction 
mixture contained 1x Qiagen Quantitect Sybr Green Mastermix 2.5 mM of dithiothreitol, 
300 nM of telomere forward primer (5’-ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGT-
TAGTGT-3’), and 900 nM of telomere reverse primer (5’- TGTTAGGTATCCCTATCCCTATCC-
CTATCCCTATCCCTAACA-3’). The PCR ran for 1 cycle at 95°C for 10 min for activation of the 
DNA polymerase, followed by 2 cycles of 15 sec at 94°C and 2 min at 49°C, and 30 cycles of 
15 sec at 94°C, 20 sec at 62°C and 1 min 40 sec at 74°C. All 40 biopsies included in Cohort 2 
passed quality control for assessment of intrarenal telomere length.
Statistical Analysis
Differences between groups were analyzed using parametric or non-parametric one-way 
ANOVA. Associations between the clinical demographics, telomere length and renal histol-
ogy were assessed by means of linear or logistic regression analysis, as appropriate, as 
well as with principal component analysis. From the principal component analysis, a two-
dimensional scatter plot was generated to represent the histologic lesions according to their 
score in the loading matrix. Multiple linear and binomial logistic regressions, with backward 
parameter selection, were used to model the determinants of telomere length. For back-
ward parameter selection, the following variables were considered for entry into the model 
for the determinants of telomere length: calendar age, gender, history of hypertension, his-
tory of diabetes mellitus and body mass index, history of cardiovascular events, living vs. 
deceased donor, brain-death vs. cardiac death, ischemic stroke as reason for death, hem-
orrhagic stroke as reason for death and renal function (eGFR (mL/min/1.73m2). The asso-
ciations between calendar age, telomere length and the different histological lesions were 
adjusted for gender and history of cardiovascular events in the multiple logistic regression 
analyses. All tests were two-sided and p values of less than 0.05 were considered to indi-
cate statistical significance. The results are expressed as numerical values and percentages 
for categorical variables and as mean ± standard deviation for continuous variables, un-
less otherwise specified. Analyses were done with SAS (version 9.2; SAS institute, Cary, NC), 
JMP9.0 (SAS institute, Cary, NC) and GraphPad Prism (version 5.00; GraphPad Software, 
San Diego, CA) software. 
mined and needed to be within strict quality limits (yield 50 ng/μL; purity ratio range 
1.5-2 and 1.5-2 for A260/280 and A260/230, respectively) for inclusion of the samples 
in the study. Extracted DNA samples were stored at -80°C until further use. Leucocyte 
telomere length was measured as the telomere repeat copy number relative to two sin-
gle gene nuclear control genes (36B4 and ACTB), by a modified version of a previously 
described PCR based assay.22 20The forward and reverse primers were 5’-ACACTAA-
GGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT-3’ and 5’- TGTTAGGTATCCCTATCCCTA-
TCCCTATCCCTATCCCTAACA-3’, respectively. The forward and reverse primers for the 
reference genes were respectively 5’-ACTCTTCCAGCCTTCCTTCC-3’ and 5’-GGCAGGACT-
TAGCTTCCACA-3’ for ACTB, and 5’-GGAATGTGGGCTTTGTGTTC-3’ and 5’-CCCAATT-
GTCCCCTTACCTT-3’ for 36B4. The telomere reaction contained Fast SYBR® Green I dye 
2x (Applied Biosystems, Lennik, BE) mastermix, forward (100 nM) and reverse (900 nM) 
primer and 12.5 ng DNA. The telomere reactions were performed in triplicate. The thermal 
cycling profile for the telomere reaction consisted of following steps: 20 sec at 95°C, 2 cy-
cles of 15 sec at 94°C and 15 sec at 49°C and 40 cycles of 15 sec at 94°C, 10 sec at 62°C and 
15 sec at 74°C. For the reference genes a 10 μl PCR reaction contained Fast SYBR® Green 
I dye 2x (Applied Biosystems, Lennik, BE) mastermix, forward (10 μM) and reverse (10 μM) 
primer and 12.5 μg DNA. Reactions were run in duplicate. Amplification specificity and ab-
sence of primer dimers was confirmed by melting curve analysis at the end of each run. 
Each PCR-plate contained two inter-run calibrators and two no-template controls. For the 
telomere assay, reference sample were included, one with relative short telomeres and one 
with relative long telomere. After thermal cycling, raw data were collected and processed. 
Cq-values of telomere were normalized relative to the two reference genes using the qBase 
software (Biogazelle, Zwijnaarde, BE). The program uses modified software from the clas-
sic comparative CT method (ΔΔ CT) that takes into account multiple reference genes and 
uses inter-run calibration algorithms to correct for run-to-run differences.23 Coefficient of 
variation for telomeres was 2.6%, for reference genes 1.6% and for the T/S ratio less than 7%. 
The corresponding numbers for tissue samples were less than 1% for telomeres and refer-
ence genes and 5% for the T/S ratio. Although this assay provides a relative measurement 
of telomere length, T/S ratios correlate well with absolute telomere lengths determined by 
Southern blot (r= 0.89, N= 20)24. Of the 352 consecutive kidney donors that were eligible 
for Cohort 1, 217 peripheral blood samples were included; one hundred thirty-five samples 
were not evaluated, either due to insufficient amount of leucocytic DNA available, or due to 
insufficient DNA quality for reliable telomere assessment. Accelerated biological aging was 
evaluated by calculating delta (Δ) biological age - calendar age. Δ (range -3 – 3) was calcu-
lated using the difference of quartile telomere length (0 = longer telomere length, 3 = short-
est telomere length) - quartile calendar age (0 = youngest age group, 3 = oldest age group).
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Results
Population characteristics 
Cohort 1 consisted of 217 unique kidney donors with sufficient amount of good-quality leu-
cocytic DNA available for evaluation of telomere length. In this cohort, 144 kidney pre-
implantation kidney biopsies were available for histological evaluation. Fourteen biopsies 
were of insufficient quality according to the Banff 1997 criteria, leaving 130 baseline biop-
sies for histological analysis. On average, 24.0±16.7 glomeruli were obtained per biopsy 
(range, 10-89). 
Cohort 2, for evaluation of intrarenal telomere length, consisted of 40 kidney donors. Of 
these 40 subjects, good-quality DNA from leucocytes was available for 32 subjects and 
good-quality DNA derived from biopsies was available for all 40 kidneys. All 40 biopsies 
included in this cohort were of sufficient quality according to the Banff 1997 criteria for his-
tological evaluation. 
Table 1 summarizes the characteristics of these two cohorts and the histology of the bi-
opsies that were included. Kidney function, expressed as eGFR, was 89.7 ± 40.9 (range 
42.3-189.3) mL/min/1.73m2 in Cohort 1 and 114 ± 42.0 (range 60.8-197.2) mL/min/1.73m2 in 
Cohort 2, respectively. 
Figure 1 — Relation between (A) leucocyte telomere length and renal arteriosclerosis in Cohort 1 (N=130) and be-
tween (B) intrarenal telomere length and renal arteriosclerosis in Cohort 2 (N=40). The p-values represent non-par-
ametric ANOVA. The horizontal lines within the boxes indicate means, the upper and lower ends of the boxes indicate 
standard deviations, and the whiskers indicate 95th percentiles.
Table 1 — Demographics and histology the subjects and biopsies included in this study. Data are expressed as mean 
± standard deviation unless otherwise specified; &N=30; #eGFR was calculated using the MDRD formula.19,35
 Cohort 1 Cohort 2
N 217 40
Leucocyte Telomere Length (log T/S ratio) 0.05 ± 0.20 0.07 ± 0.09&
Intrarenal Telomere Length (log T/S ratio) —  -0.08 ± 0.12
Calendar Age (years) 44.4 ± 15.0 48.1 ± 15.0
Male Gender % (N) 55.3 % (120) 57.5%
Deceased Donor % (N) 97.7% (212) 90.0% (36)
Brain Death / Cardiac Death  86.8%(184)/13.2%(28) 72.2 %(26)/33.3%(10)
Ischemic Stroke as Reason for Death % (N) 3.2% (7) 10% (4)
Hemorrhagic Stroke as Reason for Death % (N) 43.8% (95) 22.5% (9)
History of Hypertension % (N) 24.7% (44/178) 37.5% 
History of Diabetes Mellitus % (N) 1.8% (4) 8.3% (3)
History of Smoking % (N) 30.5% (54/177) 37.5% 
Body Mass Index (kg/m2) 24.9 ± 5.5 25.6 ± 5.5
History of Cardiovascular Events % (N) 13.9% (14) 12.5% (5)
Serum Creatinine (mg/dl) 0.89 ± 0.3 0.88 ± 0.23
eGFR (mL/min/1.73m2)# 89.7 ± 40.9 114.0 ± 42.0
Renal Function (1/creatinine) 1.4 ± 0.8 1.2 ± 0.4
Presence of Arteriolar Hyalinosis % (N)* 30.8% (40/130) 10.0% (4)
Presence of Interstitial Fibrosis % (N) * 25.4% (33/130) 27.5% 
Presence of Tubular Atrophy % (N)* 50.0% (65/130) 62.5% (25)
Presence of Arteriosclerosis % (N)* 7.7% (10/130) 10.0% (4)
Presence of >10% Glomerulosclerosis% (N)* 15.4% (20/130) 20.0% (8)
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Leucocyte telomere Length, Clinical Demographics and renal Histology
In Cohort 1, arteriosclerosis in renal biopsies significantly associated with shorter leucocyte 
telomere length (log T/S ratio -0.3±0.4 vs. 0.1±0.2 in subjects with vs. without renal arte-
riosclerosis; p=0.0008 (Figure 1B and Table 3). For one standard deviation increase of the 
log T/S ratio, independent of calendar age, gender and history of cardiovascular event, the 
odds of renal arteriosclerosis decreased by 64% (Odds ratio 0.36; 95% CI 0.17-0.77; p=0.02). 
Moreover, arteriosclerosis in renal biopsies significantly associated with Δ biological age - 
calendar age (r=0.3; p=0.005). 
Interstitial fibrosis, tubular atrophy, glomerulosclerosis and arteriolar hyalinosis did not as-
sociate with leucocyte telomere length. These histological lesions associated significantly 
with calendar age: for each 10 years increase in calendar age, the odds for interstitial fibro-
sis, tubular atrophy and glomerulosclerosis increased by 79%, 208% and 63%, respectively 
(Table 3).
To further describe the complex relations between calendar age, leucocyte telomere length 
and renal histology, principal component analysis was performed. The summery plot is 
presented in Figure 2A. This analysis illustrated a dichotomy in the correlation between the 
histological findings and telomere length versus calendar age. Glomerulosclerosis, tubular 
atrophy, interstitial fibrosis and arteriolar hyalinosis clustered with calendar age, while ar-
teriosclerosis clustered with leucocyte telomere length. 
intrarenal telomere Length, Clinical Demographics and renal Histology
In Cohort 2, mean T/S ratio of intrarenal telomere length was 0.07±0.09 (range -0.16-0.24). 
Intrarenal telomere length correlated significantly with leucocyte telomere length (r=0.4, 
p=0.001). Shorter intrarenal telomere length associated with history of hypertension (log 
T/S ratio 0.04±0.02 vs. 0.10±0.02 with vs. without hypertension; p=0.05), but not with oth-
er demographics. Multivariate linear regression analysis was not performed in this smaller 
cohort to avoid overfitting of the data. 
In this cohort, shorter intrarenal telomere length associated significantly with the presence 
of arteriosclerosis (log T/S ratio -0.04±0.06 vs. 0.08±0.01 with vs. without arteriosclerosis, 
p=0.007)(Figure 1B). Intrarenal telomere length did not associate with any other histologi-
cal parameter. 
Principal component analysis was applied to further describe the complex relation be-
tween calendar age, renal histology, leucocyte telomere length and renal telomere length. 
The summery plots are presented in Figure 2B. This independent analysis confirmed the 
Calendar Age, Clinical Demographics and Leucocyte telomere Length
Mean log T/S ratio of telomere length was 0.05±0.25 (range -0.95 to 0.71). Leucocyte tel-
omere length was inversely correlated with older calendar age (r=-0.2, p=0.005) (Table 2). 
History of hypertension vs. no hypertension and history of cardiovascular events vs. no 
history were also associated with shorter telomere length. Women had longer telomere 
length. Other clinical demographics, including history of diabetes mellitus, history of smok-
ing, living versus deceased donation, brain death vs. cardiac death, ischemic and hemor-
rhagic stroke as reason for donor death, body mass index, and eGFR were not associated 
with leucocyte telomere length. In multivariate linear regression analysis, older calendar 
age, history of cardiovascular events, male gender and history of hypertension were inde-
pendent explanatory factors for shorter telomere length (Table 2). 
Table 2 — Clinical determinants of leucocyte telomere length (log T/S)  (N=217). Univariate analyses were assessed by 
linear regression. Multiple linear regression, with backward parameter selection, was used to model the determinants 
of telomere length. Multivariate analyses presented in this table were performed on 177 subjects, as history of hyper-
tension and smoking status were not available in 40 cases. When we included all 217 subjects of Cohort 1 in the mul-
tivariate models, by excluding the covariate history of hypertension from the analysis, the independent associations 
between telomere length and donor age (p=0.003), history of cardiovascular events (p=0.02), and gender (p=0.002) 
remained statistically significant. * These parameters were included in the multivariate models, but were not retained 
in the final model after backward parameter selection. ** Effect sizes (SE) express the change in log T/S ratio associ-
ated with given changes in parameters.
 Univariate linear regression Multivariate linear regression
Parameter  Parameter  Standard P value Parameter Standard P value
 estimate Error  estimate Error 
Donor age (years) -0.01 0.001 0.005 -0.003 0.002 0.02
Heart Beating Donor/Non Heart  
Beating Donor* -0.01 0.05 0.85   
Living Donor/Deceased Donor* -0.12 0.12 0.29   
Ischemic Stroke as Reason for Death* 0.15 0.1 0.12   
Hemorrhagic Stroke as Reason for Death* 0.02 0.03 0.57   
History of Hypertension -0.12 0.04 0.009 -0.13 0.06 0.02
History of Diabetes Mellitus* -0.01 0.003 0.44   
History of Smoking* 0.01 0.04 0.91   
Body Mass Index (kg/m2) * -0.002 0.003 0.44   
History of Cardiovascular Events -0.13 0.07 0.06 -0.21 0.09 0.01
eGFR (mL/min/1.73m2) *  0.00 0.00 0.58   
Gender (Female) 0.08 0.04 0.02 0.1 0.04 0.02
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Discussion
Our analysis of a cohort of prospectively collected native kidney biopsies illustrates that 
shorter telomere length (biological aging) associates with the presence of renal arterio-
sclerosis, but not with changes in the glomerular or tubulo-interstitial renal compartments. 
This association was independent of calendar age, gender, history of hypertension, and 
history of cardiovascular events, demographics all associated with telomere length. Our 
findings using leucocyte telomere length were confirmed in an independent validation co-
hort where telomere length was measured in intrarenal tissue.
The current study illustrated that intrarenal arteriosclerosis is associated with telomere 
length, independent of cardiovascular risk factors, history of cardiovascular disease and 
calendar age. Moreover, accelerated aging by means of the difference between biological 
age (telomere shortening) and calendar age associated highly significantly with intrare-
nal arteriosclerosis. This suggests a central role of telomere shortening or biological ag-
ing in the development renal arteriosclerosis and intimal hyperplasia. This finding could 
explain the previously observed association between shorter telomere length and clinical 
cardiovascular disease, also present in our study.8,12,25 Intimal hyperplasia is the universal 
response of a vessel to injury, like repeated hemodynamic stress on the endothelium. The 
increased rate of cell turnover in regions with hemodynamic stress has been associated 
with accelerated telomere attrition and with endothelial cell senescence, which further con-
tributes to endothelial dysfunction and intimal hyperplasia.26-29 Moreover the senesence 
associated secretory phenotype of senescence cells causes a full range of autocrine and 
paracrine activities, aimed at tissue repair but also fueling degenerative and proliferative 
changes contributing to arteriosclerosis.8 Injury-induced intimal hyperplasia underlies the 
pathogenesis of major cardiovascular diseases.30 Next to hemodynamic stress that could 
lead to telomere attrition and intimal hyperplasia, also oxidative stress could be implicated 
in the pathogenesis of senescence-associated intimal hyperplasia. Oxidative damage is 
repaired less well in telomeric DNA than elsewhere in the chromosome, which leads to ac-
celerate telomere loss.31 On the basis of animal studies, a role for reactive oxygen species 
in intimal hyperplasia has been proposed.30 Taken together, these data provide an expla-
nation for the association we observed between shorter telomere length and renal arterio-
sclerosis (intimal hyperplasia). 
In addition, the current study confirmed our previous data showing that older calendar 
age associates with chronic injury in the tubulointerstitial (tubular atrophy and interstitial 
fibrosis) and glomerular (glomerulosclerosis) renal compartments, while cardiovascular risk 
factors, cardiovascular disease and telomere length did not associate with these lesions.32 
It could therefore be hypothesized that these age-associated lesions represent accumula-
tion over time of events that contribute to renal injury and thus represent a very different 
dichotomy in the correlation between the histological findings and telomere length versus 
calendar age, and the significant association between intrarenal telomere length and pres-
ence of renal arteriosclerosis. 
Figure 2 — Principal component analysis using the individual histological lesions in kidney biopsies and telomere 
length in (A) Cohort 1 in (B) Cohort 2. This two-dimensional scatter represents the histologic lesions according to 
their score in the loading matrix of a principal components analysis that included the different histological lesions, 
together with calendar age and telomere length. These analyses illustrated a dichotomy between the histological le-
sions associated with calendar age and the histological lesions associated with biological age. Calendar age (Age) are 
glomerulosclerosis (gs), tubular atrophy (ct), interstitial fibrosis (ci) and arteriolar hyalinosis (ah). Arteriosclerosis lesions 
(cv) clustered with biological age [leucocyte and renal telomere length (TL; log T/S ratio)]. PC1 = Principal Component 
1; PC2 = Principal Component 2. 
Table 3 — Association between the histological lesions in kidney biopsies, leucocyte telomere length and calendar 
age (N=130). Univariate and multiple logistic regression analyses were used to model the determinants of the different 
histological lesions. In multivariate analysis, we included calendar age and telomere length and adjusted for history of 
cardiovascular events and gender. When we also included the covariate history of hypertension in the analysis multivari-
ate analysis (N=109), the independent association between telomere length and renal arteriosclerosis (Odds ratio 0.34; 
95% CI 0.17-0.93; p=0.03) remained statistically significant. *Odds ratios for telomere length are calculated per increase 
of 1 standard deviation of log T/S ratio. °Odds ratios for calendar age are given per 10 years increase. ns = not significant
  telomere length* Calendar age°
Arteriolar Hyalinosis Univariate OR=0.90 (0.61-1.34); p= 0.61 OR=1.48 (1.14-1.97); p= 0.02
 Multivariate ns OR=1.49 (1.07-2.08); p= 0.02
interstitial fibrosis Univariate OR=0.90 (0.60-1.34); p=0.58 OR=1.79 (1.22-2.37); p= 0.0002
 Multivariate ns OR=1.79 (1.23-2.62); p= 0.002
tubular Atrophy Univariate OR=0.89 (0.62-1.28); p= 0.54 OR=1.97 (1.48-2.84); p< 0.0001
 Multivariate ns OR=2.08 (1.48-2.94); p< 0.0001
Arteriosclerosis Univariate OR=0.36 (0.32-0.77); p= 0.008 OR=3.70 (1.22-12.8); p= 0.03
 Multivariate OR=0.36 (0.17-0.77); p=0.02 ns
glomerulosclerosis Univariate OR=0.93 (0.56-1.51); p= 0.77 OR=1.63 (1.10-2.37); p= 0.02
 Multivariate ns OR=1.63 (1.10-2.59); p=0.0006
78   Identification and definition of the renal senescence marker panel Identification and definition of the renal senescence marker panel   79
tion represents a missing link between cell and animal model studies associating telomere 
attrition with cardiovascular risk factors, and clinical studies associating telomere attrition 
with cardiovascular end points. Further study is necessary to elucidate whether telomere 
attrition plays a causal role in renal arteriosclerosis or is merely a sensor of other factors 
that lead to arteriosclerosis, and whether telomere attrition associates with histology of 
arteriosclerosis also in other organs. 
etiology. In contrast, senescence could be regarded as a more specific process that repre-
sents oxidative stress, endothelial dysfunction and arteriosclerosis and therefore contrib-
utes to the pathogenesis of cardiovascular disease. The differential association of calen-
dar age versus telomere length with respectively glomerulosclerosis and tubulo-interstitial 
injury, versus renal arteriosclerosis, illustrates a robust dichotomy within the phenotype of 
“nephrosclerosis”, the primary structural findings of the aging kidney on light microscopy. 
Moreover, we confirmed an association between hypertension, history of cardiovascular 
disease and shorter telomere length.11,12,33 These associations however do not prove cau-
sality. On one hand, telomere attrition and cardiovascular disease could be caused by 
common risk factors (smoking, hypertension, high total cholesterol level, obesity, physical 
inactivity), which contribute to inflammation and oxidative stress, and from this to acceler-
ated telomere attrition.12 On the other hand, hypertension could increase hemodynamic 
stress and herewith associated telomere attrition.28 Finally, a prior study in a telomerase 
knockout mice model illustrated that short telomere length could even be the cause of hy-
pertension, rather than its consequence.26
Our study has some limitations. Although donor clinical demographics were collected pro-
spectively, some kidney donor parameters that could be of importance could have been 
recorded incompletely. This could explain the lack of association between telomere short-
ening and smoking in our study, and between telomere shortening and diabetes mellitus, 
as was described previously.10,15 The fact that the number of patients with histological le-
sions was relatively small in this cohort, indicates that we might not have had precision in 
our point estimates. Finally, it has to be acknowledged that the reproducibility of semi-
quantitative histologic scoring of kidney biopsies is moderate at best, and that sampling 
error is inherent to any biopsy study. For this reason, all biopsies were obtained in a stand-
ardized fashion (wedge biopsies), and one single pathologist rescored all biopsies in batch, 
blinded for any clinical information. Wedge biopsies mostly include outer cortex, the zone 
where glomerulosclerosis and fibrosis are most severe. Arteriosclerosis, in contrast, most 
prominently affects larger arteries and therefore could be under-represented in a wedge 
biopsy.34 Despite these shortcomings, the independent validation of the association be-
tween telomere length and renal arteriosclerosis supports the robustness and reproduc-
ibility of our data.  
In conclusion, shorter leucocyte and intrarenal telomere length associated with renal ar-
teriosclerosis, but not with other histological changes observed in older kidneys, like glo-
merulosclerosis or tubulo-interstitial injury. Our study therefore suggests a central role of 
replicative senescence in the progression of renovascular disease in humans. This associa-
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3.2
Intrarenal arteriosclerosis and telomere  
attrition associate with dysregulation of  
the cholesterol pathway 
Abstract
Background
Recently, we demonstrated that arteriosclerosis in the smaller intrarenal arteries is 
associated with shorter telomere length, independent of history of cardiovascular 
events and calendar age. This suggests that intrarenal arteriosclerosis reflects rep-
licative senescence, although the underlying molecular alterations remain unclear.
Methods 
This study included a test cohort of 40 consecutive kidney donors, with biopsies 
obtained prior to transplantation. Intrarenal leucocyte telomere length content was 
assessed using quantitative RT-PCR. Whole genome microarray mRNA expression 
analysis was performed using Affymetrix Gene 2.0 ST arrays. The associations be-
tween mRNA gene expression, telomere length as marker of replicative senescence, 
and intrarenal arteriosclerosis were investigated using adjusted multiple regression 
models. For biological interpretation and pathway overrepresentation analysis, In-
genuity Pathway Analysis were used. The significant pathways and genes were 
validated in an independent validation cohort of 173 kidney biopsies obtained prior 
to transplantation. 
results
Shorter intrarenal telomere length associated significantly with the presence of re-
nal arteriosclerosis (T/S ratio 0.91±0.15 vs. 1.20±0.23 with vs. without arteriosclero-
sis, p=0.007, test cohort; T/S ratio 0.98 ±0.26 vs. 1.03 ±0.18 with vs. without arterio-
sclerosis, p=0.02, validation cohort). Expression of 1472 transcripts was significantly 
associated with the presence versus absence of intrarenal arteriosclerosis. Pathway 
analysis revealed enrichment of molecules involved in the superpathway of choles-
terol biosynthesis as the most significant. The differential expression of these genes 
was confirmed in the independent validation cohort. Furthermore, the expression 
of the molecules in the superpathway of cholesterol biosynthesis associated sig-
nificantly with intrarenal telomere length, and with history of cardiovascular events.
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Introduction
Telomeres are complexes of tandem TTAGGG repeats of 5000 to 15000 base pairs that 
reside at the ends of chromosomes.1 Their main function is to cap these chromosome ends 
and prevent chromosomal instability.2 Telomeres shorten by each cell division, until a criti-
cal length is reached. This leads to permanent and irreversible growth arrest, referred to as 
replicative senescence.3 Telomere length is a well-established marker of biological age.4 
Although telomere length is partly heritable, there are major differences in telomere length 
even among monozygotic twins, which illustrates that environmental factors are impor-
tant in telomere attrition rate.5 
Recently, we illustrated and validated that arteriosclerosis in smaller intrarenal arteries of 
kidneys is associated with shorter telomere length, suggesting a role of telomere shorten-
ing or biological aging in the development renal arteriosclerosis. Moreover, we described 
that shorter (intrarenal) telomere length associates with history of hypertension and car-
diovascular events in a cohort of native kidneys used for transplantation.6 This associa-
tion between shorter telomere length and clinical cardiovascular disease has also been 
described in the cardiovascular field.7-9 It could therefore be hypothesized that renal arte-
riosclerosis reflects a specific senescence process. In contrast, other lesions included in the 
phenotype of “nephrosclerosis” (glomerulosclerosis, interstitial fibrosis, tubular atrophy) did 
not associate with history of cardiovascular events, hypertension or telomere length, and 
likely represent cumulative non-specific injury processes, rather than specific aging pro-
cesses.6
The lesions of arteriosclerosis begin as the intima of the arterial wall fills up with the depo-
sition of cellular wastes and ends with a thickening and loss of elasticity of the arterial 
walls.10,11 Different molecular pathways like cell proliferation regulatory pathways includ-
ing genes involved in the cell cycle regulation checkpoints, cytokine-associated signaling 
pathways and lipoprotein pathways have been associated with the presence of arterio-
sclerosis.12-14  
Given the recent suggestions that intrarenal arteriosclerosis associates with replicative se-
nescence, but the lack of molecular underpinning of these findings, we investigated the 
association between intrarenal telomere length and intrarenal arteriosclerosis at the mo-
lecular level using micro-array gene expression analyses.
interpretation
Our study illustrates that the superpathway of cholesterol biosynthesis interacts 
with the previously published association between shorter telomere length and ar-
teriosclerosis. Whether these association reflect causality, warrants further study. 
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DNA extraction was performed by the Allprep DNA/RNA/miRNA Universal Kit (Qiagen, 
Venlo, The Netherlands) on a QIAcube instrument (Qiagen, Venlo, The Netherlands). Both 
DNA yield (ng/μL) and purity ratios A260/280 and A260/230 were determined using a 
Nanodrop ND-1000 spectrophotometer (Isogen Life Science, De Meern, the Netherlands) 
and needed to be within strict quality limits (yield 50 ng/μL; purity ratio range 1.5-2 and 
1.5-2 for A260/280 and A260/230, respectively) for inclusion of the samples in the study. 
Extracted DNA samples were stored at -80°C until further use.
Telomere length in renal tissue samples was measured based on a modified quantita-
tive real-time PCR protocol.17 Telomere lengths were expressed as the telomere repeat 
copy number relative to a single-copy gene (36B4). DNA samples were diluted to 5ng and 
checked using the Quant-it PicoGreen dsDNA assay kit (Life Technologies) to ensure uni-
form DNA input for PCR quantification. The telomere reaction mixture contained 1x Qia-
gen QuantiTect SYBR Green Mastermix, 2.5 mM of dithiothreitol, 300 nM of telg primer 
(5’-ACACTAAGGTTTGGGTTTGGGTTT- GGGTTTGGGTTAGTGT-3’), and 900 nM of telc 
primer (5’- TGTTAGGTATCCC- TATCCCTATCCCTATCCCTATCCCTAACA-3’). Telomere PCR 
conditions were: 1 cycle at 95°C for 10 min, followed by 2 cycles of 15 sec at 94°C and 2 
min at 49°C, and 30 cycles of 15 sec at 94°C, 20 sec at 62°C and 1 min 40 sec at 74°C. The 
single-copy gene (36B4) reaction mixture contained 1x Qiagen QuantiTect SYBR Green 
Mastermix, 300nM 36B4U primer (5’-CAGCAAGTGGGAAGGTGTAATCC-3’) and 500nM 
36B4D primer (5’-CCCATTCTATCATCAACGGGTACAA-3’). Single-copy gene PCR condi-
tions were: 1 cycle at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec, and 58°C for 
1 min 10 sec. Samples were run in triplicate on an Applied Biosystems 7900HT Fast Real-
Time PCR system in a 384-well format. PCR efficiency was calculated based on a 6-point 
serial dilution (20ng-0.08ng) of pooled buffy-coat DNA and was accepted between lim-
its of 90-110%. Relative average telomere lengths were calculated using qBase software 
(Biogazelle, Zwijnaarde, Belgium) and expressed as the ratio of telomere copy number to 
single-copy gene number (T/S) compared to the average T/S ratio of the entire population. 
We achieved a coefficient of variation within telomere and single-copy gene triplicates of 
0.70% and 0.51% respectively. All biopsies passed quality control for assessment of intra-
renal telomere length. 
Whole genome micro array mrNA expression analysis 
In the test cohort (N=40), whole genome microarray mRNA expression analysis was per-
formed using Affymetrix Gene 2.0 ST arrays (N=40), which covers in total 40.716 RefSeq 
transcripts and 11.086 lincRNA transcripts. Total RNA (150 ng) was used to analyse the 
mRNA expression via human Gene 2.0 ST arrays according to manufacturer’s manual 
(4475209 Rev.B; Applied Biosystems, CA and 702808 Rev.6 ; Affymetrix, CA). Briefly, in 
Methods
inclusion and exclusion criteria
A test cohort of 40 consecutive kidneys, for transplantation in adult recipients between 
February 2013 and September 2013 at the University Hospital Leuven (Leuven, Belgium), 
was included in this study. Pre-implantation biopsies were performed in these kidneys, for 
evaluation of telomere length, gene expression and histological evaluation available. The 
validation cohort included kidney biopsies 173 consecutive kidney donors for transplanta-
tion in adult recipients, transplanted between September 2013 and April 2015 at this same 
institution. This study was approved by the Ethics Committee/Institutional Review Board 
of the University Hospitals Leuven, Leuven, Belgium (OG032; ML7499 and ML9785; clini-
caltrials.gov NCT01331668). 
Clinical data collection
Clinical data were obtained from the Eurotransplant database (“Eurotransplant Donor Re-
port”), which is maintained prospectively and is the central source of donor data for organ 
transplantation in the Eurotransplant region (www.donordata.eu). The following data were 
collected: calendar age, gender, cause of death, weight and length, living vs. deceased do-
nor, brain death vs. cardiac death donor, body mass index, history of cardiovascular events 
prior to donation (including reason for death in deceased donors) and terminal serum cre-
atinine levels before organ recovery. Renal function was estimated by the 4-variable Modi-
fication of Diet in Renal Disease (MDRD) equation (estimated glomerular filtration rate; 
eGFR).15 
Kidney biopsies and histologic evaluation
One pathologist (EL) reviewed all pre-implantation kidney biopsies, without knowledge 
of any demographic information. The biopsy specimens were wedge biopsies with slides 
containing 4 to 10 paraffin sections (2 μm) that were stained with hematoxylin eosin, pe-
riodic acid–Schiff, and a silver methenamine staining method (Jones). The severity of his-
tologic lesions, interstitial fibrosis (Banff “ci” score), tubular atrophy (Banff “ct” score), arte-
riolar hyalinosis (Banff “ah” score) and arteriosclerosis (Banff “cv” score = vascular fibrous 
intimal thickening = intimal hyperplasia), were scored semiquantitatively according to the 
Banff criteria.16 In addition, the total number of glomeruli in each biopsy, and the number 
of globally sclerosed glomeruli, were calculated separately. Only biopsies with >10 glomer-
uli (A quality) were included for evaluation of glomerulosclerosis. 
telomere length in kidney biopsies
Since November 2012, next to the wedge biopsy that was used for histological evaluation, 
a full renal cortical biopsy core was obtained prior to implantation, and immediately stored 
in Allprotect Tissue Reagent (Qiagen, Venlo, The Netherlands) solution, until extraction. 
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QuantStudio 12K flex software. Gene expression in each sample was calculated relative to 
the expression of a reference RNA sample, using the ΔΔCt method with log2 transforma-
tion. 
Statistical analysis
For the microarray gene expression analysis, multivariable linear regression was performed 
to examine the association between telomere length and log
2
-transformed gene expres-
sion level of each probeset, adjusted for calendar age, gender and batch number. Second, 
also multivariable logistic regression analysis was performed to examine the association 
between the presence of arteriosclerosis (Banff grade absent vs. present) and log
2
-trans-
formed gene expression levels. Genes with a p-value smaller than 0.05 were classified as 
being significantly associated with telomere length or presence of arteriosclerosis, although 
Benjamini-Hochberg false discovery rate-adjusted p-value were also calculated. For bio-
logical interpretation, the differentially expressed genes, based on unadjusted p-values, 
were uploaded into Qiagen’s Ingenuity® Pathway Analysis (IPA®) platform (www.qiagen.
com/ingenuity). Pathways with a q-value (Benjamini-Hochberg false discovery rate-ad-
justed p-value) below 0.05 were considered significantly overrepresented. 
In the validation cohort, gene expression differences between groups were analyzed using 
parametric or non-parametric one-way ANOVA. Associations between telomere length 
and gene expression were assessed by means of Spearman correlations. To integrate gene 
expression data for different transcripts, principal component analysis was used. From the 
principal component analysis, a principal component represents a linear combination of 
gene expression levels of a range of selected genes with as weights the eigenvectors. Prin-
cipal components having eigenvalues >1 were selected. 
For variance analysis of continuous variables in different groups, non-parametric Wil-
coxon-Mann-Whitney U, non-parametric ANOVA and parametric one-way ANOVA were 
used, as appropriate. Dichotomous variables were compared using the chi-square test. All 
tests were two-sided and p-values less than 0.05 were considered to indicate statistical 
significance. The results are expressed as numerical values and percentages for categori-
cal variables and as mean ± standard deviation for continuous variables, unless stated 
otherwise. Analyses were done with SAS (version 9.2; SAS institute, Cary, NC), JMP9.0 (SAS 
institute, Cary, NC), GraphPad Prism (version 5.00; GraphPad Software, San Diego, CA) 
and Qiagen’s Ingenuity® Pathway Analysis (IPA®; Redwood City, CA).
the first cycle, double stranded cDNA was prepared with random hexamers tagged with a 
T7 promoter sequence followed by the generation of cRNA using the GeneChip WT Syn-
thesis and Amplification kit (Applied Biosystems, CA). cRNA concentration after cleanup 
was measured with the NanoDrop ND-1000 spectrophotometer (NanoDrop Technolo-
gies). In the second cycle, sense oriented single-stranded DNA containing dUTP was gen-
erated and the concentration was, after cleanup, measured using the NanoDrop spectro-
photometer. cRNA was hydrolysed and the single-stranded DNA was fragmented using 
uracil DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE1) (GeneChip 
WT terminal Labeling kit, Affymetrix). The quality of fragmentation (fragments should be 
between 40 and 70 nucleotides) was checked on the Bioanalyzer (Agilent, Waldbronn, Ger-
many). The fragmented DNA was labeled by terminal deoxynucleotidyl transferase (TDT) 
with the Affymetrix DNA Labeling reagent that is covalently linked to biotin (GeneChip WT 
terminal Labeling kit, Affymetrix). Labeled DNA was hybridized to the array during 17h at 
45°C. The arrays were washed and stained in a fluidics station using the GeneChip hybridi-
zation, Wash end Stain kit (Affymetrix) and scanned using the Affymetrix 3000 GeneS-
canner. All image files were generated using the Affymetrix GeneChip command console 
(AGCC). The raw data were analysed with RMA sketch using the standard settings for Gene 
2.0 ST arrays of Expression Console in the AGCC software.
mrNA gene expression analysis  
RT-PCR was performed in the validation cohort using OpenArray™ technology, a real-
time PCR–based solution for high-throughput gene expression analysis (Quantstudio 12K 
Flex Real-Time PCR system,Thermofischer Scientific; Ghent, Belgium). After analysis of the 
intersecting pathways enriched in the micro-array gene expression analyses, expression 
of individual genes from the most robust pathway was validated. 14 genes were selected 
from the micro-array model (FDPS; DHCR7; LSS; HMGCR; FDFT1; IDI1; ACAT2; NSDHL; 
HMGCS1; CYP51A1; SQLE; MSMO1; MVD; HSD17B7) together with 3 housekeeping genes 18s, 
HPRT and GAPDH (Supplementary Table 1).
RNA extraction was performed by the Allprep DNA/RNA/miRNA Universal Kit (Qiagen, 
Venlo, The Netherlands) on a QIAcube instrument (Qiagen, Venlo, The Netherlands).  cDNA 
synthesis was performed according the manufacture with 50 ng mRNA (Superscript VILO 
cDNA synthesis kit, Thermo Fisher Scientific, Gent, Belgium). Preampliciation was per-
formed according the manufacture. The pre-amplified cDNA was mixed with TaqMan 
Universal PCR Master Mix and injected on the OpenArray™ slide using OpenArray Accufill 
System (Thermo Fisher Scientific, Gent, Belgium). The OpenArray™ slides were spotted 
with the requested assays and the three endogenous controls 18S, HPRT and GAPDH by 
the manufacture (Thermo Fisher Scientific, Gent, Belgium). Data were analyzed using the 
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Validation of the superpathway of cholesterol biosynthesis 
Given the significant enrichment of the superpathway of cholesterol biosynthesis in both 
the analysis of telomere length and intrarenal arteriosclerosis (Supplementary Table 1), we 
validated selected genes of this pathway (Table 1; Figure 2 and Supplementary Table 2-3) 
in the independent validation cohort (N=159). In 14 biopsies (8%) there was no evaluation of 
arteriosclerosis because there was no vessel present in the biopsy. Telomere length corre-
lated significantly with the expression of FDFT1 (p= 0.01, r=-0.20), MSMO1 (p= 0.03, r=-0.16), 
MVD (p= 0.01, r=-0.16), HSD17B7 (p= 0.002, r=-0.24) and SQLE (p= 0.02, r=-0.17)(Figure 3). 
When the transcripts involved in this pathway were expressed as the first principal compo-
nent of the whole pathway, also this parameter correlated highly significantly with intrare-
nal telomere length (p= 0.002). 
Presence of arteriosclerosis associated significantly with expression of SQLE, FDPS, MVD, 
HMGCS1, HSD17B7 and HSF1 (all p≤0.05) (Supplementary Table 4, Figure 4). When the 
transcripts involved in this pathway were expressed as the first principal component of the 
whole pathway, also this parameter associated highly significantly with intrarenal arterio-
sclerosis (p= 0.006).
the superpathway of cholesterol biosynthesis and history of cardiovascular 
events
History of cardiovascular events associated significantly with the expression of FDFT; 
DHCR7; FDPS; HMGCS1; IDI1; LSS; MSMO1; MVD; NSDHL; SQLE; CYP51A1 (Supplementary 
Table 4, Figure 5). When the superpathway of cholesterol biosynthesis was expressed as 
the first principal component of all transcripts involved in this pathway, this parameter as-
sociated highly significantly with history of cardiovascular events (p= 0.004).
Results
Population characteristics 
Between February 2013 and April 2015, 297 renal transplantations were performed at the 
University Hospitals Leuven, of which 213 had a a pre-implantation renal allograft biopsy 
for evaluation of telomere length, gene expression and histological evaluation available 
(40 test cohort, 173 validation cohort). In the test cohort mean T/S ratio of intrarenal tel-
omere length was 1.17±0.20 (range 0.69-1.74). In the validation cohort mean T/S ratio of in-
trarenal telomere length was 1.02±0.19 (range 0.59-1.74). Table 1 summarizes the character-
istics of our cohort and the histology of the biopsies that were included. Shorter intrarenal 
telomere length associated significantly with the presence of renal arteriosclerosis in the 
test cohort (T/S ratio 0.91±0.15 vs. 1.20±0.23 with vs. without arteriosclerosis; p=0.007) and 
in the validation cohort (T/S ratio 0.98 ±0.26 vs. 1.03 ±0.18 with vs. without arteriosclerosis, 
p=0.02).
Micro-array gene expression and intrarenal telomere length
In total, expression of 1300 transcripts significantly associated with intrarenal telomere 
length at p<0.05 in multivariable linear regression analysis (adjusted for calendar age, gen-
der and batch), of which 629 were significantly higher expressed in samples with shorter 
telomeres. These individual transcripts did not pass Benjamini-Hochberg FDR adjustment. 
Pathway analysis revealed enrichment of transcripts coding for proteins of the oxidative 
phosphorylation pathway (q=5.75x10-10), transcripts involved in the superpathway of cho-
lesterol biosynthesis (q=2.96x10-8) and transcripts involved in the mitochondrial dysfunc-
tion pathway (q=1.26x0-6) as the top three significant pathways (Figure 1A; Supplementary 
Table 2). The 36 genes that were implicated in these pathways, significantly associated 
with intrarenal telomere length, all had upregulated expression with telomere shortening 
(Supplementary Table 3). 
Micro-array gene expression and intrarenal arteriosclerosis 
In total, 1472 transcripts significantly associated with intrarenal arteriosclerosis (adjusted for 
calendar age, gender and batch), of which 674 were significantly upregulated in biopsies 
with arteriosclerosis (N=5/40). These individual transcripts did not pass Benjamini-Hoch-
berg FDR adjustment. Pathway analysis revealed enrichment of transcripts coding for pro-
teins of the superpathway of cholesterol biosynthesis (q=0.0003), transcripts involved in 
the superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)(q=0.02) 
and transcripts involved in the mevalonate pathway I (q=0.03) as the three top significant 
pathways (Figure 1B; Supplementary Table 2). In these pathways, 14 genes were signifi-
cantly associated with presence of arteriosclerosis; 12 upregulated and 2 downregulated in 
biopsies with arteriosclerosis (Supplementary Table 4). 
Demographics Test Cohort Validation Cohort
N 40 173
Donor Characteristics  
Calendar Age (years) 48.0 ± 15 48.7 ± 15
Male Gender % (N) 57.5%43 49.1% (85)
Living/Deceased Donor % (N) 10.0% (4)/90.0% (36) 11.6% (20)/88.4% (153)
Brain Death/Cardiac Death % (N) 72.2% (26)/27.8% (10) 79.0% (120)/21.0% (32)
Body Mass Index (kg/m2) 29.0 ± 5.3 28.5 ± 11.9
History of Cardiovascular Events % (N) 40.0% (16) 43.4%44
Cold Ischemia Time (hours) 12.0 ± 5.8 11.5 ± 5.9
Histological Characteristics   
Intrarenal telomere length (T/S ratio) 1.17±0.20 1.02±0.19
Banff Arteriosclerosis grade % (N) (159) 0= 87.5%45  0= 87.4% (139)
 1-2= 12.5% (5) 1-2= 12.6% (20) 
Table 1 — Demographics and histology of the subjects and biopsies included in this study. Data are expressed as 
mean ± standard deviation unless otherwise specified; #eGFR was calculated using the MDRD formula.15,42
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Figure 1A — List of the 9 significant canonical pathways associated with telomere length. The significance of the 
pathways is expressed as the Benjamini-Hochberg-adjusted p value (q value), which is corrected for multiple testing. 
The percentage on the left y axis represents the of up- and downregulated genes in the pathway. Pathway analysis 
revealed enrichment of transcripts coding for proteins of the oxidative phosphorylation pathway  (q=5.75x10-10), tran-
scripts involved in the superpathway of cholesterol biosynthesis (q=2.96x10-8) and transcripts involved in the mito-
chondrial dysfunction pathway (q=1.26x0-6) as the first three most significant pathways. 
Figure 1B — List of the 3 significant canonical pathways associated with intrarenal arteriosclerosis. The significance 
of the pathways is expressed as the Benjamini-Hochberg-adjusted p value (q value), which is corrected for multiple 
testing. The percentage on the left y axis represents the up- and downregulated genes in the pathway. Pathway analy-
sis revealed enrichment of transcripts coding for proteins of the superpathway of cholesterol biosynthesis  (q=0.0003), 
transcripts involved in the superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate)(q=0.02) and 
transcripts involved in the mevalonate pathway I (q=0.03) as the three significant pathways.
Figure 2 — The superpathway of cholesterol biosynthesis with the genes significant in the test cohort and validated 
in the validation cohort marked in yellow. LSS = lanosterol synthase, FDPS = farnesyl diphosphate synthase; DHCR7 
=7-dehydrocholesterol reductase; HMGCR = 3-hydroxy-3-methylglutaryl-CoA reductase; FDFT1 = farnesyl-diphos-
phate farnesyltransferase 1; IDI1 = isopentenyl-diphosphate delta isomerase 1; ACAT2 = acetyl-CoA acetyltransferase 
2; NSDHL = NAD(P) dependent steroid dehydrogenase-like; HMGCS1 = 3-hydroxy-3-methylglutaryl-CoA synthase 1; 
CYP51A1 =cytochrome P450, family 51, subfamily A, polypeptide 1; SQLE = squalene epoxidase; MSMO1 =methylsterol 
monooxygenase 1; MVD = mevalonate (diphospho) decarboxylase; HSD17B7 = hydroxysteroid (17-beta) dehydroge-
nase 7.
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Figure 3 — The correlation between telomere length and gene expression in the validation cohort. Associations be-
tween telomere length and gene expression were assessed by means of spearman correlations.
Figure 4 — Relation between intrarenal arteriosclerosis and gene expression in the validation cohort. The p-values 
represent non-parametric ANOVA. The horizontal lines within the boxes indicate means, the upper and lower ends of 
the boxes indicate standard deviations, and the whiskers indicate 95th percentiles. 
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Discussion
In the current study, whole genome expression analyses in kidney biopsies revealed signifi-
cant enrichment of the superpathway of cholesterol biosynthesis in the transcripts associ-
ated with telomere attrition and presence of intrarenal arteriosclerosis. The most relevant 
genes of this pathway were confirmed in an independent validation cohort. Interestingly, 
selected genes of the cholesterol pathways also associated with history of cardiovascular 
events. 
The superpathway of cholesterol biosynthesis summarizes the three routes of choles-
terol biosynthesis. Less than half of the cholesterol in the body derives from biosynthesis 
de novo. Biosynthesis in the liver accounts for approximately 10%, and in the intestines 
approximately 15% of the amount produced each day, but all human cells can produce 
cholesterol. There is evidence of the expression of cholesterol pathways and production of 
cholesterol by the kidney, more specifically by the proximal tubular cells, mesangial cells 
and podocytes.18,19-21 Moreover, there is endogenous production of cholesterol by vascular 
cells, also present in the kidney.22 Synthesis of cholesterol originates from the transport of 
acetyl-CoA from the mitochondria to the cytosol. The mevalonate pathway of cholesterol 
synthesis initiates with formation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
from acetyl-coenzyme A, through enzymatic interaction by HMG-coenzyme A synthase 
(HMGCS). HMGCS was upregulated in our analysis, both in the test and in the valida-
tion cohort. The rate-limiting step in cholesterol synthesis occurs at HMG-CoA reductase 
(HMGCR), which was overexpressed in our micro-array analysis in the presence of telomere 
attrition and presence of arteriosclerosis, but which was not validated. The synthesis of 
squalene represents the first cholesterol-specific step in the cholesterol synthesis path-
way, and several transcripts in this specific pathway were overexpressed in our analyses, 
like squalene epoxidase, farnesyl diphosphate synthase and transferase. Squalene then 
undergoes a two-step cyclization to yield lanosterol, which is finally converted to choles-
terol, depending on a large chain of intermediary products (Figure 3). Several of the key 
enzymes in this cascade were differentially expressed in our analyses. 
Intracellular lipid content is importantly influenced by the rate of uptake of lipids from the 
circulation, and by this from circulating lipid levels.23 In patients with homozygous familial 
hypercholesterolemia, the superpathway of cholesterol synthesis is upregulated because 
of defective binding of lipoproteins to cells.24,25 Intracellular lipid synthesis is regulated by 
sterol regulatory element binding proteins (SREBP), and intracellular cholesterol content is 
heavily regulated to prevent toxicity from progressive intracellular accumulation of choles-
terol.26 Competitive inhibitors of HMG-CoA Reductase (HMGCR), better known as statins, 
inhibit cholesterol synthesis and diminish cardiovascular risk by inhibition of the first step 
of this pathway. The contribution of lipid metabolism to atherosclerosis has been reviewed 
Figure 5 — Relation between history of cardiovascular events in the validation cohort and gene expression. The p-
values represent non-parametric ANOVA. The horizontal lines within the boxes indicate means, the upper and lower 
ends of the boxes indicate standard deviations, and the whiskers indicate 95th percentiles. 
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are rather protective in nature. Further evaluation of these very different hypotheses will be 
necessary to better understand the likely complex interplay between renal arteriosclerosis, 
senescence and cholesterol homeostasis. Given the suggestion that renal arteriosclerosis 
represents specific senescence processes, and the fact that cholesterol homeostasis can be 
influenced by relatively safe therapeutic interventions, our data-driven results provide first 
clues how progressive renal arteriosclerosis could be slowed down. 
Our study has several limitations. First, it should be acknowledged that the associations 
between gene expression, telomere length and renal arteriosclerosis was not strong, and 
statistical analysis did not pass stringent Benjamini-Hochberg criteria for multiple testing. 
Nevertheless, the downstream pathway evaluation and independent validation of indi-
vidual targets largely overcomes this drawback. Given this intrinsic drawback, it could be 
that this approach decreases the sensitivity to detect other significant genes or pathways 
associated with these phenotypes. Next, it should be emphasized that the primary micro-
array analysis was performed on a low number of heterogeneous samples, especially with 
low prevalence of renal arteriosclerosis in the test cohort. Again, independent validation of 
the main findings decreases this issue, although the potential for type 2 errors remains. 
Another limitation of this study is that global intrarenal gene expression does not provide 
any spatial information nor insight in the cellular origin of the detected signals. Given the 
apparent importance of cellular cholesterol homeostasis in our analysis, information on 
circulating and intrarenal cholesterol levels would be important for interpretation of our 
data, but these levels were not available. Although clinical demographics were collected 
prospectively, some kidney donor parameters that could be of importance could have 
been recorded incompletely. Finally, it has to be acknowledged that the reproducibility of 
semi-quantitative histologic scoring of kidney biopsies is moderate at best, and that sam-
pling error is inherent to any biopsy study. Despite these shortcomings, the independent 
validation of the association between telomere length, renal arteriosclerosis and the cho-
lesterol pathways supports the robustness and reproducibility of our data. 
 
In conclusion, our study suggests that there is an association between overexpression of 
intrarenal cholesterol biosynthesis, shorter intrarenal telomere length and increased renal 
arteriosclerosis in humans, although no causality can be inferred from our data. Further 
studies are necessary to elucidate the cell types involved, the impact of circulating cho-
lesterol levels and the causal relations. Whether treatment aimed at inhibiting cholesterol 
biosynthesis has beneficial effects on renal biological aging or renal arteriosclerosis in hu-
mans, warrants further study. 
previously.23,27,28 Intracellular lipid accumulation is proatherogenic through an array of 
secondary effects, including immune cell stimulation and endothelial cell dysfunction.23 
Moreover, transformation of contractile smooth muscle cells to migratory, proliferative and 
synthetic smooth muscle cells has been associated with alterations of cellular lipid homeo-
stasis and upregulation of genes involved in cholesterol biosynthesis29, although it should 
be emphasized that these last data need further validation. Moreover, homocysteine leads 
to dysregulated cholesterol synthesis in endothelial cells, which could be involved In the 
proatherogenic effects of hyperhomocysteinemia.30
Intrarenal lipid metabolism was investigated only scarcely. Zager et al have shown that is-
chemic injury leads to alterations in intracellular lipids, associated with changed expression 
of HMGCR.20,31-34 Also other renal injury processes are associated with altered renal lipid 
homeostasis.34 These responses are considered primarily protective, and protect injured 
cells from additional injury. This earlier research focused on glomeruli and tubular cells. 
The regulation in renal vascular cells is less clear. Given the fact that the current study used 
core renal biopsies for gene expression evaluation, the cellular origin of the differentially 
expressed cholesterol pathway genes remains unclear. 
Intimal hyperplasia is the universal response of a vessel to injury, like repeated hemody-
namic and oxidative stress on the endothelium.35,36 Injury-induced intimal hyperplasia 
underlies the pathogenesis of major cardiovascular diseases.37 The increased rate of cell 
turnover in regions with hemodynamic stress has been associated with accelerated tel-
omere attrition and with endothelial cell senescence, which further contributes to endothe-
lial dysfunction and intimal hyperplasia.7,38-40 Moreover, the senescence-associated secre-
tory phenotype of senescent cells causes a full range of autocrine and paracrine activities, 
aimed at tissue repair, but also fueling degenerative and proliferative changes contributing 
to arteriosclerosis.9 
In the current study, we demonstrate for the first time that there are significant associa-
tions between renal arteriosclerosis, intrarenal telomere attrition and dysregulation of cho-
lesterol biosynthesis in kidney biopsies. Notwithstanding the interest of this finding, the 
current study is not suited to distinguish causal relations between these factors. Telomere 
attrition and renal dysregulation of cholesterol metabolism could be caused by common 
risk factors that contribute to intrarenal arteriosclerosis. On the other hand, upregulation 
of the cholesterol biosynthesis gene expression could accelerate intrarenal arteriosclerosis 
and from this accelerated telomere attrition, as a protective mechanism.41 Furthermore, it 
could be hypothesized that telomere attrition in itself leads to altered cholesterol biosyn-
thesis and arteriosclerosis. Finally, it could be hypothesized that the observed alterations 
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 telomere model  intrarenal arteriosclerosis model
Ingenuity Canonical Pathways q value  Ratio q value Ratio
Oxidative Phosphorylation 5.80E-10 2.45E-01 — —
Superpathway of Cholesterol  2.70E-08 4.44E-01 3.31E-04 3.70E-01 
Biosynthesis 
Mitochondrial Dysfunction 1.31E-06 1.56E-01 — —
Cholesterol Biosynthesis I 1.31E-05 5.38E-01 0.21 3.08E-01
Cholesterol Biosynthesis II  1.31E-05 5.38E-01 0.21 3.08E-01 
(via 24.25-dihydrolanosterol) 
Cholesterol Biosynthesis III  1.31E-05 5.38E-01 0.21 3.08E-01 
(via Desmosterol) 
Superpathway of Geranylgeranyl   
diphosphate Biosynthesis I  0.01 3.12E-01 0.02 3.75E-01
Mevalonate Pathway I 0.04 3.33E-01 0.03 4.17E-01
Zymosterol Biosynthesis 0.04 5.00E-01 — —
Symbol gene  Pathway    P value Estimate°
ACAT2* acetyl-CoA acetyltransferase 2 Superpathway of Superpathway of Mevalonate 0,01 -2.09
  cholesterol biosynthesis geranylgeranyldiphosphate Pathway  
ATP5A1 ATP synthase, H+ transporting,  Oxidative Phosphorylation Mitochondrial dysfunction  0.02 -0.59
 mitochondrial F1 complex, 
 alpha subunit 1  
ATP5G1 ATP synthase, H+ transporting,  Oxidative Phosphorylation Mitochondrial dysfunction   0.03 -0.90
 mitochondrial Fo complex, 
 subunit C1 (subunit 9) 
ATP5I ATP synthase, H+ transporting,  Oxidative Phosphorylation Mitochondrial dysfunction   0.01 -0.84
 mitochondrial Fo complex, subunit E 
ATP5L ATP synthase, H+ transporting, 
 mitochondrial Fo complex, subunit G Oxidative Phosphorylation Mitochondrial dysfunction   0.01 -1.09
ATP5S ATP synthase, H+ transporting,  
 mitochondrial Fo complex, subunit S Oxidative Phosphorylation Mitochondrial dysfunction   0.02 -0.90
COX4I2 cytochrome c oxidase subunit IV  Oxidative Phosphorylation Mitochondrial dysfunction   0.01 -1.03 
 isoform 2 
COX5B cytochrome c oxidase subunit Vb Oxidative Phosphorylation Mitochondrial dysfunction   0.006 -1.23
COX6B1 cytochrome c oxidase subunit VIb  Oxidative Phosphorylation Mitochondrial dysfunction   0.01 -1.09
 polypeptide 1  
COX7B cytochrome c oxidase subunit VIIb Oxidative Phosphorylation Mitochondrial dysfunction   0.01 -0.87
CYC1 cytochrome c-1 Oxidative Phosphorylation Mitochondrial dysfunction   0.02 -0.89
CYP51A1* cytochrome P450, family 51,   Superpathway of Superpathway of  0.02 -1.38 
 subfamily A, polypeptide 1 cholesterol biosynthesis cholesterol biosynthesis  
DHCR7* 7-dehydrocholesterol reductase Superpathway of  Cholesterol biosynthesis  0.006 -2.37 
  cholesterol biosynthesis I-II-III 
FDFT1* farnesyl-diphosphate  Superpathway of Cholesterol biosynthesis  0.007 -1.24
 farnesyltransferase 1 cholesterol biosynthesis I-II-III 
FDPS* farnesyl diphosphate synthase Superpathway of  Superpathway of  0.004 -1.12
  cholesterol biosynthesis geranylgeranyldiphosphate 
HMGCR* 3-hydroxy-3-methylglutaryl- Superpathway of Superpathway of
 CoA reductase cholesterol biosynthesis geranylgeranyldiphosphate Mevalonate  0.007 -1.63
    Pathway  
HMGCS1* 3-hydroxy-3-methylglutaryl- Superpathway of Superpathway of Mevalonate 0.02 -1.97
 CoA synthase 1  cholesterol biosynthesis geranylgeranyldiphosphate Pathway    
IDI1* isopentenyl-diphosphate delta  Superpathway of Superpathway of Mevalonate 0.01 -1.83
 isomerase 1 cholesterol biosynthesis geranylgeranyldiphosphate Pathway  
LSS* lanosterol synthase  Superpathway of Cholesterol biosynthesis  0.006 -1.80
 (2,3-oxidosqualene-lanosterol cyclase) cholesterol biosynthesis I-II-III 
MSMO1* methylsterol monooxygenase 1 Superpathway of  Cholesterol biosynthesis Zymosterol 0.03 -1.97
  cholesterol biosynthesis I-II-III biosynthesis  
NDUFA1 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.02 -0.84
 1 alpha subcomplex, 1 
NDUFA10 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.03 -0.53
 1 alpha subcomplex, 10  
NDUFA9 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.04 -0.74
 1 alpha subcomplex, 9 
NDUFB1 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.02 -0.69
 1 beta subcomplex, 1 
NDUFB8 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.01 -0.60
 1 beta subcomplex, 8 
NDUFB9 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.01 -0.74
 1 beta subcomplex, 9  
NDUFS1 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.01 -0.90
 Fe-S protein 1, (NADH-coenzyme Q 
 reductase)
NDUFS3 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.02 -0.68
 Fe-S protein 3, (NADH-coenzyme Q 
 reductase) 
NDUFS7 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.005 -0.96
 Fe-S protein 7, (NADH-coenzyme Q 
 reductase)
NDUFS8 NADH dehydrogenase (ubiquinone)  Oxidative Phosphorylation Mitochondrial dysfunction   0.004 -1.18
 Fe-S protein 8, (NADH-coenzyme Q 
 reductase) 
NSDHL* NAD(P) dependent steroid  Superpathway of Superpathway of  0.01 -1.01
 dehydrogenase-like cholesterol biosynthesis cholesterol biosynthesis  
PINK1 PTEN Induced Putative Kinase 1 Mitochondrial dysfunction    0.01 -0.78
SQLE* squalene epoxidase Superpathway of  Cholesterol biosynthesis Epoxysqualene
  cholesterol biosynthesis I-II-III biosynthesis 0.02 -2.18
UQCRC1 ubiquinol-cytochrome c reductase  Oxidative Phosphorylation Mitochondrial dysfunction   0.007 -0.77
 core protein I 
UQCRC2 ubiquinol-cytochrome c reductase  Oxidative Phosphorylation Mitochondrial dysfunction   0.001 -1.09
 core protein II 
VPS9D1 VPS9 domain containing 1 Oxidative Phosphorylation Mitochondrial dysfunction   0.005 -0.91
Supplementary Table 1 — Significantly Enriched Pathways in association with Telomere Length and Arteriosclerosis 
For biological interpretation, the significantly differentially expressed genes in the adjusted linear regression analysis 
for the telomere and intrarenal arteriosclerosis model respectively, were uploaded into Qiagen’s Ingenuity® Pathway 
Analyis platform (IPA®; Redwood City. CA), to identify overrepresented pathways. Pathways with a q-value (false dis-
covery rate adjusted p-value) below 0.05 were considered significantly overrepresented. The ratio expresses the log 2 
fold change in pathway expression adjusted for the q value.
Supplementary Table 2 — Significant genes in the 9 canonical pathways enriched in association with telomere 
length Multiple linear regression for association of gene expression with telomere length, adjusted for calendar age, 
gender and microarray batch number, was used to model the determinants (gene expression) of telomere length. ° 
The estimate expresses the log2 fold change in gene expression for 1 standard deviation increase log T/S ratio. * Genes 
significant in test cohort selected for validation.
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Symbol gene  Pathway    P value Estimate°
ACAT2* acetyl-CoA acetyltransferase 2 Superpathway of Superpathway of Mevalonate 0.04 0.55
  cholesterol biosynthesis geranylgeranyldiphosphate Pathway  
CPSF2 Cleavage And Polyadenylation  Cleavage and   0.04 -2.09
 Specific Factor 2 polyadenlyation of pre RNA 
PAPOLA Poly(A) Polymerase Alpha Cleavage and    0.04 -1.09
  polyadenlyation of pre RNA 
FDFT1* farnesyl-diphosphate  Superpathway of Cholesterol biosynthesis  0.009 0.38
 farnesyltransferase 1 cholesterol biosynthesis I-II-III 
FDPS* farnesyl-diphosphate  Superpathway of Superpathway of Trans trans farensyl 0.02 0.26
 farnesyltransferase 1 cholesterol biosynthesis geranylgeranyldiphosphate diphosphate 
    biosynthesis 
HMGCR* 3-hydroxy-3-methylglutaryl- Superpathway of Superpathway of Mevalonate 0.02 0.44
 CoA reductase cholesterol biosynthesis geranylgeranyldiphosphate Pathway  
HMGCS1* 3-hydroxy-3-methylglutaryl- Superpathway of Superpathway of Mevalonate 0.04 0.75
 CoA synthase 1 cholesterol biosynthesis geranylgeranyldiphosphate Pathway  
IDI1* isopentenyl-diphosphate  Superpathway of Superpathway of Mevalonate 0.02 0.56
 delta isomerase 1 cholesterol biosynthesis geranylgeranyldiphosphate Pathway  
LSS* lanosterol synthase  Superpathway of Cholesterol biosynthesis  0.02 0.47
 (2,3-oxidosqualene- cholesterol biosynthesis I-II-III
 lanosterol cyclase)   
MSMO1* methylsterol monooxygenase 1 Superpathway of  Cholesterol biosynthesis Zymosterol 0.03 -1.98
  cholesterol biosynthesis I-II-III biosynthesis  
NSDHL* NAD(P) dependent steroid  Superpathway of Cholesterol biosynthesis  0.01 -1.01
 dehydrogenase-like cholesterol biosynthesis I-II-III 
SQLE* squalene epoxidase Superpathway of  Cholesterol biosynthesis Epoxysqualene 0.02 0.67
  cholesterol biosynthesis I-II-III biosynthesis 
MVD* mevalonate (diphospho)  Superpathway of Mevalonate Superpathway of 0.04 0.3
 decarboxylase cholesterol biosynthesis Pathway geranylgeranyl-
    diphosphate 
HSD17B7* hydroxysteroid (17-beta)  Superpathway of Cholesterol biosynthesis  0.02 0.55
 dehydrogenase 7 cholesterol biosynthesis I-II-III 
Supplementary Table 3 — Significant genes in the 9 canonical pathways enriched in association with intrarenal ar-
teriosclerosis Multiple linear regression adjusted for calendar age, gender and microarray batch number, was used to 
model the determinants (gene expression) of intrarenal arteriosclerosis. ° The estimate expresses the log2 fold change 
in gene expression for 1 standard deviation increase in presence of arteriosclerosis. * Gene expression validated in 
validation set.
Supplementary Table 4 — Relation between intrarenal arteriosclerosis and donor history of cardiovascular events in 
the validation cohort and gene expression. The p-values represent non-parametric ANOVA. 
intra renal     Donor history
arteriosclerosis    of cardiovascular events
Symbol gene  gene P value Symbol Donor history Donor history P value
 expression  expression   of cardiovascular of cardiovascular
 without  with   events absent events present
 arteriosclerosis arteriosclerosis  
SQLE 2.41 ± 0.10 3.24 ± 0.5 p=0.01 SQLE 2.16 ± 0.1 2.93 ± 0.19 p=0.0004
FDPS 1.22 ± 0.02 1.39 ± 0.11 p=0.04 FDPS 1.21 ± 0.03 1.32 ± 0.05 p=0.03
MVD 1.42 ± 0.07 1.60 ± 0.04 p=0.02 MVD 1.41 ± 0.04 1.68 ± 0.06 p=0.0003
HMGCS1 1.83 ± 0.07 2.30 ± 0.33 p=0.05 HMGCS1 1.74 ± 0.09 2.16 ± 0.16 p=0.009
HSD17B7 2.30 ± 0.10 5.86 ± 3.52 p=0.004 FDFT 1.21 ± 0.04 1.49 ± 0.06 p=0.0004
HSF1 0.88 ± 0.05 1.89 ± 1.02 p=0.007 CYP51A1 1.52 ± 0.05 1.77 ± 0.07 p=0.003
    DHCR7 1.88 ± 0.09 2.29 ± 0.12 p=0.005
    IDI1 0.93 ± 0.03 1.05 ± 0.04 p=0.01
    LSS 1.28 ± 0.05 1.44 ± 0.06 p=0.04
    MSMO1 2.28 ± 0.1 2.77 ± 0.17 p=0.01
    NSDL 1.16 ± 0.03 1.36 ± 0.05 p=0.0008
Supplementary Table 5 — List of the genes evaluated using Taqman gene expression assays. 
Symbol Entrez gene Name Lifetech array nr 
FDPS farnesyl diphosphate synthase Hs01578769_g1 
DHCR7 7-dehydrocholesterol reductase Hs01023087_m1
LSS lanosterol synthase (2.3-oxidosqualene-lanosterol cyclase) Hs00158906_m1
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase Hs00168352_m1
FDFT1 farnesyl-diphosphate farnesyltransferase 1 Hs00926054_m1
IDI1 isopentenyl-diphosphate delta isomerase 1 Hs01057440_m1
ACAT2 acetyl-CoA acetyltransferase 2 Hs00255067_m1
NSDHL NAD(P) dependent steroid dehydrogenase-like Hs00210873_m1
HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) Hs00940429_m1
CYP51A1 cytochrome P450, family 51, subfamily A, polypeptide 1 Hs01567880_g1
SQLE squalene epoxidase Hs01123768_m1
MSMO1 methylsterol monooxygenase 1 Hs00932159_m1
MVD mevalonate (diphospho) decarboxylase Hs00159403_m1
HSD17B7 hydroxysteroid (17-beta) dehydrogenase 7 Hs00367686_m1
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4.1
Replicative senescence and arteriosclerosis  
after kidney transplantation
Abstract
Background
Replicative senescence is associated with telomere shortening. In native kidneys, 
obtained prior to transplantation, we recently described and validated a significant 
association between shorter intrarenal telomere length and renal arteriosclerosis. 
After renal transplantation, animal experiments suggested that ischemia-reperfu-
sion injury, acute rejection episodes, and cytomegalovirus disease associate with 
accelerated renal allograft senescence. The association between post-transplant 
events and replicative senescence has not yet been evaluated in a human setting. 
Methods 
In a cohort of 134 kidney allograft recipients, we performed protocol-specified re-
nal allograft biopsies at three months, one year, two years and five years after 
transplantation (N=579 biopsies). We used quantitative real-time PCR to measure 
intrarenal relative average telomere length (T/S ratio). The association between do-
nor and recipient demographic factors, post-transplant clinical/histological events, 
renal allograft histological evolution by five years post-transplant, and intrarenal 
telomere length at five years after transplantation was studied using multiple re-
gression models.
results
At 5 years after transplantation, shorter intrarenal telomere length was associated 
with male donor gender, and older donor age, donor history of hypertension, and 
donor cardiovascular risk, which confirms the associations observed in native kid-
neys. Recipient characteristics and post-transplant events like delayed graft func-
tion, acute rejection episodes, presence of donor-specific antibodies, cytomegalo-
virus disease and immunosuppressive regimen did not associate with alterations of 
intrarenal telomere length at 5 years. Independent of donor age and donor cardio-
vascular risk, intrarenal arteriosclerosis in protocol biopsies obtained at five years 
after transplantation, and progressive arteriosclerosis over time after transplanta-
tion, associated with shorter telomere length, while this was not the case for other 
histological lesions. 
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Introduction
Telomeres are complexes of tandem TTAGGG repeats of 5000 to 15000 base pairs that 
reside at the ends of chromosomes.1 Their main function is to cap these chromosome ends 
and prevent chromosomal instability.2 Telomeres shorten by each cell division until a criti-
cal length is reached, which leads to permanent and irreversible growth arrest, referred to 
as replicative senescence.3 Telomere length is a well-established marker of biological age.4 
Although telomere length is partly heritable, there are major differences in telomere length 
even among monozygotic twins, which illustrates that environmental factors are impor-
tant in telomere attrition rate.5 
Accelerated telomere attrition plays a leading role in the development of age-related pa-
thologies like atherosclerosis and cardiovascular disease, as was shown in large epidemio-
logical studies.6 Obesity and smoking are associated with leucocyte telomere attrition, as 
well as hypertension, insulin resistance and diabetes, male gender and lower socioeco-
nomic status.6-12 
Recently, in a cohort of native kidneys used for transplantation, we have illustrated that tel-
omere attrition associates with histology of arteriosclerosis.13 Arteriosclerosis of the smaller 
intrarenal arteries was associated with shorter telomere length, independent of potential 
confounders including calendar age and cardiovascular risk, which suggests a central role 
of replicative senescence in the progression of renovascular disease.
Accelerated senescence after transplantation, caused by the cumulative burden of injury 
and the intrinsic donor characteristics, has been suggested to be one the main drivers of 
graft deterioration. In animal studies, there is some evidence that ischemia reperfusion 
injury, acute rejection, drug toxicity and viral infections in the peri- and post-transplant 
period lead to accelerated senescence.14-16 In addition, animal models illustrated that renal 
allograft senescence plays a role in the ability to repair and remodel the transplanted kid-
neys in order to maintain tissue integrity and function.17 It remains however unclear wheth-
er these animal data can be translated to the human situation.18
Therefore, in the current study in human renal allograft recipients, we evaluated the asso-
ciation between intrarenal telomere length late after transplantation, as marker of biologi-
cal age, renal allograft histology, pretransplant donor/recipient demographics, and post-
transplant clinical events.
 
Moreover, telomere attrition augments the association between older donor age 
and the presence of severe arteriosclerosis. In the group with the oldest donor age 
and shortest telomere length, there was significantly more severe arteriosclerosis 
(43%) in protocol biopsies at five year after transplantation, compared to other 
combinations (13-28%)(p=0.001). Intrarenal arteriosclerosis at 5 years after trans-
plantation did not associate with post-transplant clinical events.
interpretation
We demonstrate that intrarenal telomere length at 5 years after transplantation, as 
marker for replicative senescence, associates with renal arteriosclerosis, and reflects 
kidney donor characteristics, but not post-transplant events. 
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Kidney Biopsies and Histologic Evaluation
One pathologist (EL) evaluated all kidney biopsies. We stained the core biopsies with slides 
containing 4 to 10 paraffin sections (2 μm) with hematoxylin eosin, periodic acid–Schiff 
(PAS), and a silver methenamine staining method (Jones). An immunohistochemical C4d 
stain (monoclonal antibody, dilution 1:500, Quidel corporation, Santa Clara,CA) was per-
formed on frozen tissue. The severity of histologic lesions (tubulitis, interstitial inflamma-
tion, intimal arteritis, glomerulitis, interstitial fibrosis, tubular atrophy, arteriolar hyalinosis, 
vascular intimal thickening, transplant glomerulopathy and increase in mesangial matrix), 
were scored semiquantitatively according to the updated Banff criteria.20 In addition, the 
total number of glomeruli in each biopsy, and the number of globally sclerosed glomeruli, 
were calculated separately (0=<25%; 1=>25%). Peritubular capillaritis was scored based on 
the score described in the Banff 2007 classification.21 C4d deposition in the peritubular 
capillaries was scored from 0 to 3 (with 0= negative, 1= <25%, 2=25%-75% and 3= <75% of 
peritubular capillaries positive), given the use of immunohistochemistry on frozen tissue 
for this marker. Biopsy adequacy was assessed according to the Banff 1997 criteria. Only 
biopsies with >10 glomeruli were included for evaluation of glomerulosclerosis. 
We calculated delta (Δ) histology as the semiquantitative Banff score of the histological 
lesion in the five-year protocol biopsy (range 0-3) – the semiquantitative Banff score of 
the histological lesion in the three-month biopsy. Positive values represented biopsies with 
progression. Zero values represented biopsies without histological progression.
telomere Length in Kidney Biopsies 
We stored half a core of the biopsies performed at 5 years after renal transplantation im-
mediately in Allprotect Tissue Reagent (Qiagen, Venlo, The Netherlands), until extraction. 
We extracted DNA with the Allprep DNA/RNA/miRNA Universal Kit (Qiagen, Venlo, The 
Netherlands) on a QIAcube instrument (Qiagen, Venlo, The Netherlands). We determined 
both DNA yield (ng/μL) and purity ratios A260/280 and A260/230 using a Nanodrop 
ND-1000 spectrophotometer (Isogen Life Science, De Meern, the Netherlands). DNA qual-
ity needed to be within strict quality limits (yield 50 ng/μL; purity ratio range 1.5-2 and 1.5-2 
for A260/280 and A260/230, respectively) for inclusion. We stored extracted DNA sam-
ples at -80°C until further use.
We measured telomere length in renal tissue samples based on a modified quantitative 
real-time PCR protocol.22 Telomere lengths were expressed as the telomere repeat copy 
number relative to a single-copy gene (36B4). DNA samples were diluted to 5 ng and 
checked using the Quant-it PicoGreen dsDNA assay kit (lifetechnologies) to ensure uni-
form DNA input for PCR quantification. The telomere reaction mixture contained 1x Qia-
Methods
inclusion and exclusion criteria
All prospective adult recipients of a single kidney transplant, performed between January 
2006 and July 2009 at the University Hospitals Leuven (Leuven, Belgium), were eligible 
for this study. In the University Hospitals Leuven, renal allograft biopsies are routinely per-
formed at time of transplantation, and at 3, 12, 24 and 60 months after transplantation, in 
addition to clinically indicated biopsies. We included all patients with a five-year protocol 
biopsy, and with a sufficient amount of good-quality kidney DNA available for evaluation 
of telomere length (see below). The Ethics Committee/Institutional Review Board of the 
University Hospitals Leuven (Leuven, Belgium) approved this study (OG032; ML7499 and 
ML9785; clinicaltrials.gov NCT01331668). 
Donor Clinical Data Collection
We obtained clinical donor data from the Eurotransplant database (“Eurotransplant Do-
nor Report”), which is maintained prospectively and is the central source of donor data 
for organ transplantation in the Eurotransplant region (www.donordata.eu). We collected 
the following data: calendar age, gender, cause of death, weight and length, living vs. de-
ceased donor, brain death vs. cardiac death donor, body mass index, history of hyperten-
sion, diabetes mellitus, smoking, history of cardiovascular events prior to donation (includ-
ing reason for death in deceased donors) and terminal serum creatinine levels before organ 
recovery. We estimated renal function using the 4-variable Modification of Diet in Renal 
Disease (MDRD) equation (estimated glomerular filtration rate; eGFR).19 
recipient Clinical Data Collection
Clinical demographics of the renal allograft recipients were prospectively collected in elec-
tronic clinical patient records and transferred to SAS data files (SAS institute, Cary NC). The 
following data were collected: calendar age at time of transplantation, gender, weight and 
length, body mass index, new onset diabetes mellitus after transplantation (defined as the 
need to start insulin treatment after transplantation), smoking after transplantation, cardi-
ovascular events after transplantation (defined as the occurrence of a cardiovascular event 
post transplantation), treated CMV disease, the presence of one or more treated acute re-
jection episode after transplantation, delayed graft function after transplantation (defined 
as the need for dialysis in the first seven days after transplantation), immunosuppressive 
protocol, serum creatinine levels at 3, 12, 24 and 60 months after transplantation, presence 
of donor-specific HLA antibodies (DSA; either pretransplant or de novo after transplanta-
tion). Post-transplant renal function was estimated by the 4-variable Modification of Diet 
in Renal Disease (MDRD) equation (estimated glomerular filtration rate; eGFR).19 
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donor body mass index, donor history of cardiovascular events, living vs. deceased donor, 
brain-death vs. cardiac death and renal function (eGFR), recipient calendar age, recipient 
gender, recipient history of diabetes mellitus, recipient history of cardiovascular events, cold 
ischemia time, delayed graft function, treated cytomegalovirus (CMV) disease, the pres-
ence of one or more treated acute rejection episodes after transplantation (either T-cell 
mediated or antibody-mediated), biopsy-proven T cell mediated rejection, biopsy-proven 
antibody-mediated rejection, renal function at 3, 12, 24 and 60 months after transplanta-
tion (eGFR (mL/min/1.73m2), presence of DSA (pretransplant or de novo post-transplant) 
and immunosuppressive protocol. We used multiple linear regressions, with backward pa-
rameter selection, to model the determinants of the different chronic histological lesions, 
including the same explanatory parameters.
All tests were two-sided and p values of less than 0.05 were considered to indicate statisti-
cal significance. The results are expressed as numerical values and percentages for cat-
egorical variables and as mean ± standard deviation for continuous variables, unless oth-
erwise specified. We performed the analyses with SAS (version 9.2; SAS institute, Cary, NC) 
and GraphPad Prism (version 5.00; GraphPad Software, San Diego, CA) software. 
 
gen QuantiTect SYBR Green Mastermix, 2.5 mM of dithiothreitol, 300 nM of telg primer 
(5’-ACACTAAGGTTTGGGTTTGGGTTT- GGGTTTGGGTTAGTGT-3’), and 900 nM of telc 
primer (5’- TGTTAGGTATCCC- TATCCCTATCCCTATCCCTATCCCTAACA-3’). Telomere PCR 
conditions were: 1 cycle at 95°C for 10 min, followed by 2 cycles of 15 sec at 94°C and 2 
min at 49°C, and 30 cycles of 15 sec at 94°C, 20 sec at 62°C and 1 min 40 sec at 74°C. The 
single-copy gene (36B4) reaction mixture contained 1x Qiagen QuantiTect SYBR Green 
Mastermix, 300nM 36B4U primer (5’-CAGCAAGTGGGAAGGTGTAATCC-3’) and 500nM 
36B4D primer (5’-CCCATTCTATCATCAACGGGTACAA-3’). Single-copy gene PCR condi-
tions were: 1 cycle at 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec, and 58°C for 
1 min 10 sec. Samples were run in triplicate on an Applied Biosystems 7900HT Fast Real-
Time PCR system in a 384-well format. We calculated PCR efficiency based on a 6-point 
serial dilution (20ng-0.08ng) of pooled kidney tissue DNA. PCR efficiency was accepted 
between limits of 90-110%. We calculated relative average telomere lengths using qBase 
software (Biogazelle, Zwijnaarde, Belgium). Relative telomere length was expressed as the 
ratio of telomere copy number to single-copy gene number (T/S), relative to the average 
T/S ratio of the entire population (N=134). We achieved a coefficient of variation within tel-
omere and single-copy gene triplicates of 0.70% and 0.51% respectively. All biopsies in-
cluded passed quality control for assessment of intra-renal telomere length. The results for 
T/S ratio were normally divided and in the same order of magnitude as the results of our 
recently published paper13, where the results were 10log transformed because T/S ratios 
were not normally distributed in this prior publication. In the current analyses, no log trans-
formation of the data was necessary.
We evaluated accelerated biological aging by calculating delta (Δ) renal biological age - 
donor calendar age. Δ (range -3 – 3) was calculated using the difference of quartile tel-
omere length (0 = longest telomere length, 3 = shortest telomere length) - quartile calendar 
age (0 = youngest age group, 3 = oldest age group). Positive values represented biopsies 
with older biological than calendar age. Negative values represented biopsies with young-
er biological age than calendar age. 
Statistical Analysis
We assessed the associations between the clinical donor and recipient demographics, tel-
omere length and renal histology by means of linear or regression analysis, as well as 
spearman correlations. We used multiple linear regressions, with backward parameter se-
lection, to model the determinants of intrarenal telomere length at 5 years after transplan-
tation. For backward parameter selection, we considered the following variables for entry 
into the model for the determinants of intrarenal telomere length at 5 years: donor calendar 
age, donor gender, donor history of hypertension, donor history of diabetes mellitus and 
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Results
Population Characteristics 
Between January 2006 and July 2009, 486 renal transplantations were performed at the 
University Hospitals Leuven, of which 213 underwent a five-year protocol biopsy. Of these 
biopsies, 134 had sufficient amount of good-quality renal DNA available for evaluation of 
telomere length. In this cohort, 579 (N= 125 3 months, N= 121 12 months, N= 126 24 months 
and N= 134 60 months and 73 indication) biopsies were available for histological evalua-
tion. Table 1 summarizes the characteristics of our cohort and the histology of the biopsies 
that were included.  In total 11/579 biopsies (1.9%) were inadequate according to these crite-
ria and the individual histological features that were not interpretable were excluded from 
the analyses. All the patients included in this study had an adequate five-year protocol 
biopsy. 
Demographics Percentage (N) or mean ± Standard Deviation
N 134
Donor Characteristics
Donor Calendar Age (years) 44.5 ± 14.8
Male Gender % (N) 53.7 % (72)
Deceased Donor % (N) 92.6% (124)
Brain Death / Cardiac Death  83.0%(103)/14.0%(21)
History of Hypertension % (N) 18.7% (25)
History of Diabetes Mellitus % (N) 2.2% (3)
History of Smoking % (N) 25.7% (34)
Body Mass Index (kg/m2) 25.5 ± 4.3
History of Cardiovascular Events % (N) 38.1% (51)
Cold Ischemia Time 14.5 ± 6.4
recipient Characteristics
Recipient Calendar Age (years) 51.4 ± 12.8
Male Gender % (N) 53% (71)
Repeat transplantation % (N) 8.1%(11)
Pretransplant Donor-Specific Antibodies % (N) 13.4% (18)
Post-transplant factors
Delayed Graft Function 10.4% (14/134)
Immunosuppressive Protocol  56/74/4
(CsA-MMF-Cs / TAC-MMF-Cs / other)  
Presence of One or More Treated Acute 
Rejection Episodes after Transplantation % (N) 14.9% (20)
Biopsy-Proven Acute Cellular Rejection % (N)  23.8% (32) 
Acute Antibody-Mediated Rejection % (N)  2% (3)
Post-transplant Diabetes Mellitus % (N)  27.6% (37)
Body Mass Index at 5 years post-transplant  24.9 ± 5.5
(kg/m2)
Post-transplant Cardiovascular Events % (N) 26.1% (35)
Serum Creatinine 3 months (mg/dl) 1.62 ± 0.45
eGFR 3 months (mL/min/1.73m2)# 46.8 ± 15.0
Serum Creatinine 12 months (mg/dl) 1.44 ± 0.38
Table 1 — Demographics and histology of the subjects and biopsies included in this study. Data are expressed as 
mean ± standard deviation unless otherwise specified; #eGFR was calculated using the MDRD formula.19,28
* Post transplant Hypertension is defined as start of new hypertensive medication after transplantation.
Legend: CsA = cyclosporine, MMF = mycophenolate mofetil, Cs = Corticosteroids, TAC = Tacrolimus 
eGFR 12 months (mL/min/1.73m2)# 52.8 ± 15.3
Serum Creatinine 24 months (mg/dl) 1.46 ± 0.23
eGFR 24 months (mL/min/1.73m2)# 53.0 ± 17.1
Serum Creatinine 60 months (mg/dl) 1.53 ± 0.44
eGFR 60 months (mL/min/1.73m2)# 49.3 ± 14.9
Biopsy characteristics 3 months 1 years 2 years 5 years indication
N 125 126 134 134 73
Telomere Length (T/S ratio) –– –– –– 0.94 ± 0.18 ––
Banff Arteriolar Hyalinosis grade % (N) 0 = 76.0%  0 = 81.7%  0 = 72.4%  0 = 32.0% 0 = 86.4%
 (95) (103) (97) (43) (63)
 1 = 20.8%  1 = 15.1%  1 = 22.4%  1 = 36.6%  1 = 6.8% 
 (26) (19) (30) (49) (5) 
 2-3 = 3.2%  2-3 = 3.2%  2-3 = 5.2% 2-3 = 31.4%  2-3 = 6.8% 
 (4) (4) (7) (42) (5)
Banff Interstitial Fibrosis/Tubular Atrophy  0 = 79.2%  0 = 55.6%  0 = 47.0%  0 = 36.6%  0 = 83.6% 
grade % (N)  (99) (70) (63) (49) (61) 
 1 = 19.2%  1 = 38.1%  1 = 36.6%  1 = 37.3%  1 = 11.0% 
 (24) (48) (49) (50) (8)
 2-3 = 1.6%  2-3 = 6.3%  2-3 = 16.4%  2-3 = 26.1%  2-3 = 5.4% 
 (2) (8) (22) (35) (4)
Banff Arteriosclerosis grade % (N) 0 = 52.8%  0 = 46.0%  0 = 44.7%  0 = 36.6%  0 = 65.8% 
 (66) (58) (60)  (49) (48)
 1 = 32.8%  1 = 34.9%  1 = 29.9%  1 = 35.8%  1 = 13.7% 
 (41) (44) (40) (48) (10)
 2-3 = 14.4%  2-3 = 19.1%  2-3 = 25.4%  2-3 = 27.6%  2-3 = 20.5% 
 (18) (24) (34) (37) (15)
Presence of >25% Glomerulosclerosis% (N) 0 = 94.4%  0 = 93.7%  0 = 84.3%  0 = 67.9%  0 = 94.5% 
 (118) (118) (113) (91) (69)
 1 = 5.6%  1 = 6.3%  1 = 15.7%  1 = 32.1%  1 = 5.5% 
 (7) (8) (21) (43) (4)
Biopsy-Proven Acute Cellular Rejection % (N)  5.6% (7) 2.4% (3) 0.1% (1) 0.1% (1) 28.7% (21)
Acute Antibody-Mediated Rejection % (N)  0.1%(1) –– –– –– 2.7%(2)
Delta Histology progression (5 Years - 3 Months)    
Delta Arteriolar Hyalinosis Grade ≥ 1 % (N) 60.8 % (76)
Delta Interstitial Fibrosis/Tubular Atrophy  
grade ≥ 1 % (N)  59.2 % (74)
Delta Arteriosclerosis grade ≥ 1 % (N) 42.4% (53)
Delta Presence of >25% Glomerulosclerosis  
≥ 1 % (N) 29.6 % (37)
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Determinants of intrarenal telomere Length
Mean intrarenal log T/S ratio of telomere length at 5 years after transplantation was 
0.94±0.18 (range 0.54 to 1.6). Shorter telomere length correlated with older calendar age 
(r=-0.28; p=0.006)(Table 2; Figure 1). Donor history of hypertension vs. no hypertension 
(T/S ratio 0.88±0.22 vs. 0.98±0.24 with vs. without hypertension; p=0.03) and donor his-
tory of cardiovascular events vs. no history (T/S ratio 0.91±0.20 vs. 1.01±0.19with vs. with-
out history of cardiovascular events; p= 0.002) were also associated with shorter telomere 
length (Table 2)(Figure 1). Male donor kidneys had a shorter intrarenal telomere length 
compared to female donor kidneys (T/S ratio 0.92±0.19 vs. 0.10±0.22; p= 0.02). Other clini-
cal demographics, including history of diabetes mellitus, history of smoking, living versus 
deceased donation, brain death vs. cardiac death, donor body mass index, cold ischemia 
time and donor terminal eGFR were not associated with telomere length. 
 Univariate linear regression Multivariate linear regression
 
Parameter  Parameter  Standard P Parameter Standard P 
 estimate Error value estimate Error value
Donor Characteristics      
Donor Age (per Year) -0.003 0.001 0.006 -0.003 0.001 0.01
Donor Gender (Female) 0.08 0.04 0.02 0.1  0.04 0.002
Heart Beating Donor/Non Heart  0.02 0.05 0.56 
Beating Donor*    
Living Donor/Deceased Donor* -0.01 0.06 0.84   
History of Hypertension -0.01 0.04 0.02 -0.1 0.04 0.03
History of Diabetes Mellitus* 0.19 0.18 0.31   
History of Smoking* -0.002 0.04 0.04   
Body Mass Index (kg/m2) * -0.002 0.004 0.57   
History of Cardiovascular Events -0.11 0.03 0.002 -0.12 0.04 0.001
eGFR (mL/min/1.73m2)  0.00 0.00 0.57   
recipient characteristics      
Recipient Age (years)* -0.003 0.001 0.05   
Recipient Gender (Female) -0.06 0.05 0.25    
CMV Disease     
Presence of one or more Treated  
Acute Rejection Episodes  
after Transplantation * -0.02 0.04 0.6   
Biopsy-proven Acute Cellular Rejection  -0.003 0.03 0.9   
Acute Antibody-Mediated Rejection  0.01 0.06 0.8   
Delayed Graft Function^ -0.08 0.05 0.1   
Pretransplant Donor-Specific  
Antibody Presence 0.05 0.05 0.4   
Immunosuppressive Protocol  
(CsA-MMF-CS versus TAC-MMF-Cs) 0.1 0.03 0.02   
eGFR (mL/min/1.73m2) 3 Months after TX  0.00 0.00 0.5   
eGFR (mL/min/1.73m2) 1 Year after TX -0.05 0.04 0.1   
eGFR (mL/min/1.73m2) 2 Year after TX  -0.05 0.03 0.2   
eGFR (mL/min/1.73m2) 5 Years after TX  0.00 0.002 0.7   
Cold Ischemia Time* -0.01 0.00 0.07   
Cardiovascular Events after Transplantation* -0.05 0.04 0.2   
Post-transplant Diabetes Mellitus * -0.03 0.03 0.4   
Table 2 — Clinical determinants of telomere length (log T/S) in five-year protocol biopsies (N=134). Univariate analy-
ses were assessed by linear regression. Multiple linear regression, with backward parameter selection, was used to 
model the determinants of telomere length. *These parameters were included in the multivariate models, but were 
not retained in the final model after backward parameter selection. ** Effect sizes (SE) express the change in log T/S 
ratio associated with given changes in parameters. ^Defined as the need for dialysis within the first 7 days after trans-
plantation.
Figure 1 — Relation between telomere length and (A) donor cardiovascular risk, (B) donor calendar age, (C) donor 
history of hypertension and (D) donor gender. The p-values represent non-parametric ANOVA. The horizontal lines 
within the boxes indicate means, the upper and lower ends of the boxes indicate standard deviations, and the whiskers 
indicate 95th percentiles.
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In univariate analysis, intrarenal telomere length at five years after transplantation in-
versely correlated with older recipient calendar age (r=-0.24, p=0.03). None of the other 
recipient factors or post-transplant events associated with intrarenal telomere length at 
5 years (Table 2). In multivariate linear regression analysis, older calendar age, donor his-
tory of cardiovascular events, male donor gender and donor history of hypertension were 
independent explanatory factors for shorter intrarenal telomere length at five years after 
transplantation (Table 2). 
intrarenal telomere Length, Clinical Demographics and renal Histology
In univariate analysis, there was a borderline significant association between intrarenal 
telomere length at 5 years after transplantation and intrarenal arteriosclerosis (p= 0.09)
(Table 3). If intrarenal arterioscleroris was dichotomized in severe arteriosclerosis vs. non 
severe arteriosclerosis (cv 0-1 vs. cv 2-3), there was a significant association with intrare-
nal telomere length (T/S ratio 0.99±0.19 vs. 0.91±0.27 in cv=2-3 vs. cv=0-1; p=0.03). There 
was no association between intrarenal telomere length and the other histological lesions 
(Table 3). Given the collinearity of telomere length with donor demographics (see above), a 
multivariate analysis was performed, with adjustment for donor age, donor history of hy-
pertension, donor cardiovascular risk and male donor gender, and including an interaction 
term between telomere length and donor age. In this analysis, intrarenal telomere length 
significantly and independently associated with intrarenal arteriosclerosis, but not with 
other histological lesions (Table 3). Moreover, presence of severe arteriosclerosis  in renal bi-
opsies associated with donor age (donor age 50.81±18.0 vs. 42.81±15.2 in cv=2-3 vs. cv=0-1; 
p=0.003) and donor cardiovascular risk  (56% cv vs. 37% cardiovascular risk in presence vs. 
absence of severe arteriosclerosis; p=0.05)(Figure 2). 
The significant interaction between donor age and telomere length for association with 
arteriosclerosis illustrates that the association between intrarenal telomere length and ar-
teriosclerosis depends on donor age. To further elucidate this interaction between calendar 
age and telomere length, we calculated Δ accelerated biological aging. This parameter as-
sociated significantly with the presence of arteriosclerosis at 5 years after transplantation 
(range -3 – 3; p=0.001)(Figure 3A). Telomere attrition augments the association between 
older donor age and the presence of severe arteriosclerosis. In the group with the oldest do-
nor age and shortest telomere length, there was significantly more severe arteriosclerosis 
(43%) in protocol biopsies at five year after transplantation, compared to other combina-
tions (13-28%)(Figure 3B). Figure 2 — Relation between severe intrarenal arteriosclerosis in the five year protocol biopsy and (A) telomere 
length in the five year protocol biopsy, (B) interaction term (telomere length X donor age), (C) donor age, (D) donor 
history of cardiovascular risk. The p-values represent non-parametric ANOVA. The horizontal lines within the boxes 
indicate means, the upper and lower ends of the boxes indicate standard deviations, and the whiskers indicate 95th 
percentiles. Severe arteriosclerosis was defined as Banff cv score 2-3. 
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sis/tubular atrophy (IFTA) associated with older donor age (donor age 47.5±161 vs. 41.3±19.0 
years with vs. without IFTA; p=0.01) but not with telomere length. Progression of the other 
histological lesions (glomerulosclerosis, arteriolar hyalinosis) did not associate with donor 
age or shorter telomere length.
Sensitivity analysis
To investigate the robustness of our findings, we performed a sensitivity analyses in the 
subgroup male kidney donors and female kidney donors. In the male subgroup, telomere 
length correlated significantly with donor age (r=-0.4 p=0.002) and with history of cardio-
vascular events (0.92 ± 0.27 vs. 1.1 ± 0.39 with vs. without history of cardiovascular events 
p=0.0004). 
In univariate analysis, there was no association between intrarenal telomere length at 5 
years after transplantation and severe arteriosclerosis. When multivariate analysis was 
performed, with adjustment for an interaction term between telomere length and donor 
age, intrarenal telomere length significantly and independently associated with intrare-
nal arteriosclerosis (T/S ratio 0.94±0.17 vs. 0.88±0.14 in cv=2-3 vs. cv=0-1; p=0.05). Also 
in the female subgroup, telomere length correlated significantly with donor age (r=-0.38 
p=0.003), and also with history of cardiovascular events (0.97 ± 0.05 vs. 1.0 ± 0.04 with 
vs. without history of cardiovascular events p=0.5). When multivariate analysis was per-
formed, with adjustment for an interaction term between telomere length and donor age, 
the association between intrarenal telomere length and intrarenal arteriosclerosis reached 
borderline significance (T/S ratio 0.94±0.15 vs. 1.01±0.28 in cv=2-3 vs. cv=0-1;p=0.07).
telomere length and graft function or graft outcome
After the 5-year protocol biopsy, 3.7% of recipients (N=5) experienced graft failure: two re-
cipients returned to dialysis due to graft loss and three recipients died with a function-
ing graft. For this, the association between telomere length and graft survival could not 
be evaluated. There was no association between telomere length and renal function at 3 
months, 12, 24 and 60 months (Table 2). 
Progressive arteriosclerosis and telomere length
Next, we evaluated delta histology over time after transplantation (Table 1; Figure 3C). At 
3 months, severe arteriosclerosis was present in 14.4 % of the biopsies (18/125). At 5 years, 
severe arteriosclerosis was present in 27.6% (37/134) of the biopsies. Delta cv score was ≥ 
1 in 42% of patients (53/125). Kidneys with  progression of arteriosclerosis had a signifi-
cantly shorter telomere length at 5 years compared to kidneys without progressive arte-
riosclerosis (T/S ratio 0.91±0.19 vs. 1.00±0.21; with or without progression p=0.005) (Figure 
3D). In addition, arteriosclerosis progression was associated with older donor age (48.8±17.1 
vs. 42.6±18.3 with or without progression; p=0.02) and history of cardiovascular events 
(0.58±0.3 vs. 0.39±0.2 with or without progression; p=0.03). Progression of interstitial fibro-
 Univariate linear regression Multivariate linear regression
if/tA grade (Banff Score) Parameter Standard P Parameter Standard P
 estimate Error value estimate Error value
Telomere length (T/S )      
Donor age (years) 0.01 0.006 0.002 0.02 0.006 0.004
Donor age (years) x Telomere Length      
Arteriolar hyalinosis grade (Banff) Parameter Standard P Parameter Standard P
 estimate Error value estimate Error value
Telomere length (T/S )      
Donor age (years) 0.01 0.005 0.02   
Donor age (years) x Telomere Length      
Arteriosclerosis Parameter Standard P Parameter Standard P
 estimate Error value estimate Error value
Telomere length (T/S ) -0.4 0.24 0.09 -0.9 0.003 0.0001
Donor age (years) 0.02 0.005 0.0003 0.02 0.3 0.003
Donor age (years) x Telomere Length    0.02 0.005 0.0005
glomerulosclerosis Parameter Standard P Parameter Standard P
 estimate Error value estimate Error value
Telomere length (T/S )      
Donor age (years) 0.005 0.003 0.08 0.01 0.002 0.02
Donor age (years) x Telomere Length      
Table 3 — Clinical determinants of histological lesions in five-year protocol biopsies (N=134). Multiple linear regres-
sion with backward parameter selection was used to model the determinants of the five years histological lesions. 
Multivariate analyses presented in this table were performed on 134 subjects. Interaction terms for donor age and do-
nor telomere length were included in the multivariate model (chi square statistical test). The associations between the 
histological lesions, telomere length and donor age were adjusted for donor calendar age, donor gender, donor history 
of hypertension, donor history of diabetes mellitus, donor body mass index, donor history of cardiovascular events, 
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Discussion
In the current study, we demonstrated that the associations between intrarenal telomere 
length and older donor calendar age, donor history of hypertension and donor cardiovas-
cular events remain present many years after transplantation, irrespective of post-trans-
plant injury processes. This illustrates the long-term, persisting impact of donor charac-
teristics on kidney graft telomere length, independent of immune and non-immune injury 
processes after transplantation, such as ischemia reperfusion injury, acute rejection and 
viral infections. Moreover, we confirmed the significant relation between telomere length 
(biological aging) and renovascular disease (arteriosclerosis) in our five-year protocol bi-
opsy cohort. Also here, despite significant progression of arteriosclerosis over time after 
transplantation, this progression related to pretransplant donor factors, hypertension and 
cardiovascular risk, and not to post-transplant injury processes. 
Recently, we illustrated and validated that shorter (intrarenal) telomere length associates 
with older calendar age, history of hypertension and cardiovascular events in a cohort of 
native kidneys before transplantation.13 This association between shorter telomere length 
and clinical cardiovascular disease has also been described in the cardiovascular field.6,9,23 
Moreover, we described that arteriosclerosis in smaller intrarenal arteries of native kidneys 
is associated with shorter telomere length, suggesting a significant relation between repli-
cative senescence or biological aging and renovascular disease.13
Previous literature suggested that after kidney transplantation, immune and non-immune 
injury to the kidney can cause accelerated aging of the graft.16,18 An observational study in 
allogeneic bone marrow transplants found a 15 year acceleration of telomere shortening in 
the grafted cells.24 In transplanted renal cells, there is evidence for an increased cell turno-
ver at the time of transplantation and a phase of increased cell regeneration directly after 
transplantation that correlates with cold ischemia time.14,15 Also a small study showed that 
shorter telomere length in biopsies obtained at implantation was associated with lower 
graft function at 12 months after transplantation, but no correlation with p21 or p53 was 
found.17 In human renal transplants with interstitial fibrosis/tubular atrophy and impaired 
graft function, Melk et al described increased p16 expression, suggestive of accelerated 
senescence25, although this is a non-specific marker, largely telomere-independent. Fur-
thermore, a rapid increase in p16 expression after transplantation was described in murine 
kidney grafts, which was most pronounced in older animals.26 Notwithstanding the afore-
mentioned studies, suggesting the presence of post-transplant accelerated senescence, 
no definite proof of accelerated telomere shortening has been described in human kidney 
grafts. In contrast, our findings illustrate that post-transplant telomere length, even five 
years after transplantation, is not primarily dependent on the immune and non-immune 
factors associated with kidney transplantation. These findings question the hypothesis of 
Figure 3 — (A) Relation between accelerated aging and presence of arteriosclerosis in the five-year protocol biopsy. 
Accelerated biological aging was evaluated by calculating delta (Δ) biological age - calendar age. Δ (range -3 – 3) was 
calculated using the difference of quartile telomere length (0 = longest telomere length, 3 = shortest telomere length) - 
quartile calendar age (0 = youngest age group, 3 = oldest age group). The p-values represent non-parametric ANOVA. 
(B) The correlation between telomere length and donor age in the five-year protocol biopsies with and without pres-
ence of severe arteriosclerosis. The percentage indicates the amount of biopsies with presence of severe arterioscle-
rosis (cv = 2-3) in the different groups (group 1= age < 47,TL ≤ 0.94; group 2= age < 47, TL > 0.94; group 3= Age ≥ 47, TL > 
0.94; group 4= Age ≥ 47, TL < 0.94). Severe arteriosclerosis was defined as Banff cv score 2-3. The p-values represent 
chi-squaere testing between group 4 vs. group 3 (p=0.001); group 4 vs. group 1 (p<0.0001). 
(C) The evolution of chronic histological lesions between 3 months and 5 years after transplantation transplanta-
tion.The p-values represent represents non-parametric ANOVA.
(D) Relation between progression of intrarenal arteriosclerosis and intrarenal telomere length in the five-year pro-
tocol biopsies. Delta histology was calculated as the severity of the histological lesion in the five-year protocol biopsy 
– the severity of the histological lesion in the three-month biopsy (range 0-3). Positive values represented biopsies 
with progression. Zero values represented biopsies without histological progression. The p-value represents non-par-
ametric ANOVA. 
The horizontal lines within the boxes of the box-whisker plots in this figure indicate means, the upper and lower ends 
of the boxes indicate standard deviations, and the whiskers indicate 95th percentiles.
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because of the selected study population, associations between telomere length and graft 
survival could not be explored. Not all ageing processes are mediated by telomere attrition, 
and no conclusions can be drawn regarding the impact of post-transplant events on these 
other ageing mechanisms. Finally, the study design does not allow drawing conclusions 
on causality between donor characteristics, post-transplant telomere attrition and post-
transplant histology.
In conclusion, we demonstrated that intrarenal telomere length at 5 years after trans-
plantation, as marker of replicative senescence, is associated with donor characteristics, 
but not with post-transplant events. Similar to what we observed in native kidneys, post-
transplant renal arteriosclerosis primarily represents biological organ aging. Further study 
is necessary to elucidate whether telomere attrition plays a role in the long-term outcome 
after kidney transplantation. 
accelerated replicative senescence as consequence of specific injury processes after renal 
transplantation. 
Interestingly, the current study sheds new light on the risk factors for arteriosclerosis (vas-
cular intimal thickening) after renal transplantation. Both in zero-time biopsies13 and in the 
current study in biopsies at 5 years after transplantation, intrarenal telomere length signifi-
cantly associated with arteriosclerosis. Moreover, also accelerated biological age, expressed 
as the difference between biological age and calendar age, associated with intrarenal ar-
teriosclerosis. The robust association of telomere shortening and histology of arteriosclero-
sis could explain the previously observed association between shorter telomere length and 
clinical cardiovascular disease, also present in our study. Similarly, in a large cohort study, 
Loupy et al recently described a significant association between graft arteriosclerosis and 
donor-related cardiovascular risk factors (age, diabetes mellitus, cardiovascular risk and 
hypertension). These authors hypothesized that post-transplant accelerated arteriosclero-
sis may be partially donor-transmitted.27 Taken together with our findings, this is convinc-
ing evidence that post-transplant arteriosclerosis is, at least partly, a senescence phenom-
enon. Nevertheless, also other factors likely play a role as well. The study by Loupy et al 
has illustrated that antibody-mediated injury could contribute to graft arteriosclerosis.27 In 
our analysis, which is underpowered for this analysis due to very low prevalence of patients 
with donor-specific antibodies, we could not confirm a role of circulating donor-specific 
anti-HLA antibodies in the development of arteriosclerosis. 
Our study has some limitations. Although donor clinical demographics were collected pro-
spectively, some kidney donor parameters that could be of importance could have been 
recorded incompletely. This could explain the lack of association between telomere short-
ening and diabetes mellitus, as was described previously.7,12 In addition, we are aware of 
the fact that our study only includes a relatively low number of patients, with inherent 
selection bias by the inclusion of only patients with at least 5-year graft survival. In our 
hospital, 5-year protocol biopsies were routinely performed between 2009 and 2014, but 
even in this situation many patients decline participation. Obviously, patients who did not 
undergo the 5-year protocol biopsy, who lost their graft, or who died before 5 years after 
transplantation, were not included in this study. The exclusion of these patients could have 
impacted the results, likely by underestimation of the histological lesions at 5 years and of 
the most deleterious post-transplant events (CMV disease, therapy-resistant acute rejec-
tion etcetera). Moreover, the low number of patients with antibody-mediated rejection or 
donor-specific antibodies implies that our study is underpowered to detect an association 
between these parameters and telomere attrition or 5-year histology. Absence of asso-
ciation in our analysis therefore should not be over-interpreted. We also recognize that, 
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Because of the limited supply and the increasing demand for kidney grafts, the criteria for 
accepting kidneys for transplantation have been expanded.1 Organs, which before would 
have been considered unacceptable, are now transplanted routinely. With the use of these 
expanded criteria donors, older donor age and pre-transplant kidney quality are becom-
ing main determinants of outcome after transplantation. A good understanding of the 
interaction between donor age, senescence mechanisms and pathways, and kidney graft 
quality was the main goal for this thesis project. To that end we formulated 3 distinct, but 
related aims (Chapter 1). 
To evaluate the intrinsic quality of donor organs, many centers perform zero-time biopsies, 
prior to transplantation.2-4,5,6 Several composite histological scoring schemes have been 
proposed for prediction of graft survival. But whether assessing pre-implantation biopsies 
prior to transplantation for allocation purposes is beneficial, and which histological cut-off 
values or score could be used for discarding a kidney for transplantation, is currently not 
known. 
In the first part of this dissertation we evaluated the impact of the histological appearance 
of implantation biopsies on long-term renal allograft outcome, and assessed the histology 
of implantation biopsies as prognostic clinical tool (Aim 1; Chapter 2).7 We demonstrated 
that donor age and the histology of the graft at time of transplantation are major deter-
minants of long-term graft outcome. Moreover, for the first time, we illustrated that the 
predictive performance of previously published and widely used histological scoring sys-
tems was insufficient to use any of these scoring systems for kidney discard or acceptance. 
Notwithstanding this, we demonstrated that it is possible to create a scoring system with 
sufficient predictive performance to guide clinical decisions at time of transplantation, al-
though it should be acknowledged that the clinical benefits or drawbacks of this approach 
were not evaluated. 
Two recent reviews, published by CJ Wang and M Naesens, discussed the use of zero-time 
biopsies for allocation or discard. Both concluded that despite the great appeal of using 
biopsies, and despite existing literature on this topic, further research remains necessary to 
clarify which histological lesions/scores are most predictive of long term graft outcome and 
could be used for kidney allocation purposes.8,9 In concordance with our findings7, kidney 
discard on the other hand based on histology should be avoided in routine clinical practice. 
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terstitial injury, versus renal arteriosclerosis, illustrates a robust dichotomy within the phe-
notype of “nephrosclerosis”, the primary structural findings of the aging kidney on light 
microscopy. 
Given our finding that arteriosclerosis in smaller intrarenal arteries independently asso-
ciated with shorter telomere length, we evaluated the mechanism of this association in 
untargeted whole-genome expression and pathway enrichment analyses. In the second 
study of Aim 2.1, we discovered that the expression of genes involved in the “superpathway 
of cholesterol metabolism” significantly associates with shorter telomere length and arteri-
osclerosis. Different hypotheses could be formulated to explain this association. It could be 
that a common harmful environment triggers upregulation of this pathway and telomere 
attrition, resulting in cardiovascular disease and presence of arteriosclerosis. On the other 
hand, a beneficial effect of senesence on atherosclerosis could also explain the found as-
sociations. Arteriosclerosis might trigger cellular senescence and therefore telomere short-
ening as a protective feedback mechanism. This by triggering pro senescent pathways 
that limit the proliferative capacity of the associated cells and thereby restricting the for-
mation of atherosclerosis (Chapter 3.2).16 
The senescence phenotype in native kidneys, as discussed above, possibly becomes more 
obvious when older kidneys are transplanted and are exposed to ischemia/reperfusion or 
preservation stresses, post-transplant stresses like size mismatch, hypertension, drug tox-
icity, CMV infection and immune stresses (donor-specific antibodies and acute rejection 
episodes).17 Previous literature even suggested that after kidney transplantation, immune 
and non-immune injury to the kidney could cause accelerated aging of the graft.12,17 How-
ever, no definite proof of accelerated telomere shortening has been described in kidney 
grafts. In the second part of the second aim we evaluated renal senescence in post trans-
plantation biopsies (Aim 2.2).
In Chapter 4.1, we evaluated telomere length in a prospective cohort of kidney transplant 
recipients, followed with protocol biopsies up to 5 years after transplantation. In this unique 
cohort, we showed that the intrarenal telomere length at 5 years after transplantation as-
sociated with older donor calendar age, donor history of hypertension and donor cardio-
vascular events, irrespective of post-transplant injury processes. Moreover, we confirmed 
the significant relation between telomere length and renal arteriosclerosis in five-year pro-
tocol biopsies. Despite significant progression of arteriosclerosis over time after transplan-
tation, this progression related to pre-transplant donor factors, hypertension and cardio-
vascular risk, and not to post-transplant injury processes. 
Of the wide spectrum of mechanisms of aging, cellular/replicative senescence is classically 
seen as one of the most important. Cellular senescence comprises exhaustion of a prede-
termined proliferative capacity, depends on telomere shortening with increasing age, but 
can also be induced by extrinsic factors. Telomeres comprise tandem TTAGGG repeats of 
5000 to 15000 base pairs that normally reside at the ends of chromosome ends as pro-
tection and prevent end-to-end fusion of chromosomes. Telomere length is regulated by 
telomerase.10,11 Most somatic cells do not express telomerase, and mature telomeres tend 
to progressively shorten with every cell division.11 Telomere length thus reflects time and 
the number of cell cycles. Replicative senescence has only been studied scarcely in native 
kidneys.12 In adult human kidneys, telomerase activity is very low, which results in telomere 
shortening by every cell division, as was demonstrated by Melk et al. Telomere length de-
creases more rapidly in the renal cortex than in the medulla.13 
In the second part of this dissertion we wanted to assess the phenotype and risk factors 
of replicative senescence in human kidneys and to elucidate the importance of replicative 
senescence for renal allograft histology, function and survival in humans (Aim 2). 
First, we identified the renal senescence phenotype in implantation biopsies and defined a 
renal senescence marker panel (Aim 2.1). In the first study of this aim, we illustrated that in-
trarenal arteriosclerosis associates with telomere length, independent of kidney donors’ his-
tory of cardiovascular disease and donors’ calendar age, in a cohort of 257 kidney donors 
for transplantation (Chapter 3.1).14 Moreover, accelerated aging, evaluated as the difference 
between biological age (telomere shortening) and calendar age, associated highly signifi-
cantly with intrarenal arteriosclerosis. For the first time, this study suggests a role of biologi-
cal aging in the development renal arteriosclerosis and intimal hyperplasia. This finding is in 
concordance with other literature in the cardiovascular field, where telomere attrition associ-
ates with age-related diseases like atherosclerosis and cardiovascular disease.15 This study 
also confirmed our previous data7 that older calendar age associates with chronic injury in 
the tubulo-interstitial (tubular atrophy and interstitial fibrosis) and glomerular (glomeru-
losclerosis) renal compartments, while cardiovascular risk factors, cardiovascular disease 
and telomere length did not associate with these lesions. 
It could therefore be hypothesized that calendar age-associated lesions represent accu-
mulation over time of events that contribute to cumulative non-specific renal injury. In con-
trast, senescence could be regarded as a more specific process that represents oxidative 
stress, endothelial dysfunction and arteriosclerosis, and thereby contributes directly to the 
pathogenesis of cardiovascular disease and clinical events. The differential association of 
calendar age versus telomere length with respectively glomerulosclerosis and tubulo-in-
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These data illustrate the long-term, persisting impact of donor characteristics on kidney 
graft telomere length, independent of immune and non-immune injury processes after 
transplantation, such as ischemia/reperfusion injury, acute rejection and viral infections. 
These findings question the hypothesis of accelerated replicative senescence as conse-
quence of specific injury processes after renal transplantation, although it needs to be ac-
knowledged that further evaluation of other senescence mechanisms in post-transplant 
biopsies remains necessary.
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Niertransplantatie blijft de therapie bij uitstek voor de meeste patiënten met eindstadium 
nierziekte. De vraag naar beschikbare donororganen is echter veel groter dan het aanbod. 
Hierdoor maken transplantatieteams meer en meer gebruik van oudere organen en or-
ganen van donoren met een aanzienlijke co-morbiditeit. Het gebruik van deze ‘extended 
criteria’ organen blijkt echter niet zonder gevolg.1 Door het gebruik van deze donoren zijn 
leeftijd en kwaliteit van het donororgaan de belangrijkste determinanten geworden van 
de lange termijn overleving. Het bekomen van een beter begrip van de interacties tussen 
donorleeftijd, verouderingsmechanismen en -netwerken, en de kwaliteit van donornieren 
was het hoofddoel van dit onderzoeksproject. Hierrond formuleerden we in Hoofdstuk 1 
drie doelstellingen.
Om de kwaliteit van donororganen voor transplantatie te evalueren, worden er in veel cen-
tra pre-implantatie biopsies uitgevoerd.2-6 Verschillende auteurs hebben al enkele histolo-
gische scores voorgesteld voor het voorspellen van de overleving van transplantnieren op 
lange termijn. Ondanks deze publicaties was het nog niet duidelijk of we deze scores kun-
nen gebruiken om transplantnieren toe te wijzen. Het was eveneens onduidelijk of we deze 
scores kunnen gebruiken bij het afwijzen van donornieren. 
In een eerste studie van dit onderzoeksproject evalueerden we daarom de voorspellen-
de kracht van de histologie van donornieren op nieroverleving na transplantatie, en eval-
ueerden we het gebruik hiervan als prognostisch scoresysteem (Doelstelling 1; Hoofdstuk 
2).7 Ten eerste kon onze studie aantonen dat zowel donorleeftijd als de histologie van do-
nornieren belangrijke en onafhankelijke voorspellers zijn van de transplantnieroverleving 
op lange termijn. Ten tweede toonden we aan dat de eerder beschreven scoresystemen 
onvoldoende voorspellende waarde hebben om gebruikt te worden om donornieren onge-
schikt te verklaren. Daarentegen konden wij wel een scoresysteem creëren met voldoende 
predictieve waarde om gebruikt te worden voor beslissingen rond de toewijzing van trans-
plantnieren. Het dient echter vermeld te worden dat het klinisch voordeel, of eventueel zelfs 
nadeel, van deze aanpak niet werd bestudeerd. 
In twee recent gepubliceerde review artikelen door CJ Wang en M Naesens werd het gebruik 
van implantatiebiopsies (op het ogenblik van transplantatie) voor toewijzing of ongeschikt 
verklaren van donornieren uitgebreid besproken. Beide artikels kwam tot een gelijkaardige 
conclusie inzake het gebruik van implantatiebiopsies voor allocatie doeleinden. Ondanks 
reeds uitgebreide literatuur over dit onderwerp, is verder onderzoek nodig om uit te klaren 
welke histologische letsels/scores de nieroverleving op de meest nauwkeurige wijze kunnen 
voorspellen.8,9 Verder werd vermeld dat het ongeschikt verklaren van donornieren op basis 
van histologische criteria ten allen tijde vermeden moet worden in de klinische praktijk, wat 
in overeenstemming is met onze bevindingen.7
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literatuur, waarbij telomeerverkorting associeert met ouderdomsziekten als atherosclerose 
en hart- en vaatziekten.15
Deze studie bevestigt ook onze eerdere bevindingen.7 Oudere kalenderleeftijd associeert ee-
rder met chronische tubulointerstitiële letsels (tubulaire atrofie en interstitiële fibrose) en de 
glomerulaire (glomerulosclerose) renale compartimenten, terwijl cardiovasculaire risicofac-
toren, hart- en vaatziekten niet associëren met deze histologie. Vermoedelijk vertegenwoor-
digen de kalenderleeftijd-geassocieerde letsels accumulatie van niet-specifieke chronische 
schade, ontstaan over een verloop van tijd. “Senescence” en telomeerverkorting daaren-
tegen lijken een meer specifieke etiologie te kennen, in een proces dat gekenmerkt wordt 
door oxidatieve stress, endotheel -dysfunctie en arteriosclerose. De associatie van kalen-
derleeftijd versus telomeerlengte met respectievelijk glomerulosclerose/tubulo-interstitiële 
schade versus renale aderverkalking, illustreert het sterke contrast binnen het fenotype van 
“nefrosclerose”, de primaire structurele bevindingen van microscopische nierveroudering.
Gezien onze bevinding, dat intrarenale arteriosclerose onafhankelijk geassocieerd is met 
kortere telomeren, werd dit verder onderzocht door evaluatie van genoomwijde genexpres-
sie-analyse en moleculaire netwerkevaluatie. In de tweede studie van Aim 2.1 ontdekten 
we dat de expressie van genen van de “superpathway van het cholesterol metabolisme” 
belangrijk associeert met kortere telomeerlengte en intrarenale arteriosclerose. We stelden 
dat deze pathway een eerste stap betekent in de associatie tussen telomeer verkorting 
en arteriosclerose. Hoewel verschillende hypothesen kunnen gevormd worden vanuit deze 
nieuwe associatie, is een strikt causaal verband leggen in deze studie opzet niet mogelijk. 
De meest waarschijnlijke hypothese lijkt dat een gemeenschappelijke schadelijke omgev-
ing zorgt voor de upregulatie van de cholesterol pathway en hierdoor voor het ontstaan 
van hart- en vaatziekten arteriosclerose (hoofdstuk 3.2). De aanwezigheid van arterioscle-
rose triggert vervolgens een upregulatie van pro senesence pathways (telomeerverkorting) 
als een protectief feedback mechanisme. Dit met een afname van de proliferatieve capac-
iteit van de geassocieerde cellen als gevolg. Op deze manier wordt de verdere vorming van 
atherosclerosie/arteriosclerose tegen gehouden.16
Er is een vermoeden dat het “senescent” fenotype, zoals hierboven beschreven, mogelijk 
duidelijker naar voren komt wanneer oudere nieren getransplanteerd en dus blootgesteld 
worden aan de stressoren voor, tijdens en na transplantatie, zoals schade door ischemie/
reperfusie, mismatch in grootte, hypertensie, geneesmiddeltoxiciteit, CMV infecties en 
immuun-gerelateerde stress (donor-specifieke antilichamen en episodes van acute nier-
afstoting.17 Er is literatuur die suggereert dat transplantatie kan leiden tot een versnelde 
veroudering van het donororgaan.12,17
Cellulaire veroudering (“senescence”) wordt klassiek gezien als een van de belangrijkste 
concepten in het verouderingsproces. Cellulaire veroudering leidt tot een permanente en 
onomkeerbare groei-stop, soms ook het Hayflick fenomeen genoemd. Deze verouderde 
(“senescent”) cellen blijven levensvatbaar maar vertonen een veranderde morfologie, een 
veranderend metabolisme en een onmogelijkheid om te delen ondanks mitogene stimuli. 
Er zijn verschillende stressoren beschreven die ervoor zorgen dat mitotisch actieve cellen 
in “senescent” modus gaan, zoals het aantal celdelingen dat een cel ondergaan heeft, de 
leeftijd van de cel, of als een antwoord op schade en stress.
Telomeren zijn tandem repeats “TTAGGG” van 5.000-15.000 baseparen die zich bevin-
den aan de uiteinden van een chromosoom. Ze dienen als bescherming en voorkomen 
“end-to-end” fusie van chromosomen. Telomeren worden in populaire terminologie soms 
vergeleken met het plastic uiteinde van een veter. Bij iedere celdeling rafelt het uiteinde 
een stukje uit en uiteindelijk kan de cel niet meer delen en sterft. De lengte van de telom-
eren stelt als het ware onze biologische klok voor. De lengte van deze telomeren wordt 
geregeld door het telomerase. Telomerase is een enzym dat in de celkern van bepaalde 
cellen voorkomt. Het bestaat voor een deel uit proteïne en voor een deel uit RNA. Het en-
zym is een reverse transcriptase, waarbij het RNA-gedeelte als matrijs gebruikt wordt om 
de verkorte telomeren terug te verlengen. De meeste somatische cellen beschikken niet 
over het telomerase enzym, waardoor volwassen telomeren bij elke celdeling verkorten.10,11 
Er is weinig literatuur over cellulaire veroudering in nierweefsel.12 In volwassen nieren is de 
telomerase-activiteit zeer laag, zoals werd aangetoond door Melk et al. Telomeerlengte 
neemt ook sneller af in de renale cortex dan in de medulla.13
Onze tweede doelstelling in dit doctoraatsproject was de bepaling van het “senescence” 
fenotype in nieren, met beschrijving van de risicofactoren voor het ontstaan van dit feno-
type. Verder wouden we het belang van dit fenotype voor de histologie, functie en overlev-
ing van transplantnieren op de lange termijn bepalen (Doelstelling 2). 
Ten eerste, wouden we het “senescence” fenotype in implantatie-biopsies identificeren 
en definiëren van een renale “senescence” merker (Doelstelling 2.1). In de eerste studie 
van deze doelstelling illustreren we dat intrarenale arteriosclerose associeert met telo-
meerlengte, onafhankelijk van een voorgeschiedenis van hart- en vaatziekten, en van de 
kalenderleeftijd van de donoren (Hoofdstuk 3.1).14 Bovendien konden we aantonen dat 
versnelde veroudering (het verschil tussen biologische leeftijd – telomeerlengte, en kalen-
derleeftijd) opvallend associeert met intrarenale arteriosclerose. Dit suggereert een rol van 
telomeerverkorting of biologische veroudering bij de ontwikkeling van renale slagader-
verkalking en intimale hyperplasie. Dit werd eerder ook al beschreven in de cardiovasculaire 
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Desondanks is er tot nu toe geen bewijs te vinden in de literatuur dat versnelde telo-
meerverkorting en “senescence” ook belang heeft na niertransplantatie in humane con-
text. In het tweede deel van de tweede doelstelling hebben we daarom het renale “senes-
cence” fenotype geëvalueerd in biopsies bekomen tijdens de opvolging na een succesvolle 
niertransplantatie (Doelstelling 2.2).
In Hoofdstuk 4.1 onderzochten we telomeerlengte in een prospectieve cohort van nier-
transplantpatiënten, die een protocolbiopsie ondergingen op vijf jaar na transplantatie. In 
deze unieke cohorte konden we voor het eerst aantonen dat intrarenale telomeerlengte 
op vijf jaar na transplantatie nog steeds associeert met de kalenderleeftijd van de nierdo-
nor, voorgeschiedenis van cardiovasculaire problematiek of hypertensie bij de donor. Intra-
renale telomeerlengte op vijf jaar na transplantatie was niet gerelateerd aan het klinisch 
post-transplant verloop. Bovendien konden we in deze studie de significante relatie tus-
sen korte telomeerlengte en toegenomen renale arteriosclerose bevestigen op vijf jaar na 
transplantatie. Ondanks de significante progressie van arteriosclerose na transplantatie, 
associeerde deze enkel met de pre-transplantatie donor kenmerken, hypertensie en car-
diovasculair risico, en niet met het post-transplantatie. 
Deze gegevens illustreren het belang en effect op lange termijn van donorkenmerken op 
de biologische leeftijd transplantnieren. De biologische leeftijd van transplantnieren lijkt 
onafhankelijk te zijn van de immuungemedieerde en niet-immuun-gemedieerde schadeli-
jke fenomenen na transplantatie, als ischemie/reperfusie schade, afstoting en acute virale 
infecties. Deze bevinding stelt de primaire hypothese in vraag, dat niertransplantatie het 
verouderingsproces versnelt. Hierbij dient vermeld te worden dat verder onderzoek naar het 
belang van andere verouderingsmechanismen na niertransplantatie nog nodig is. 
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